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V I 
Introduction 
Coronary artery disease (CAD) is one of the most important disease, in 
terms of both mortality and morbidity. According to a WHO and World Bank 
report nearly 2 million people in India die every year due to combined 
cardiovascular diseases. In addition, compared to Americans, Indians have 150 per 
cent to 400 per cent higher death rate from heart attacks. Population surveys 
carried out in the last few decades indicate that the prevalence of coronary artery 
disease (CAD) and hypertension has increased at least twofold in the last 20 years 
in both rural and urban populations in India (Dewan et al., 1974; Gupta and 
Malhotra, 1975; Gupta et al., 1995; Singh et al., 1995b). In the urban population, 
the prevalence of hypertension and CAD is 3-4 times higher than in rural subjects. 
In South India (Malhotra, 1%7; Raman et al., 1993), the prevalence rates are 
higher in the urban as well as the rural population. CAD is also more common in 
males than females. It seems that differences in diet and lifestyle and the aging of 
populations may be important in the pathogenesis of hypertension and CAD in 
different population groups of Indians (Beegom and Singh, 1995; Singh et al., 
1995a). In the United States alone, CAD accounts for fully one-half of the nearly 
] million deaths each year from cardiovascular disease, and is the leading cause of 
death in both genders (American Heart Association, 1994). Each year, about 
1.5 million Americans suffer acute myocardial infarction, and almost all 
myocardial infarctions are due to atherosclerosis of the coronary arteries. Among 
the two-tiiirds who survive the myocardial infarction, about two-thirds do not 
make a full recovery. In 19 per cent of Americans aged 15 years or older who are 
categorized as disabled, the disability is from CAD or other cardiovascular disease 
(American Heart Association, 1994). 
Risk factor reduction is the primary clinical approach to preventing CAD 
morbidity and mortality. Epidemiological studies have clearly demonstrated that 
risk factors such as dyslipidemia, hypertension, and the use of tobacco products 
act in a synergistic manner (Anderson et al, 1991). High levels of total 
cholesterol, TAG, LDL-cholesterol, VLDL-cholesterol, apoB, Lp(a) and low 
levels of HDL-cholesterol, HDL2-cholesterol, HDL3-cho!esterol, apoA-I are some 
of the Upid risk factors associated with CAD. Other non-lipid risk factors include 
physical inactivity, obesity, family history of CAD, age, gender, homeostatic 
factors, homocysteinemia, alcohol consumption, and psychological factors. The 
identification of risk factors provide a means for decreasing CAD risk, through the 
reduction of modifiable risk factors, and for informing treatment decisions, 
through more accurate determination of overall risk status. The understanding of 
risk factors and their relationship to the incidence of CAD evolved from 
prospective epidemiological studies in United States and Europe (Dawber et al, 
1957; Report of the Working Group on Arteriosclerosis of the NHLBI, 1981; 
Cooper, 1993; American Heart Association, 1994). These studies identify 
consistent associations between characteristics observed at one point of time in 
apparently healtfiy individuals, with the subsequent development of CAD in them. 
Probably the single most important contributory factor that has been implicated 
by various epidemiological studies in the development of CAD, is hyper-
cholesterolemia. 
Cholesterol which is widely distributed in the animal kingdom occurs in 
free form (unesterified) in all cell membranes (Myant, 1981), while in the plasma 
most of the cholesterol occurs in esterified form. Cholesterol has many biological 
functions. For instance, the concentration of cholesterol influences the fluidity of 
cell membranes and thereby biological activities of the cell. The cholesterol acts as 
a precursor for the synthesis of bile acids and steroid hormones. The total body 
cholesterol is derived from two sources: (i) dietary and (ii) de novo biosynthesis. 
Cholesterogenesis mostly occurs in the liver, which also regulates the level of 
circulating plasma cholesterol and serum Upoproteins. The biosynthesis of 
cholesterol also occurs in the other organs like the intestines, adrenal cortex, 
reproductive organs and skin. Although other cells and tissues do not synthesize 
cholesterol, they have the genomic information for its synthesis. Under normal 
circumstances, these cells and tissues take up cholesterol from serum lipoproteins. 
Starting from the 2-carbon unit acetyl-CoA, the biosynthesis of the 
cholesterol proceeds to several intermediates, including mevalonate and 
isopentenyl pyrophosphate (Fig. 1.1). Isopentenyl pyrophosphate is further 
processed in a series of steps to two branched pathways, one leading to 
isopentenyl tRNA and isopentenyl adenine, and the other to fames>'l 
pyrophosphate. Famesyl pyrophosphate is in turn channeled to synthesis of 
cholesterol, ubiquinone or dolichols (Ross and Glomset, 1973; Brown and 
Goldstein, 1983). The observation that cancer cells lose feedback control of 
cholesterol biosynthesis, show elevated cholesterol levels, and exhibit a higher rate 
of cholesterogenesis provided the first indication of the link between cholesterol 
biosynthesis and cancer cell growth (Coleman and Laviets, 1981). The subsequent 
realization tiiat not only cancer cells but also preneoplastic and normal 
proliferating cells show elevated levels of cholesterol as well as higher rates of 
cholesterogenesis indicated that cholesterol biosynthesis is likely to play an 
important role not only in carcinogenesis but also normal cell growth (Rao, 1986). 
Hepatic level of cholesterol are maintained by a precised balance between 
reactions catalyzed by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-
CoA reductase, EC 1.1.1.34), cholesterol 7-a hydroxylase, acyl CoA : cholesterol 
acyltransferase and cholesteryl ester hydrolase. The first two enzymes are the rate 
limiting enzymes for cholesterol and bile acid synthesis, respectively. Acyl CoA : 
cholesterol acyltransferase catalyzes esterification of free cholesterol, whereas 
cholesteryl ester hydrolase mediates release of free cholesterol from stored 
cholesteryl esters. 
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Fig 1.1. The biosynthetic pathways of mevalonate, sterols and isoprenoid compounds. 
The primary feed-back loop for regulation of cholesterol synthesis appears 
to be at the site where HMG-CoA is converted to mevalonic acid by the rate 
limiting enzyme HMG-CoA reductase (Luskey, 1991). Cholesterol and other 
oxysterols inhibit the activity of HMG-CoA reductase. Because of the strong link 
between cholesterol and coronary heart disease and its link with cancer (Rao, 
1986), Acre is currently a renewed interest in studying the regulation of HMG-
CoA reductase and several other key enzymes in cholesterol biosynthetic pathway. 
HMG-CoA reductase regulates the synthesis of cholesterol and other 
polyisoprenoid compounds (Rodwell et al.,l916; Goldstein and Brown, 1979; 
Brown and Goldstein, 1979; Brown and Goldstein, 1980; Beg et al., 1981; Beg 
and Brewer, 1982). In mammalian cells. HMG-CoA reductase is a transmembrane 
glycoprotein with its active site facing the cytosol and a carbohydrate containing 
site oriented toward the luminal surface of the endoplasmic reticulum (Liscum et 
ai, 1983a; Brown and Simoni, 1984). HMG-CoA reductase is an approximately 
100 kDa protein (Chin et ai, 1982; Edwards et ai, 1983a; Hardeman et ai, 1983; 
Chin et ai, 1984; Beg et ai, 1985). Proteolysis of the native protein results in a 
53 kDa molecular weight fragment that contains the active site of the enzyme 
(Chin et ai, 1982; Liscum et ai, 1983a; Edwards et ai, 1983a; Hardeman et ai, 
1983; Chin et ai, 1984; Beg et ai, 1985). HMG-CoA reductase is a protein of 887 
amino acids containing three potential sites for aspargine-linked glycosylation. The 
N-terminal half of the peptide is anchored to the membrane and contains seven 
hydrophobic regions, each of which is comprised of 20 amino acids and spans the 
microsomal membrane (Chin et ai, 1984). The N-terminal lacks the signal 
sequence and the hydrophilic C-terminal half of HMG-CoA reductase contains 
the catalytic site of the enzyme (Chin et ai, 1984). Since, the catalytically active 
hydrophilic tail of the enzyme extends into the cytoplasm, it is more accessible to 
the action of modulators and permits the observed multifaceted regulation of 
HMG-CoA reductase and cholesterol synthesis. The complex homeostatic 
mechanism by which the enzyme activity of HMG-CoA reductase and cholesterol 
biosynthesis are coordinately regulated in response to various physiological stimuli 
has been extensively studied. 
Isolation, purification, and characterization of rat hepatic HMG-CoA 
reductase has been well documented (Kawachy and Rudney, 1970; Heller and 
Gould, 1973; Brown et al, 1973; Heller and Gould, 1974; Heller and Shrewsburg, 
1976; Kleinsek et al, 1977; Srikantaiah et al., 1977; Edwards et al, 1979). HMG-
CoA reductase has also been studied in several other species including chicken 
liver (Beg et al, 1978; Beg et al, 1979), human liver (Beg et al, 1982a; Beg et 
al, 1982b) and human fibroblasts (Brown and Goldstein, 1983; Beg et al, 1987). 
Several different mechanisms for the regulation of enzymes in metabolic pathways 
have been elucidated such as modulation by isosteric and allosteric effectors, 
regulation of enzyme synthesis and degradation, feed-back control, and covalent 
modification (Siperstein, 1970; Holzer and Duntze, 1971; Segal, 1973; Carlson 
and Kim, 1973; Lee et al, 1976; Greengard, 1978). Three basic control 
mechanisms for HMG-CoA reductase have been reported, (a) Long-term 
regulation, which involves the modulation of HMG-CoA reductase activity by 
changes in enzyme concentration through the regulation at transcriptional level and 
post-transcriptional regulatory mechanisms such as mRNA and enzyme protein 
degradation (Kirsten and Watson, 1974; Jakoi and Quarfordt, 1974; Chan et al, 
1981; Koizumi et al, 1982; Faust et al, 1982; Edwards et al, 1983a; Edwards et 
al, 1983b; Liscum et al, 1983b; Clarke et al, 1983; Sinensky and Logel, 1983; 
Clarke et al, 1984). For instance, the product feedback regulation by mavalonate 
(Kita et al, 1980; Brown and Goldstein, 1980; Cohen et al, 1982), in vivo 
inhibition of HMG-CoA reductase by cholesterol feeding (Arebalo et al, 1981), 
cholestyramine and mevinolin (Eisenberg and Levy, 1975), and mevalonolactone 
(Arebalo et al, 1980; Beg et ai, 1984) has been reported. Tocotrienols, a naturally 
occurring class of compounds of vitamin E family, have also been reported to 
regulate HMG-CoA reductase activity at the post-transcriptional level (Pearce et 
al, 1992; Parker et al, 1993). (b) Control of HMG-CoA reductase activity through 
changes in the membrane composition and membrane fluidity in the microsomal 
enviroimient in the immediate vicinity of the enzyme (Finkel and Volpe, 1979; 
Mitropoulous et a/., 1981; Siptal and Sabine, 1981; Richert et al, 1984). (c) Short-
term regulation, that involves reversible covalent modification (phosphorylation 
and dephosphorylation) of HMG-CoA reductase (Ingebritson and Gibson, 1980; 
Beg et al, 1981; Beg and Brewer, 1982; Kennelly and Rodwell, 1985). Three 
separate kinase systems for the regulation of HMG-CoA reductase involving short-
term covalent modification have been demonstrated (Ingebritson and Gibson; 
1980, Beg et ai, 1987). Studies involving incubation of rat hepatocytes with 
insulin and glucagon or administration of glucagon to rats have been shown to 
modulate the bicyclic cascade system involving phosphorylation of both HMG-
CoA reductase and HMG-CoA reductase kinase (Ingebritson and Gibson, 1980; 
Gibson, 1985; Beg et al, 1987; Gibson and Parker, 1987). 
Altiiough cholesterol is essential to life, excess or deficit of fi^ee cholesterol 
is known to be harmful. Several factors are known which cause an overall increase 
in cholesterol concentration in the liver (Fig. 1.2) (i) uptake of lipoproteins by 
receptor mediated endocytosis, (ii) non-receptor mediated intake of lipoproteins, 
(iii) uptake of fi-ee cholesterol fi-om the cholesterol rich lipoproteins by cell 
membranes, (iv) de novo synthesis of cholesterol, and (v) hydrolysis of cholesterol 
esters by cholesteryl ester hydrolase. Under above situations, not only increased 
cholesterol levels inhibits its own synthesis by inhibiting HMG-CoA reductase and 
suppressing low-density lipoprotein (LDL) receptors (Russel, 1983), but also by 
activating cholesterol 7-a hydroxylase and acyl CoA : cholesterol acyltransferase 
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Fig. 1.2. A model for plasma triacylglycerol and cholesterol transport. 
(Adapted frcMii Biochemistry by D. Voet and J.G. Voet, J. Willey and sons. New York, 1990 
ed., p-306). 
which utilize free cholesterol for bile acid synthesis and formation of cholesteryl 
esters, respectively. Conversely, some factors are involved in the decrease of 
hepatic cholesterol, they are (a) efflux of cholesterol from membrane to nascent 
high-density lipoproteins (HDL) and HDL3 which is catalyzed by lecithin : 
cholesterol acyltransferase, (b) esterification by acyl CoA : cholesterol acyltrans-
ferase and (c) utilization of cholesterol for synthesis of steroids and bile acids. 
Under these conditions increase in cholesterol is achieved by activation of HMG-
CoA reductase and cholesteryl ester hydrolase activities as well as induction in 
synthesis of LDL receptors in order to receive cholesterol from non-hepatic tissues 
by receptor mediated endocytosis (Fig. 1.2). However, under normal conditions an 
intricate balance is maintained between the biosynthesis, utilization and transport 
of cholesterol, keeping its harmful effects to minimum. 
Lipids are transported through plasma compartment in lipoproteins, which 
are complex water soluble molecules consisting of a core of cholesteryl esters and 
triacylglycerols (TAG) covered by a surface monolayer of phospholipids, free 
cholesterol and apolipoproteins. In the last two decades, tiiere have been major 
advances in our understanding of the role of plasma lipoproteins, apolipoproteins, 
lipolytic enzymes, and lipoprotein receptors in cholesterol and lipoprotein 
metabolism. This new information has provided major insights into the role of 
cholesterol and lipoproteins in the pathogenesis of premature atherosclerosis. 
There are six major classes of human plasma lipoproteins, these include 
chylomicrons, very low density lipoproteins (VLDL), intermediate-density 
lipoprotein (IDL), low-density lipoprotein (LDL), high density lipoprotein (HDL) 
and lipoprotein (a) [Lp(a)] (Gofinan et al, 1954; Berg et al., 1974). HDL can be 
fiirther separated by hydrated density into HDL2 and HDL3. These lipoproteins are 
distinguished on the basis of their lipid content, ultra-centrifiigation size, 
electrophoretic mobility and surface proteins. 
Fourteen major human plasma apolipoproteins have been identified and 
their gene and protein structures determined (Brewer el al., 1988). The five most 
clinically relevant apolipoproteins are A-1, B-lOO, B-48, C-Il and E. The two 
major apolipoproteins on HDL are apoAl and apoAII (Oran et al, 1983; Suzuki et 
al, 1983). In human plasma apoB exist as two isoproteins designated apoBlOO 
and apoB-48, with molecular weights of 512 and 250 kDa, respectively (Kane et 
al, 1980; Kane, 1983). ApoB-48 and apoB-100 are the principal structural 
apolipoproteins on chylomicrons, VLDL, IDL and LDL. ApoB-100 is virtually the 
only apolipoprotein on LDL. 
Over the last decade three major physiological functions for the plasma 
apolipoproteins have been identified. 
(i) Apolipoproteins functions as structural proteins for the biosynthesis and 
secretion of plasma lipoproteins. ApoB-100 and apoB-48 are required for the 
secretion of TAG-rich lipoproteins fi-om the liver and intestine. ApoA-I has been 
proposed to be an important structural protein for the biosynthesis of HDL. 
Individuals with an inability to synthesize and secrete apoA-I have a virtual 
absence of plasma HDL (Narun et al, 1982; Schaefer et al, 1985). 
(ii) Apolipoproteins fimction as cofactors or activators of enzymes involved in 
lipid and lipoprotein metabolism. ApoC-Il is required for the enzymic activity of 
lipoprotein lipase, which is responsible for the perivascular hydrolysis of 
lipoprotein TAG to fi-ee fatty acids and monoacylglycerols (La Rosa et al, 1970; 
Havel et al, 1970). Lipoprotein lipase is attached to the capillary endothelium by a 
heparin-like proteoglycan allowing direct interaction of the enzyme with the 
circulating TAG-rich lipoproteins. A deficiency of lipoprotein lipase or apoC-II 
results in defective TAG hydrolysis (Breckennidge et al, 1978). Clinically, 
patients have eruptive xanthomas, severe hypertriglyceridemia and recurrent bouts 
of pancreatitis. ApoA-I activates lecithin : cholesterol acyltransferase, which 
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catalyzes the esterification of plasma cholesterol to cholesteryl esters (Fielding et 
al, 1972). 
(iii) Apolipoproteins also play a critical role in lipoprotein metabolism as ligands 
on lipoprotein particles which interact with cellular receptors for specific 
lipoproteins. ApoB-100 interacts with the LDL receptor to initiate absorptive 
endocytosis and cellular uptake of LDL (Brown and Goldstein, 1986). ApoE has 
been proposed to interact with apoE receptor which facilitates the hepatic removal 
of lipoprotein renmants secreted by the intestine and liver (Davignan et al, 1988; 
Uerzetai, 1988). 
The metabolic relationship of the major classes of lipoproteins containing 
apoB-48 and apoB-100 may be considered to consist of two major "apoB 
cascades". The fu-st apoB cascade involves the stepwise delipidation of TAG-rich 
chylomicrons secreted by the intestine. These hpoproteins transport dietary 
cholesterol and TAG from the intestine to the liver and peripheral tissues. Shortly 
after secretion, chylomicrons acquire apolipoproteins C-II and E primarily from 
HDL. As ah-eady outlined, apoC-II activates lipoprotein lipase, which initiates 
TAG hydrolysis and remodeling of the lipoprotein particles. With TAG hydrolysis 
of the hydrated density the chylomicrons increases and chylomicron remnants are 
generated with a hydrated density of VLDL and then IDL. Chylomicron remnants 
are removed primarily by a hepatic remnant receptor (Davignan et al., 1988) ApoE 
has been proposed to interact and initiate the hepatic uptake of the chylomicron 
remnants (Davignan et al., 1988; Hertz et al., 1988). The second apoB cascade is a 
parallel cascade involving TAG-rich VLDL containing apoB-100 secreted by the 
liver. ApoC-n and apoE from HDL rapidly associate with the newly secreted 
hepatogenous VLDL. ApoC-D activates hpoprotein lipase, which hydrolyzes 
VLDL triglycerides, and the VLDL are serially converted to smaller VLDL 
remnants, IDL, and fmally LDL. During die conversion of VLDL to LDL 
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approximately 50 per cent of VLDL remnants and IDL are removed directly from 
the plasma by interaction of apoE and apoB-100 with the remnant and LDL 
receptors. 
Another lipolytic enzyme, hepatic lipase and apoE have also been proposed 
to be necessary for the conversion of IDL to LDL. Hepatic hpase functions as both 
a triglyceryl hydrolase and phospholipase. LDL, the end product of the VLDL 
cascade, contains almost exclusively apoB-100 as its only protein constituent. 
ApoB-100 on LDL interacts with LDL receptor on the plasma membrane of cells 
in the liver, adrenal and peripheral cells, including smooth muscle cells and 
fibroblasts (Brown and Goldstein, 1986), where it supplies cholesterol to the 
intracellular cholesterol pool. The work of Brown and Goldstein (1979 & 1983) on 
the cellular metabolism of LDL elucidated the LDL Pathway. The high affinit>' 
receptors bind LDL particles and extract them from the fluid that bathes the cell. 
LDL is transported to lysosomes where the protein is degraded and the cholesterol 
is transferred to the intracellular cholesterol pool (Brown and Goldstein, 1986). 
The receptors displayed on the surface of the cells varies with the cellular demand 
for cholesterol. When the need is low, the cells make fewer receptors and take up 
LDL at a reduced rate, this protects the cells excess cholesterol but at a higher 
price, the reduction in the number of receptors decreases the rate of removal of 
LDL from the circulation, blood level of LDL rises and atherogenesis is 
accelerated. LDL receptor play an important role in the maintenance of plasma 
LDL-cholesterol levels. The serum concentration of LDL, therefore, depends on 
the rate that liver removes IDL from the circulation which intum, depends on the 
number of fimctioning LDL receptors on the liver cell surface (Fig. 1.3a). High 
blood cholesterol which results from the overproduction and/or underutilization of 
LDL, is known to be caused by two metabolic irregularities (i) the genetic disease 
familial hypercholesterolemia (discussed in detail later); (ii) the consumption of 
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high cholesterol diet. Familial hypercholesterolemia (FH) (Fig. 1.3b) is a dominant 
genetic defect that results in a deficiency of functional LDL receptors. FH 
homozygotes, therefore have plasma LDL-cholesterol levels tiiree to five times 
higher than average. FH heterozygotes, which are far more conmion, have about 
one half of die normal number of functional receptors and plasma LDL-cholesterol 
levels of about twice the average. The ingestion of a high cholesterol has an effect 
similar, although not as extreme, as FH (Fig. 1.3 c). Excessive dietary cholesterol 
enters the hver cells in chylomicron renmants and repress the synthesis of LDL-
receptor protein. The resulting insufficiency of LDL-receptors on the liver cell 
surface has consequenses similar to those of FH. In WHHL rabbits, with a genetic 
deficiency of LDL receptor function, extremely high plasma LDL cholesterol 
levels are observed with the development of atherosclerosis early in life (Brown 
and Goldstein, 1983). LDL receptor activity is under the metabolic regulation in 
vivo, such that receptor activit>' can be increased or decreased by appropriate 
interventions with diet and/or drugs (Mahley and Innerarity, 1983; Brown and 
Goldstein, 1983). 
Nascent HDL, primarily in the form of phospholipid-apolipoprotein A-I 
discs, are synthesized both in the human liver and intestine. The nascent HDL 
acquire cholesterol from tissues and the enzyme lecithin cholesterol 
acyltransferase catalyzes the esterification of cholesterol to cholesteryl esters. 
With the increase in hpid content the nascent HDL are converted to HDL3, these 
HDL3 lipoproteins are then converted to the larger HDL2 lipoproteins by the 
acquisition of lipids and apolipoproteins released during the stepwise delipidation 
and remodeling of the TAG rich chylomicrons and VLDL as well as the uptake of 
cholesterol fi-om peripheral tissues. HDL2 is converted back to HDL3 by the 
removal of TAG and phospholipids by hepatic lipase as well as by the transfer of 
cholesteryl esters into VLDL and LDL by the cholesteryl ester exchange protein 
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(or lipid transfer protein) as well as the transfer of cholesteryl esters to the liver 
and other tissues. In this overall process, HDL are interconverted from HDL3 to 
HDL2 and back to HDL3 as cholesterol is picked up and transferred from 
peripheral tissues to the liver (Fig. 1.4). This process is termed as reverse 
cholesterol transport (Brewer et al., 1971; Eisenberg, 1984). In this proposed 
model, HDL interacts with a putative HDL receptor (Oran et al, 1983; Suzuki et 
al, 1983; Schmitz et al, 1988) that facilitates the transfer of intracellular 
cholesterol to HDL. HDL transports this cholesterol in plasma and dehvers it to 
the liver via the HDL receptor for removal from the body by direct secretion into 
bile or following conversion to bile acids. A variable portion of tissue cholesterol 
has been proposed to be transported to the liver by HDL particles containing apoE, 
which ma>' interact with the hepatic remnant and LDL receptors (Eisenberg, 1984). 
Atherosclerosis, which is the most common form of arteriosclerosis 
(hardening of arteries), is characterized by the presence of atheromas. These 
atheromas or arterial thickenings exude a paste of yellow deposit of almost pure 
cholesteryl esters upon sectioning. Atherosclerosis is a progressive disease and 
results due to the deposition of intracellular lipids in the smooth muscle cells of the 
inner arterial wall. These lesions narrow and eventually block the arteries due to the 
formation of fibrous, calcified plaques. The rough arterial wall promotes the 
formation of blood clots, which may also block the artery. Due to the blocking of 
arteries, blood flow stops and causes the death of the deprived tissues. The stoppage 
of blood flow is known as an infarction. Atheromas mostly occur in the arteries 
supplying blood to the heart known as coronary arteries. This results in myocardial 
infarctions or heart attacks, which is the most common cause of death in Western 
man (Packer and Landvik, 1989). The earliest lesions of atherosclerosis can be found 
in young children and infants in the form of a lesion called ^t fatty streak, whereas 
the advanced lesion, the fibrous plaque, generally appears during early adulthood 
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and progresses with age (Geer et ai, 1961; Geer, 1965; Ghidoni and Oniel, 1967; 
Stary, 1983; Staiy et ai, 1994; American Heart Association, 1994). Fatty streaks 
were first obsened by Stary (1983), he demonstrated that by the age often years, the 
fatty streaks consisted principally of lipid laden macrophages and smooth muscle 
cells and appears as yellow coloured area due to large amount of lipid filled foam 
cells. The bulk of lipid is generally formed by cholesteryl esters, cholesterol derived 
firom lipoproteins. 
Stary (1983) also studied fatty streaks in coronary arteries of children and 
young adults and observed that they were localized at same anatomical sites as the 
fibrous plaques did in older individuals. Based on this observation he concluded 
that the fatty streak with age advanced to form the mature fibrous plaque in adults. 
Chemical analysis of severe atherosclerotic plaques fi"om humans and animal 
models indicate that on an average, fiilly developed atheromas are composed of 
about one half lipid and one half protein, including the cellular and extra cellular 
proteins, however, there may be great variations in these elements. 
Two decades ago, atherosclerosis was considered to be a degenerative 
process because of the accumulation of lipid and necrotic debris in the advanced 
lesions, it is, however, now recognized that it is infact a multifactorial phenomena. 
The form and content of the advanced lesions of atherosclerosis demonstrates 
results of three fundamental biological processes; accumulation of intimal smooth 
muscle cells, together with variable numbers of macrophages and T-lymphocytes, 
formation of large amount of connective tissue matrix, including collagen, elastic 
fibers, and proteoglycans by the proliferated smooth muscle cells and accumula-
tion of lipids, principally in the form of cholesteryl ester and fi^ee cholesterol 
within the cells as well as in the surrounding tissues. (Ross and Glomset, 1973; 
Ross and Glomset, 1976; Fuster et ai, 1992; Ross and Fuster, 1996). 
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Jackson and Gotto (1976) have suggested that injury to endothelial cell 
membrane at arterial wall, may occur upon exposure to chronically elevated levels 
of LDL due to an increase in the number of cholesterol molecules in plasma 
membranes of cells, including endothelial cells. Elevation of the cholesterol/ 
phospholipid ratio of endothelial cell plasma membrane can theoretically lead to 
an increase in the viscosity and decrease in the malleability of endothelial cell 
surface, which has a critical effect at particular anatomical sites, such as points of 
bifurcation in the arterial tree. This could lead to inter-endothelial cell separation 
and retraction particularly at the sites where the blood flow is modified due to the 
formation of fatty streaks, as has been found in hypercholesterolemic monkeys, 
swine and humans. 
Repeatedly epidemiological studies have established a strong association 
between elevated blood cholesterol and CAD. Risk for CAD is increased with 
increasing plasma cholesterol levels and can be decreased by decreasing plasma 
cholesterol. One of the important observational study demonstrating a positive 
relation between total cholesterol level and CAD mortality was "The Multiple Risk 
Factor Intervention Trial'" (Stamler et al, 1986). It was observed that in Japan and 
some other Mediterranean countries, where the dietary intake of saturated fat and 
mean plasma cholesterol level was relatively low, the mortality rate for CAD was 
also low. As against this, countries like Finland and United States, with a high 
average plasma cholesterol levels showed a higher CAD mortality' rate (Keys, 
1970). An important interventional study on primary prevention of CAD was the 
Lipid Research Clinic Coronar>' Primary Prevention Trial. The hypercholestero-
lemic subjects of this study received either bile acid sequestrant, cholestyramine or 
a placebo (LRCP, 1984a). The cholestyramine group, showed significant 
reductions in LDL-cholesterol. Incidence of non-fatal myocardial infarction and 
CAD death was also reduced significantly (LRCP, 1984b) in this group. The result 
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of Lipid Research Clinic Coronary Primary Prevention Trial provided the first 
major clinical substantiation to the lipid hypothesis, and were also the first to give 
rise to the rule of thumb that a 1% decrease in total cholesterol reduces the 
incidence of CAD events by 2 to 3%. 
Increased plasma levels of three lipoproteins, LDL (Gorton et al, 1977; 
Castelli et al, 1977), p-VLDL (Mehley, 1979; Brewer et al, 1983) and Lp(a) 
(Berg et al, 1974; Kostner et al, 1981; Armstrong et al, 1986) and decreased 
levels of HDL (Castelli et al, 1977; Miller et al. 1977; Naito, 1980; Yaari et al, 
1981) have been associated with the development of premature cardiovascular 
disease. Increased plasma levels of LDL may result fi^om ingestion of excess 
dietary saturated fat and cholesterol as well as fi'om primary and secondary 
hyperlipoproteinemias. P-VLDL are abnormal lipoprotein remnant particles 
present in patients with type-Ill hyperlipoproteinemia and animals fed a high 
cholesterol and fat diet (Mahley, 1979; Havel, 1982; Brewer et al, 1983). 
(3-VLDL remnant lipoproteins have been proposed to be taken up by macrophages 
by either the LDL receptor (Koo et al, 1988) or a specific macrophage P-VLDL 
receptor (Venlenter et al, 1983; Baker et al, 1984). Elevated levels of Lp(a) are 
genetically determined and associated with an increased risk of premature 
cardiovascular disease (Berg et al, 1974; Kostner et al, 1981; Armstrong et al, 
1986). The mechanism for the potential cellular uptake of Lp(a) and the 
development of premature cardiovascular disease is not known. Over the past 
30 years a considerable body of evidence has accumulated to establish that an 
elevated concentration of the Lp(a) lipoprotein, commonly referred to as 
"lipoprotein little a" in plasma is an important independent risk factor for the 
development of premature cardiovascular disease (Berg et al, 1974; Kostaer; 
1981; Armstrong et al, 1986). Lp(a) levels in plasma range from less than 1 to 
more than 100 mg/dl. Approximately 20 per cent of the population have levels 
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above 30 mg/dl; this is associated with a twofold increase in tfie relative risk of 
coronary atherosclerosis. With elevations of both Lp(a) and LDL. the relative risk 
of vascular disease increases to approximately fivefold (Armstrong el al, 1986). 
An inverse association has been established between HDL-cholesterol level 
and CAD incidence in numerous epidemiological studies. For example, in the 
Framingham Heart Study, men and women with HDL-cholesterol of 35 mg/dl or 
less had an eight fold increase in CAD incidence compared with men and women 
with HDL-cholesterol of 65 mg/dl or greater (Gordon el al. 1977). Women have 
significantly higher plasma levels of HDL2 than men (James and Pometta, 1990); 
increased levels of these larger, less dense particles may be partially responsible 
for the relative cardioprotection seen in premenopausal women. Each 1 mg/dl 
increase in HDL-cholesterol is estimated to decrease CAD risk 2 per cent in men 
and 3 per cent in women (Gordon ei al, 1989). The low HDL in men with 
clinically significant CAD is due to a reduction in both HDL2 and HDL3; however, 
the reduction in HDL2 is greater than that in HDL3 (Miller et al, 1981b; Laakso et 
al, 1985; Wallentin and Sundin, 1985; Hamsten et al, 1986). These studies 
support the concept that HDL: is a better predictor of coronary artery disease than 
is HDL3 (Drexel et al, 1992). The question, however, as to whether quantitation 
of HDL2 as a screening test is superior to total HDL-cholesterol has not been 
definitively answered due to variability in results of the indi\idua] reported 
studies. 
The results of the studies in which apoA-I was evaluated as a discriminator 
for CAD also do not permit a definitive conclusion to be drawn as to whether 
apoA-I is a better discriminator than HDL-cholesterol. In the majority of patients 
with angjographically documented CAD or survivors of myocardial infarction, 
plasma apoA-I concentrations were lower than control groups (Bnmzell et al, 
1984; Miller, 1987; Alauporic et al, 1988). In some studies apoA-I has been 
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shown to be a better discriminator than lipids and hpoprotein cholesterol levels in 
identifying patients with CAD, while in other studies the apoB/apoA-1 ratio 
appeared to be an even more powerful predictor than the individual lipoproteins 
(Brunzell et al, 1984; Miller, 1987; Alauporic et al., 1988). However, in other 
studies HDL-cholesterol was found to be a better predictor than apoA-I (Brunzell 
et al., 1984; Miller, 1987; Alauporic ei al., 1988). 
The relation between plasma TAG and CAD is not as well established as 
the relation between plasma cholesterol and CAD. Epidemiological evidence, 
however, suggests that TAG plays an important role in determining CAD risk. In 
Helsinky Heart Study (Manninen et al., 1992) it was established that the relative 
risk for cardiac events was significantly more in the subgroup with a higher TAG 
and LDL cholesterol : HDL cholesterol ratio as compared to the subgroup with 
lower TAG and LDL cholesterol : HDL cholesterol ratio. Diabetes is frequently 
associated with hypertriglyceridemia, and is ofiten combined with reduced HDL-
cholesterol (Haward, 1987). Recently, there has been increasing evidence of an 
association between TAG and increased risk of cardiovascular disease (Austin, 
1991), a risk that is especially high in subjects with low HDL-cholesterol (Castelli, 
1986). One of the major causes of hypertriglyceridemia with low HDL-cholesterol 
in diabetes is the decrease in lipoprotein lipase activity, an enzyme that plays 
crucial role in both TAG removal and HDL-cholesterol production, due to insulin 
deficiency, because lipoprotein lipase is known to be an insulin-dependent enzyme 
(Garfinkel et al., 1976; Murase et al., 1981). 
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A classification of dyslipidemias as recommended by Fredrickson is shown 
in Table A. 
Table A 
Phenotype 
I 
na 
lib 
III 
IV 
V 
Lipoprotein(s) 
Elevated 
Chylomicrons 
LDL 
LDL and VLDL 
IDL 
VLDL 
VLDL and 
chylomicrons 
Plasma 
Cholesterol 
Level 
Normal to T 
n 
n 
n 
Normal to t 
t to Tt 
Plasma 
Triglyceride 
Level 
Tttt 
Normal 
Tt 
t t t 
Tt 
t t t t 
Atherogenecity 
Not seen 
+ + + 
+ + + 
+ + + 
+ 
+ 
(Source: International Lipid Information Bureau: The ILIB Lipid Handbook for Clinical Practice: 
Blood Lipids and Coronan> Heart Disease. Houston, International Lipid Information Bureau, 1995). 
Elevated levels of plasma apoB and LDL cholesterol may be due to dietary excess, 
genetic hypercholesterolemias or other diseases. Approximately 10 per cent of the 
patients with hypercholesterolemia have a monogenic disease causing elevated 
plasma LDL levels. The monogenic disease, familial hypercholesterolemia, is an 
autosomal codominant disease characterized clinically by tendon and tuberous 
xanthomas, arcus, xanthelasma and premature cardiovascular disease (Brown and 
Goldstein, 1986). The molecular defect in familial hypercholesterolemia is one of 
several mutations in the gene coding for the LDL receptor (Brown and Goldstein, 
1986). The deficiency of the LDL receptor leads to a decreased rate of removal of 
plasma LDL. The reduction in the number of LDL receptors has been previously 
demonstrated to be proportional to the elevated levels of plasma LDL (Sprecher et 
ai, 1985). The fi^equency of familial hypercholesterolemia is approximately 1 in 
500 and the heterozygotes and homozygotes have plasma LDL cholesterol levels 
>250 mg/dl and >750 mg/dl, respectively. Plasma apoB levels are usually greater 
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than 140 mg/dl. The clinically important complication of familial hypercholes-
terolemia is premature atherosclerosis. In homozygous patients coronary and 
myocardial infarctions are frequent in young adults. For heterozygous men, the 
chance of having a myocardial infarction is approximately 5 per cent by age of 30, 
51 per cent by the age of 50 and 85 per cent by 60. 
Familial combined hyperlipidemia is probably the most frequent monogenic 
dyslipoproteinemia (frequency 1 in 300) in the population associated with an 
increased risk of premature cardiovascular disease (Goldstein et al., 1973; Rose et 
ai, 1973). Clinically the patients may have arcus and xanthelasmas; however, 
tendon xanthomas are rare and this may be used as a diagnostic clue to distinguish 
these patients from patients with familial hypercholesterolemia. Plasma cholesterol 
and TAG levels are generally moderately elevated. A characteristic feature of 
combined hyperlipidemia is that the lipoprotein elevation is variable and may 
change from elevated LDL (phenotype Ila) to VLDL and LDL (phenotype Ifb) and 
VLDL (phenotype IV). In addition, several different phenotypes may be observed 
in a single family. In contrast to familial hypercholesterolemia, the cholesterol 
levels may not be elevated in childhood and the hyperlipidemia frequently is not 
expressed until after age 30. 
The molecular defect(s) in combined hyperlipidemia has not been 
elucidated. In the patients studied, the characteristic metabohc defect is the over 
production of apoB-containing lipoproteins (Tenz et al, 1986). The LDL present 
in patients with combined hyperlipidemia is abnormal in hydrated densitv' and 
lipid composition. The "dense LDL" characteristic of combined hyperlipidemia 
has a hydrated density of approximately 1.055 gm/ml and has a ratio of LDL 
cholesterol to LDL apoB of < 1.3 as compared with a normal ratio of >1.3 
(Sniderman et al, 1980; Krauss et al, 1988; Mushner and Krauss, 1988). The 
LDL apoB level in these patients is usually >120 mg/dl. The presence of "dense 
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LDL" may be an important causative factor in tiie development of atherosclerosis 
observed in these patients. Elevated plasma level occur in type III hyperlipopro-
teinemia and in experimental animals fed diets high in cholesterol and saturated fat 
(Mahley, 1979; Havel, 1982; Brewer et al, 1983). Epidemiological studies have 
established a correlation between the apoE phenotype and alterations in the plasma 
level of remnant lipoproteins, apoB and LDL cholesterol (Davignan et al, 1988). 
Recent studies in non-human primates have demonstrated injury by free 
radicals as another possible mechanism of initiation of atherogenesis, which was 
protected by the antioxidant, probucol (Sasahara et al, 1994). The fact that 
probucol prevents the formation of fatty streaks and suppresses the inflammatory 
processes required for lesion development bears evidence to this effect. These 
studies have provided new insights into the role of oxidation and other chemical 
modifications of LDL, such as glycation in the process of atherogenesis. In 
particular, the oxidative modification of LDL enhances its atherogenecity 
(Steinberg, 1988; Duthie et al, 1989; Palinski et al, 1989). Recent studies have 
demonstrated that oxidized lipids, especially oxidized fatty acids and cholesterol in 
the diet are atherogenic (Staprans el al, 1998). 
Thus, even though oxidative metabolism clearly has many advantages, but 
free radicals generated through this process are highly reactive and can damage 
innocent bystander molecules, such as DNA, proteins, lipids, and carbohydrates 
(Southom and Povis, 1988). The unpaired electron in the outer shell of free 
radicals is in a high energ\ state and determines its high reactivity. Oxygen free 
radicals found in biological systems include the superoxides, hydroxyl, and 
hydroperoxyl radical. Hydrogen peroxide though not in itself a free radical, easily 
produces oxygen free radicals. Singlet oxygen is another highly reactive species 
that gets transformed into free radical by absorption of a single photon. These 
oxygen free radicals will oxidize any nearby molecule, such as fatty acid, in an 
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attempt to shed the high energy electron. Free radicals initiate lipid peroxidation, a 
chain reaction resulting in the formation of a new fatty acid free radical which will 
in turn attack another fatty acid and in the process transform it into a lipid 
hydroperoxide. This propagation reaction initiated by a single free radical results 
in damage to thousands of fatty acid molecules. Free radical reactions terminate 
when two free radicals meet and combine in such a way that their unpaired 
electrons bind together. 
As humans evolved to use oxidative metabolism, many mechanisms have 
been developed to control this process and minimize random free radical 
oxidation. Firstly oxidative metabolism is compartmentalized for example, in the 
mitochondria. Secondly molecular oxygen and its reactive free radical species are 
tightly bound to en2ymes, as in case of the cytochrome systems during oxidative 
phosphorylation. Thirdly in order to pre\ent free radical formation, transition 
metals like copper and iron which in the free form catalyze free radical formation, 
are tightly bound to transport and storage proteins. Fourthly several enzymes exist 
within the cells to neutralize free radicals. Superoxide dismutase catalyses the 
transformation of superoxide radicals to h\ drogen peroxide. Similarly, catalase 
and glutathione dismutase neutralize hydrogen peroxide and fatty acid radicals. 
Finally damage caused by oxidation can be repaired by specific enzymes. 
If, however, inspite of the availability of all the above mentioned protective 
mechanisms against oxidative damage, due to any reason, the free radical 
peroxidation of LDL Upids occurs, it results in numerous structural changes, all 
depending on a conmion initiating event i.e., peroxidation of polyunsaturated fatty 
acids on LDL (Jurjens et al, 1987; Steinbrecher et al., 1990). Also, all the major 
cells of arterial wall (endothelial cells, macrophages, smooth muscle cells) can 
oxidatively modify LDL. Both forms of oxidised LDL are taken up more avidly by 
the macrophages than the LDL itself and this aviditiy appears to be facilitated by 
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scavenger receptor mechanism (Juijens et al, 1987; Steinbrecher et al, 1990). The 
biological efifects of oxidised LDL reported to date could contribute to initiation 
and progression of atherosclerotic process. Oxidised and partially oxidised LDL 
itself or the oxidised products derived from it can have a number of deleterious 
effects, including chemotaxis for monocytes (Qureshi et al, 1991), inhibition of 
nitric oxide mediated relaxation of coronary tone (Schaefer et al, 1995). To 
summarise, recognition of uncontrolled uptake of oxidised LDL by macrophages 
leads to a chain of biochemical events which can result in ttie formation of foam 
cells, fatt\ streaks and later atherosclerosis. 
Pharmacological control over cholesterol biosynthesis has long been sought 
as a means for regulating the amount of cholesterol in the blood and for the 
prevention and treatment of atherosclerosis (Kolata, 1983). Probucol has been 
reported to effectively reduce plasma cholesterol in human and a number of animal 
species (Miettinen and Toinonen, 1975; Martz, 1979; Sunson et al, 1981). It also 
affects the composition and in vitro catabolism of LDL in Type Ila hypercholes-
terolemia (Baudet et al, 1986). It increases the activity of plasma lipoprotein 
Hpase and decrease HDL- and LDL-cholesterol concentration in rats. Probucol 
prevents the development of macrophages into foam cells by inhibiting the lipid 
storage in macrophages (Yamamoto et al, 1986a). These observations probably 
accounts for the clinical findings that probucol causes a more marked regression of 
xanthomas than would be expected from the of lowering of LDL-cholesterol levels 
alone. Probucol seems to act by increasing LDL removal from the plasma by an 
LDL receptor independent mechanism (Kasaniemi and Grundy, 1984), as it causes 
moderate reduction in LDL-cholesterol in non-familial hypercholesterolemia 
(Sunson et al, 1981) and a smaller decrease in familial hypercholesterolemic 
patients (Durrington and Miller, 1985; Fellin, 1986). A marked decrease in 
cholesterol has been constant finding (Kasaniemi and Grundy, 1984; Fellin, 1986) 
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but circulating HDL-cholesterol in probucol treated patients is less than in controls 
(Yamamoto et al, 1986b), which minimizes the use of probucol as a 
h>pocholesterolemic agent. 
Fibrates are orally active compounds with relative long plasma half life. 
Among fibrates, clofibrates, with combined maximal effectiveness and minimal 
toxicity in the initial screen, was widely used in the management of 
h>perlipoproteinemia in humans. More recently, however, due to questionable 
acti\ity in the secondary prevention of atherosclerosis (Coronary Drug Project, 
1975) and to the observation of untoward effects in primary prevention 
(Committee of Principal Investigators. 1978), the use of clofibrates has become 
limited. Among side effects, proliferation of peroxisomes in rodents has been a 
key target for chemical and pharmacological studies. A number of clinical trials 
have constantiy shown that clofibrates reduces plasma TAG levels substantially, 
affecting both VLDL and LDL associated TAG. This reduction is more evident in 
hypertriglyceridemic patients but less marked in normotriglyceridemic subjects 
(Hunninghake et al, 1981; Crouse and Grundy, 1981). 
Halofenate, structurally related to clofibrate, is hypolipidemic and 
hypourecemic (Sirtory et al, 1972) and is effective in lowering serum TAG in rats 
(Kovanen et al, 1981). Bezafibrate, a fibric acid derivative, has been reported to 
lower plasma TAG in hypertriglyceridemic patients (Eisenberg et al, 1984) and 
was effective in reversing most if not all, of the abnormalities in lipoprotein 
compositions, structure and function detected in these patients. Fenofibrate, 
another analogue, is more potent than the previously described compounds, being 
fiilly active at a daily dose of 300 mg (Rossner and Oro, 1981). It is markedly 
effective in patients with type 11 and IV hyperlipidemias (Franceschini et al, 1985) 
as well as in subjects with familial combined hyperlipidemia (Weisweiler et al, 
1984) in decreasing total plasma cholesterol and TAG levels. However, HDL-
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cholesterol levels were unchanged in type 11 and combined hyperlipidemia 
(Mahnendier and Delcroise, 1985). The mechanism of hypolipidemic effect of 
fenofibrate is different from that of parent compound involving its effect on 
lipoproteins as seen in subjects with familial hypercholesterolemia as well as 
combined hyperlipidemia. 
Nicotinic acid is possibly the oldest lipid lowering drug. Large doses of this 
drug rapidly reduce plasma TAG by lowering VLDL in normal and sucrose diet 
fed mice (Oliver et ai, 1988). The reduction in TAG was reported to be due to 
decreased production of VLDL (Grundy et al, 1981). To overcome the difficulty 
of obtaining adequate compliance with nicotinic acid treatment, because of drug's 
numerous side effects, several analogues and derivatives have been tested but no 
clear advantages have been gained over the parent drug (Cretaldi et al., 1988). 
An alternate approach to the control of cholesterol level is the use of bile 
sequestrant resin, such as cholestyramine. The mode of action of bile acid binding 
resin is apparently fairly simple: bile acids, which are bound to these resins in the 
intestinal lumen are not reabsorbed, and are excreted with faeces. These 
sequestrant agents thus interfere with the enterohepatic circulation of bile acids, 
and since bile acids are synthesized in the liver from cholesterol, cholesterol 
catabolism is enhanced. After prolonged treatment h>'pocholesterolemia is 
observed. Homozygous t>'pe II patients are insensitive to cholestyramine inspite of 
increased level of fecal bile acids (Moutafis et al., 1971). The LDL pathway 
receptor plays a role in the action of bile acid binding resin (Shepherd et al., 
1980). 
An encouraging development in the treatment of h>'percholesterolemia has 
been the introduction of a new class of fimgal-derived compounds that are potent 
competitive inhibitors of HMG-CoA reductase. These drugs are extremely 
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effective in lowering plasma concentrations of LDL-cholesterol. The development 
of these specific inhibitors of HMG-CoA reductase has considerably widened the 
therapeutic opportunities in h>percholesterolemic patients. Compactin and 
lovastatin (mevinolin) are potent competitive inhibitors of HMG-CoA reductase. 
The molecular structure closely resemble the HMG moiety of HMG-CoA, and the 
enzyme HMG-CoA reductase binds both the compounds with high affinity 
(PaoUetti and Poli, 1987). These drugs have been used to reduce plasma 
cholesterol levels in many animal species (Alberts et ai, 1980; Kovanen et ai, 
1981; Tobert et al, 1982). In clinical studies, lovastatin and compactin effectively 
reduce plasma LDL in normal (Tobert et al, 1982) as well as in subjects with 
heterozygous familial hypercholesterolemia (Bilheimer et al, 1983). A 
compensatory increase in the receptor mediated catabolism of LDL also occurs 
(Grundy and Bilheimer, 1984). In patients with type Ila and type lib 
hypercholesterolemia, reduction in serum cholesterol was reported after lovastatin 
treatment. Goldstein and Brown (1984a) proposed tiiat statins (compactin, 
lovastatin and simvastatin) lower plasma LDL cholesterol by inhibiting cholesterol 
biosynthesis and increasing the number of LDL receptors. Although an increase in 
HDL levels has also been reported in several studies (Hoeg et al, 1986; Mol et al, 
1988), others (Mabuchi et al, 1981; Illingworth and Sextan, 1984) have found no 
change in HDL levels. 
The mechanism of action of lovastatin differs from that of probucol (Helve 
and Tikkanen, 1988). Lovastatin therapy resulted in the increase of both HDL and 
HDL2-cholesterol whereas with probucol HDL-cholesterol was markedly 
decreased mainly because of reduction in HDL2. Triacylglycerols remain unaltered 
during lovastatin treatment and no significant changes in Upase activity was 
observed indicating that these enzymes were not involved in its action. 
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3-Hyclroxy-3-methylglutaric acid (HMG), which is fonned by the 
hydrolysis of HMG-CoA catalysed by HMG-CoA hydrolase in liver, is also 
known to inhibit cholesterogenesis between HNiG-CoA and mevalonate 
(Rabinowitz and Gurin, 1954) and competitively inhibit the enzyme HMG-CoA 
reductase (Fimognari and Rodwell, 1965). The hypolipidemic activity of HMG has 
been studied in rats (Yousufzai and Siddiqi, 1976a, 1977; Francesconi et al, 
1987), rabbits (Lupien et al, 1973), hamster (Padova et al., 1982) and humans 
(Lupien et al., 1973; Yousufzai and siddiqui, 1976b). A support to the 
hypolipidemic action of HMG is also obtained from the observation that low 
incidence of CHD in Massai tribesman is related to tiieir high consumption of 
cow's milk (Richardson, 1978), known to contain HMG (Mann, 1977). 
Inhibitors of HMG-CoA reductase block synthesis of cholesterol in the 
liver, thereby triggering compensatory reactions that lead to a reduction m plasma 
LDL. Much of the information about the mechanism for this reduction comes from 
studies in cell culture and in experimental animals (Groot et al., 1992). Cultured 
human fibroblasts respond to an inhibition of HMG-CoA reductase by 
accumulating increased amounts of the enzyme (Brown et al., 1978). The increase 
is attributable to an increase in the rate of transcription of the HMG-CoA 
reductase gene, an increase in the rate of translation of the mRNA, and a decrease 
in the rate of degradation of the protein. Through these compensatory mechanisms, 
cultured cells can increase the amount of HMG-CoA reductase sufficiently to 
restore rates of cholesterol synthesis almost to normal, even in the presence of 
relatively high concentrations of the inhibitor. An increase in HMG-CoA reductase 
also occurs in the livers of rabbits, hamsters, and rats (Endo et al., 1979; Tanaka et 
al., 1982) treated with these inhibitors. A similar adaptation is presumed to occur 
in humans. Hamster has been reported to respond to hypocholesterolemic drugs 
(Suckling et al., 1991) and develop atherosclerosis under appropriate conditions 
30 
(Nistor et al, 1987; Sima et al, 1990), although differences between the hamster 
and man which hamper the use of this species as a model for human 
atherosclerosis have been noted (Nikkari et al., 1991). Rats also respond to 
hypocholesterolemic drugs but in a different way to hamsters. Rats are very 
capable of modulating their hepatic cholesterol synthesis and tiiis is the first 
response to drugs such as bile acid sequestrants and HMG-CoA reductase 
inhibitors. However, hyperlipidemia can be induced and in some cases this can 
lead to atherosclerosis (Russell et al, 1990; Vance and Russell, 1990; Russell et 
al, 1991). Inhibition of mevalonate and cholesterol synthesis by inhibitors of 
HMG-CoA reductase such as mevastatin and lovastatin prevents famesylation and 
blocks cells growth (Maltese and Robishaw, 1990). It has been postulated that 
inhibitors of HMG-CoA reductase such as lovastatin used in the treatment of 
hypercholesterolemia, may also be usefiil for cancer chemotherapy (Schafer et al, 
1989). HMG-CoA reductase inhibitors and/or inhibitors of Ras famesyl : protein 
transferase could prevent famesylation of Ras proteins, inhibiting the growth of 
Ras-dependent tumour cells (Goldstein and Brown, 1990). Lovastatin and sodium 
phenylacetate, an inhibitor of isopentenyl pyrophosphate synthesis are in clinical 
trials for the treatment of malignant gliomas (Shack et al, 1994). 
One of the areas which has attracted a great deal of attention is antioxidant 
nutrition in the control of degenerative diseases such as atherosclerosis and cancer 
(Ames, 1983; Ong and Packer, 1992). Peroxidation of the cellular membrane lipids 
is a basic reaction which results in the deterioration of unsaturated fatty acids in 
the membrane. This process has been implicated in several human diseases and in 
the toxicity of xenobiotics (Yagi, 1982; Halliwell and Gutteridge, 1989; Sies, 
1991). If lipid peroxidation is triggered, it can inactivate cellular components and 
its products can have serious consequences on almost all the crucial molecules 
leading to diseased conditions (Halliwell and Gutteridge, 1989; Sies, 1991). The 
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peroxidation products can also cause the formation of 8-hydroxydeoxyguanosine 
whose presence in the genetic material can lead to mutagenesis and carcinogenesis 
(Kuchino et al., 1987; Park and Floyd, 1992). The susceptibility of tissues to lipid 
peroxidation is influenced by the lipid and antioxidant composition of cellular 
membranes which in turn may be controlled by dietary composition (Clegg, 1973; 
Manorama and Rukmini, 1992). 
The greater stability of vegetable oils versus animal fats under oxidative 
conditions is known to be due to the higher levels of natural antioxidants in the 
oils. An important and commonly occurring class of natural antioxidants in 
vegetable oils is tocopherols (T) of vitamin E family. There are 8 naturally 
occurring forms of vitamin E; a-, (3-, y-, 8-tocopherols and tocotrienols (T3). 
Tocotrienols are minor plant constituents especially abundant in cereal grains 
(such as barley, oat, wheat and rye), rice bran, palm oil and latex (Kasparek, 
1980b). The vitamin E antioxidant property reflects the similarity in chemical 
structures of T and T3, which differ only in possessing a famesyl or unsaturated 
phytyl side chain, respectively (Kasparek, 1980a) (Fig. 1.5). Tocopherols 
predominate in certain oils such as com oil, soyabean oil and olive oil. Whereas, 
the T3 series predominates in rice bran oil (RBO), palm oil and barley oil. Small 
amounts of T3 are found in carrots, sweetcom and germ oils (Shin and Godber, 
1994). Several lines of research have estabUshed that populations which consume 
large amounts of cereal grain and vegetable oils tend to have a lower incidence of 
cardiovascular disease (Sacks et al., 1975; Burslem et al., 1978; Gould et al., 
1980). Furthermore, studies on cereal grains demonstrated that barley is 
particularly effective in lowering lipid levels in animal models (Qureshi et al., 
1980 a,b&c). The ability of barley extracts to lower lipids in vivo led to the 
purification and identification of biologically active compound tocotrienol 
(Qureshi et al., 1986). There are scattered reports that neither rice bran nor RBO 
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Fig. 1.5. Structures of tocotrienols and tocopherols. 
lowered cholesterol levels. These findings may be explained by reports that some, 
but not all, rice cultivars contain tocotrienols which exert a powerful 
hypocholesterolemic action (Qureshi et al, 1986; Qureshi et al, 1989). Qureshi et 
al. (1986) have demonstrated the hypocholesterolemic effect of tocotrienols 
isolated from barley, oats, rice and palm oil in various animal models. 
Anticholesterol impact of tocotrienols has also been demonstrated in 
hypercholesterolemic subjects (Qureshi et al, 1995). Out of a-, 3-, y- and 8-T3, y 
and 5-T3 have been found to be most potent in terms of their HMG-CoA reductase 
inhibition as well as cholesterol lowering effects. The efficiency of hypocho-
lesterolemic action as well as the degree of inhibition of HMG-CoA reductase 
activity mediated by a-Ts was substantially lower than y and 5- T3 (Pearce et al, 
1992). p-form of T3 failed to exhibit any anticholesterol activity. Rice bran oil is 
the richest source of T3, whereas com, groundnut, mustard, soyabean and coconut 
oils and butter fat contain only T, which have no lipid lowering effect. The T3 are 
highly effective in lowering total blood cholesterol and LDL-cholesterol 
apparently by reducing the HMG-CoA reductase activity. The T on the other hand 
do not inhibit cholesterol synthesis and thus do not lower serum cholesterol. A 
dose dependent effect of tocotrienol rich fraction (TRF) isolated from palm oil was 
observed for lowering the serum cholesterol and LDL-cholesterol in normo-
lipidemic and hypercholesterolemic swine, quail and chicken (Pearce et al, 1992; 
Qureshi and Qiu-eshi, 1993). 
In several respects T3 appear to operate in similar manner to oxysterols. 
Certain oxysterols have been shown to regulate cholesterol biosynthesis by 
transcriptional down-regulation of reductase gene (Kandutsch et al, 1978; 
Schroepfer et al, 1979; Schroepfer et al, 1981; Schroepfer et al, 1982; Miller et 
al, 1982). It has been postulated that endogenously produced oxysterols are 
natural regulators of cholesterol biosynthesis. These oxysterols are potent 
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repressors of HMG-CoA reductase and bind strongly to cytosolic oxysterol 
binding protein (Spencer et al, 1985; Saucier et al, 1985). Since oxysterols, are 
natural regulators of cholesterol biosynthesis and acts by suppressing HMG-CoA 
reductase gene, the T3 may have a similar function, but it acts at post-
tianscriptional level as has been experimentally demonstrated in HepG2 cells 
(Parker e/a/., 1993). 
The human hepatoma HepG2 cell culture model was employed to compare 
the intrinsic activities of T3. In HepG2 cells, inhibition of sterol synthesis correlate 
with rapid suppression of HMG-CoA reductase when incubated with T3. The 
recemic synthetic tocotrienols exhibit comparable biological activity to the natural 
tocotrienols in the cholesterol suppression activity. Gamma-Tocotrienol has been 
shown to mediate the suppression of enzymatic activity and protein mass of HMG-
CoA reductase in HepG2 cells, through decreased synthesis (57% of control) and 
enhanced degradation (2.4 fold versus control) of the enzyme (Parker et al., 1993). 
Thus, tocotrienols influence the mevalonate pathway in mammahan cells in vitro, 
by post-transcriptional suppression of HMG-CoA reductase, and appear to 
specifically modulate the intracellular mechanism for controlled degradation of the 
reductase protein (Parker et al, 1993). These activities of tocotrienols in HepG2 
cells mirror the actions of the putative non-sterol feedback regulators derived fi-om 
me\'alonate in cultured cells (Goldstein and Brown, 1990). In contrast to the 
effects of 25-hydroxycholesterol, T3 does not suppress LDL receptor protein in 
HepG2 cell membranes as demonstrated by western blotting. 
Since the discovery of vitamin E, in Berkeley by H.M. Evans in 1992, when 
it was first described as antisterility agent, many scientists and physicians have 
sought to elucidate its biochemistry, health benefits and clinical applications 
(Lester, 1992). Vitamin E has been well accepted as natures most effective lipid 
soluble, chain-breaking antioxidant. It is the first line of defense against lipid 
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peroxidation protecting polyunsatiirated fatty acids in cell membranes through its 
free radical quenching activity in biomembranes at an early stage of free radical 
attack (Horwitt, 1986). After being oxidized in this process and before being 
decomposed, vitamin E can be re-reduced by ascorbic acid and glutathione. This 
reaction is dependent on the concentration of these substances and/or the enzymes 
that maintain them in their reduced form. 
The antioxidant activity of T and T3 is mainly due to their abihty to donate 
their phenolic hydrogens to lipid free radicals (Burton and Ingold, 1986; Pokomy. 
1987; Burton and Ingold, 1988; Burton and Traber, 1990). The mechanism for the 
inhibition of lipid peroxidation in biological membranes by T and T^  can be 
outlined as follows: The peroxidation proceeds in 3 phases; initiation, propagation 
and termination (Burton and Traber, 1990). In the initiation phase a carbon-
centered lipid radical R* is produced from a polyunsaturated fatt>' acid RH. This R* 
reacts with molecular oxygen in the propagation phase to form ROO', which reacts 
with other RH forming a hydroperoxide, ROOH. 
R* + 02 -^ ROO* 
ROO* + RH ^ ROOH + R* 
This propagation process continues and consumes the valuable polyunsaturated 
fatty acids. In the termination phase, the chain reaction stops when a perox>l 
radical (ROO*) combines with another ROO*. 
ROO* + ROO* ^ Inactive product 
However, tocotrienols (T3-OH) and tocopherols (T-OH) can intercept the perox\'l 
radical more rapidly than can polyunsaturated fatty acids by the following 
reactions: 
T3-OH + ROO* -^ T3-O* + ROOH 
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T.rO* + ROO* -> Inactive product 
The T3-O' radical is unable to continue the chain and reacts with the peroxyl to 
form inactive product. 
Although, it is generally agreed that the relative antioxidant activity of T in 
vivo is in the order of a>p>Y>S (Dillard et ai, 1983; Burton and Ingold, 1986; 
Burton and Traber, 1990; VERIS, 1993), there is a wide spread confusion 
concerning their relative potency in vitro (Burton and Ingold, 1981). The chemical 
structures of T and T3 support hydrogen-donating power in the order of a>P>y>6 
(Pokomy, 1987). This order also was obtained when the activity of the four T was 
compared in a homogenous solution in dichlorobenzene (Burton and Ingold, 
1981), but a reverse order (5>y=P>a) was obtained when the relative antioxidant 
properties were compared in fats, oils and lipoproteins in vitro (Lea and Ward, 
1959; Olcott and Van Der Ven, 1968; Parkhurst ei al, 1968; Koskas et ai, 1984; 
Esterbauer et al, 1989; Gottstein and Grosch, 1990). The reason behind this order 
is not yet clearly imderstood. Several studies have demonstrated the ability of 
tocopherols to prevent ex vivo and in vitro LDL-C oxidation and significantly 
reduce the development of atherosclerotic lesions (Carew et ai. 1987; Esterbauer 
et ai, 1991; Mao et ai, 1991), risk of coronary heart disease (CHD) (Rimm et ai, 
1993; Stampfer et ai, 1993) and ischemic heart disease (Gey, 1995). Even though, 
a-T has been labeled as the most efficient chain-breaking antioxidant, tocotrienols 
are known to be more potent antioxidant than tocopherols (Suama et ai, 1993; 
Kamat and Devasagayam, 1995; Kamat et ai, 1997). Tocotrienols have been 
shown to have greater free radical scavenging properties as cell membrane 
constiments than T (Yamaoka and Carrillo, 1990; Serbinova et ai, 1991). 
Recently, it was shown that compared to a-T, a-Ts possesses a 40-60 times higher 
antioxidant activity against Fe^" + ascorbate- and Fe^ ^ + NADPH-induced lipid 
peroxidation in rat liver microsomal membranes and 6.5 times greater protection of 
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c\tochrome P-450 against oxidative damage (Serbinova et al., 1991). This higher 
antioxidant potency of a-T^ as compared to a-T is attributed to the combined 
effects of three properties; its higher recycling efficiency from chromanox>'l 
radical, its more uniform distribution in membrane bilayer, and its stronger 
disordering of membrane lipids which makes interaction of chromanols with lipid 
radicals more efficient. 
Several animal studies have been conducted to test the hypothesis that 
antioxidants delay atherosclerosis. Wojcicki reported a statistically significant 25 
per cent reduction in aortic atherosclerotic lesions in hypercholesterolemic 
mongrel rabbits fed 10 mg/kg/day of vitamin E compared to controls (Wojcicki et 
al.. 1991) and Verlangieri reported a 54 per cent lesion reduction in monkeys fed 
108 lU of vitamin E per day compared to controls (Verlangieri and Bush, 1992). 
Qureshi et al. (1991 a&b) have reported a reduction in both total and LDL-
cholesterol in human hyperlipidemics and pigs supplemented with T3. Supplemen-
tation of y-Ts along with an atherogenic diet to rats for six weeks have been shown 
to lead to decreased plasma lipid and lipoprotein concentrations. In addition, a 
decrease in the plasma lipid peroxidation was shown (Watkins et al., 1993). 
Similar observations were reported in hypercholesterolemic rabbits by Teoh et al. 
(1994). Wahlquist et al. (1992), however, observed a differential response to T and 
T3 supplementation in human subjects without any change in serum lipids. Tomeo 
et al. (1995) also reported that T3 significantly decreased plasma lipid peroxidation 
in patients with hyperlipidemia and carotid stenosis with no change in their lipid 
and lipoprotein parameters. Similarly, Mensink et al. (1999) recently reported that 
T3 had no markedly favourable effects on the serum lipoprotein profile in men 
with slightly elevated hpid concentrations. Experiments involving the effects of T3 
on apoB (LDL) and apoA-I (HDL) and apoB/apoA-I ratio has been reported in 
chickens, svmie and humans. The apoB/apoA-I ratio, considered to be a better 
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indicator than LDL/HDL ratio, for assessment of CHD, was reduced in T3 treated 
subjects (Qureshi et ai, 1991 a&b). Recently, the mechanism of action of T3 on 
apoB metabolism in HepG2 cells has been investigated (Wang et al, 1998; 
Theriauhera/., 1999b). 
For a long time now it has been shown tiiat dietary regimen in conjunction 
with exercise favourably alter the lipid parameters in hypercholesterolemic 
individuals. Based on the current knowledge dietary recommendations to optimize 
plasma lipid profiles and thus reduce the risk of coronary heart disease are 
currently focused on the total fat content, the fatty acid profile, and the cholesterol 
content of the diet (Dietary Guidelmes, 1988). Public health programmes for 
prevention of CAD in developed countries recommend changes in dietary habit 
and patterns of various components of diets, especially dietary fat. Recently a 
reduction in dietar\ intake of total fat, particularly animal fat with a limited 
amount of saturated fatty acid and polyunsaturated fatty acid, has been suggested 
(Lesserre et al, 1985). The American Heart Association (1982) recommends that 
total fat content of the diet should not exceed 30% of total calories, saturated fatty 
acid should not exceed 10%, monounsaturated fatty acid should not exceed 10% 
and polyunsaturated fatty acid should not exceed 10% of calories. Lasserre et al. 
(1985) reported that linolenic acid (18:3) should provide 0.5-1.0% of total calories. 
Polyimsaturated fatty acids are abundantly available in vegetable oils like 
safflower oil, sunflower oil and com oil which were found to lower blood total and 
LDL-cholesterol le\'els, as revealed by epidemiological studies (Berkson and 
Stamler, 1981). A number of studies in humans and animals have shown that RBO 
is as effective as other vegetable oils in lowering plasma cholesterol levels 
(Rukmini and Raghuram, 1991; Lichtenstein et al., 1994). In some cases, RBO 
lowered plasma cholesterol more effectively than other commonly used vegetable 
oils rich in linoleic acid (Rukmini and Raghuram, 1991); this effect was attributed 
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to the presence of T and T^  in the RBO (Nicolosi et al, 1991). However. Qureshi 
e/ a/. (1991a & b), confirmed the impact of tocotrienols on cholesterol, specifically 
the LDL-choiesterol, in animal and human studies. The tocopherols on the other 
hand do not lower serum cholesterol (Qureshi et al., 1989). Recently, biological 
properties of tocotrienols such as hypolipidemic, antioxidant and anti-tumour, 
have been reviewed in detail (Theriault et al., 1999a). 
Rice is one of the foremost food crops of the world. It is staple food for 
more than half of the worlds population. More than 90% of the worlds rice 
production is concentrated in Asia, especially in China, India, Indonesia, 
Bangladesh, Thailand, Burma and Japan. India is the largest producer of rice in the 
world outside mainland China. The total paddy production in 1996 was 120 
million tons, whereas projected paddy production in India for year 2000 is 
expected to be 1440 million tons. The rice bran availability for 1996 was 60 
million tons (at the rate of 7.5% of rice) and projected bran production for the year 
2000 is 70 million tons (Food and Civil Supplies Department, NewDelhi, India, 
1996). Rice bran refers to the coating removed from the brown rice during the 
process of milling. The bran constitutes nearly 8.5-10% of the total grains and is 
highly nutritious. It is rich in lipids, proteins, minerals and vitamins. Rice bran is 
most valuable by product of rice milling industr>. It contains 12-15% proteins, 14-
20% oil if paddy is raw and 18-25% if paddy is parboiled. About 60% of paddy 
produced in India is parboiled. Although the US produces only 1-2% share of the 
total world rice crop, it is a major exporter having a 20-30%, share of the world 
export trade (Migura, 1989). Rice bran processed in the US is a potential source of 
over 100,000 metric tons of tocotrienol rich oil. In the last 10 to 15 years US 
scientists have shown interest in the cholesterol lowering property of rice bran 
(Haumanh, 1989) and rice bran products have been introduced in supermarkets. 
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Rice bran oil has the potential of being the oil of choice for health-conscious 
consumers in the US. 
Rice bran oil, though not a popular edible oil worldwide, is in steady 
demand as the so called healthy oil not only in Japan but also in other Asian 
countries, particularly India. Only 0.5 million ton of RBO corresponding to 8.5% 
of total vegetable oils is consumed annually in India (Central Organisation for Oil 
Industry and Trade, hidia, 1998). Similarly, 1000 ton of RBO corresponding to 
3.5% of total vegetable oils is consumed in Japan. Further RBO is characterized b\ 
its relatively high content of unsaponifiable material. The content of the 
unsaponifiable material in refined edible grade RBO is less than 5% under Japan 
Agricultural Standards. This value of non-saponifiable fraction of RBO is 
considerably higher than that of other vegetable oils including palm oil where it is 
less than 1-1.5%. 
Rice bran oil, therefore, has the potential of being the oil of choice for 
population with a high risk of CAD due to increase in plasma lipid levels. Rice 
bran oil as an edible oil may be one of the healthiest and safest oils for human 
nutrition. The use of RBO or other commonly used edible oil supplemented with 
optimal concentration of T3 by normal population will prevent the occurrence of 
hypercholesterolemia and cardiovascular diseases. Furthermore, daily consumption 
of RBO as cooking oil by subjects suffering from lipid abnormalities will be useful 
in the treatment of hypercholesterolemia and coronary heart disease. 
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1.1 Objectives of the present investigation 
Current worldwide interest in the use of tocotrienols (T3) in the prevention 
and treatment of cardiovascular diseases, creates a need to develop a simple and 
cost-effective methodology for the isolation of tocotrienol and tocopherol rich 
fraction (TRF) from rice bran/rice bran oil (RBO). Since, a systematic and detailed 
investigation related to hypolipidemic and antioxidant properties of TRF isolated 
from RBO, in normolipidemic and hyperUpidemic rats has been lacking, we have 
undertaken a detailed investigation pertaining to hypolipidemic and antioxidant 
impacts, including elucidation of possible mechanism of cholesterol lowering 
action of TRF in normolipidemic and hyperlipidemic rats. In addition, due to the 
availabihty of a rare familial hypercholesterolemic (FH) patient with severe 
rapidly growing skin xanthomas, we investigated the impact of TRF on cholesterol 
dynamics of this patient. Hypolipidemic property of RBO. rich in tocotrienols was 
also investigated in normolipidemic humans. 
The efficacy of TRF in the prevention of experimentally-induced 
hyperlipidemia in rats was investigated by administration of TRF along with 
atherogenic diet. In addition, efficiency of TRF in the treatment of hyperlipidemia 
after the withdrawal of atherogenic diet was also investigated in hyperlipidemic 
rats. The minimum dose of TRF required to exert the maximum hypolipidemic 
effect in normoUpidemic and hyperlipidemic rats was also determined. 
There are scattered reports showing the varying hypocholesterolemic 
activity of rice bran or rice bran oil (RBO) and some have shown that neither rice 
bran nor RBO lowered cholesterol levels. These fmdings may be explained by 
other reports that some, but not all, rice cultivars contain tocotrienols (T3), which 
exert a powerfiil hypocholesterolemic action. Because of these variation in types 
and content of T3, one finds variation in the cholesterol lowering effects of different 
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RBO isolated from different cultivars of rice. Out of a-, (3-, y- and 6-T3, y- and 5-
T3. were the most potent in terms of cholesterol lowering effect, a-T3 has very low 
effect, whereas, P-form has no anti-cholesterol activity. Therefore, we have 
investigated the hypolipidemic potency of TRF isolated from RBO of two rice 
cultivars, Basmati and Saket-4, based on their y- and 5-T3 content. 
Earlier reports indicate that a-, y- and 5-T3, isolated from palm oil, exert 
their in vivo hypocholesterolemic effect in chickens, by reducing the HMG-CoA 
reductase activity. In another report in HepG2 cells, T3 have been shown to 
suppress cholesterol formation by reducing the enzymatic activity of HMG-CoA 
reductase. This reduction in enzymatic activity was due to decrease in HMG-CoA 
reductase protein mass, involving its enhanced degradation at post-transcriptional 
level. However, the mechanism of T3-mediated in vivo regulation of HMG-CoA 
reductase activity has not been reported. In the present study we have investigated 
the possible mechanism of lipid lowering action of tocotrienols (TRF) in 
normolipidemic and hyperlipidemic rats. This objective was achieved by 
quantifying the enzymatic activity of HMG-CoA reductase and its immuno-
reactive protein mass in the liver of normolipidemic and hyperlipidemic rats 
treated with TRF. 
Published reports indicate that oxidized-LDL is more atherogenic than 
native-LDL and over-production of free radicals is linked with acceleration of 
atherosclerotic process. Tocotrienols, in comparison to tocopherols, have been 
shown to exert more potent antioxidant activity in vitro and ex vivo in hepatic 
microsomes and plasma LDL of normal rats. Therefore, in vivo impact of TRF, as 
antioxidant, in the prevention of lipid peroxidation and plasma LDL oxidation was 
investigated in normolipidemic and experimentally induced hyperlipidemic rats. 
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In familial hypercholesterolemic patients an elevated plasma total and LDL-
cholesterol and high levels of apoB are major risk factors in the development of 
coronar> heart disease (CHD). Numerous studies have also demonstrated an 
inverse relationship between plasma levels of HDL-C and CHD incidence and 
coronary atherosclerosis. Case-control studies indicate that the inverse relationship 
with CHD is mainly due to HDL subfraction, HDL2-C, which is the strongest 
predictor of the both presence and extent of CAD. Intervention studies with 
repeated angiographics to monitor disease progression have consistently shown 
that HDL-C and its apoA-1 and LDL-C and its apoB concentrations or the TC to 
HDL-C ratio are independently associated with growth of atherosclerotic lesions. 
The most effective approach for controlling FH is by inhibiting cholesterol 
synthesis at the level of HMG-CoA reductase, the rate limiting enzyme. Therefore, 
based on known inhibitory action of TRF on hepatic HMG-CoA reductase activity, 
we have investigated the impacts of TRF on plasma trigycerides, total cholesterol, 
VLDL-C and LDL-C including apoB, in a 5 year-old FH boy with rapidly growing 
xanthomas on buttocks extending to thighs, elbows and knee. Since, HDL-C sub-
fraction. HDL2-C has been shown to be a strongest predictor of both presence and 
extent of CAD in humans, the impact of TRF on plasma HDL-C including apoA-1 
and its sub-fractions, HDL2-C and HDL3-C, was also investigated. In addition, the 
long-term impact of TRF on the growth and size of skin xanthomas was 
investigated. 
Since earlier reports indicate a similar hypolipidemic effects of both RBO 
and TRF in hyperlipidemic subjects, we have investigated the impact of dietary 
RBO on plasma lipids of normolipidemic human volunteers. 
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^ExperimentaC 
MATERIALS 
2.1.1 Chemicals 
The chemicals were obtained from various sources listed below. 
Chemical 
Bovine Serum Albumin 
Cholesterol 
Cholic Acid 
Commassie Brilliant Blue G250 
Digitonin 
Ferric Chloride 
Glycine 
Heparin 
Hexane for HPLC 
HMG-CoA 
HRP-conjugate 
TMB'H:02-Substrate 
Isopropanol for HPLC 
Methanol for HPLC 
NADPH 
Rat Chow 
Refined Edible Grade RBO 
Sodium Dodecyl Sulfate 
Thiobarbutric Acid 
(±)-a-Tocopherol 
Tween-20 
Source 
Miles Laboratories Inc., USA 
Sigma Chemical Co., USA 
CDH, hidia 
Polysciences Inc., USA 
Sigma Chemical Co., USA 
Loba Chemie, India 
SRL, India 
Sigma Chemical Co., USA 
Spectrochem. Pvt. Ltd., India 
Pharmacia, Sweden 
Genei, Bangalore, India 
Genei, Bangalore, India 
Merck, Germany 
SD Fine Chem. Ltd., India 
Calbiochem, USA 
Hindustan Lever Ltd., India 
Foods, Fats and Fertilizers Ltd., 
India 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
Sigma Chemical Co., USA 
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We acknowledge our immense gratitude to Dr. V.W. Rodwell, Department of 
Biochemistry, Purdue University, Lafayette, Indiana, USA, for kindly providing 
purified hamster HMG-CoA reductase and its antibody, HMG-CoA, NADPH and 
leupeptin as gifts. Gamma-tocotrienol was a gift from Dr. R. A. Parker, Department 
of Metabolic Diseases, Bristol-Myers Squibb Pharmaceutical Research Institute, 
Princeton, USA. Alpha-tocotrienol and tocotrienol rich fraction were a gjft from 
Dr. A.A. Qureshi, Advanced Research Laboratory, Madison, Wisconsin, USA. 
HMG-CoA reductase and Anti-rat hepatic HMG-CoA reductase antiserum were a 
gift from Dr. Z.H. Beg. 
All other chemicals and reagents used were of analytical grade. 
2.1.2 Animals 
Male albino rats, weighing about 175-200 g purchased from Central Animal 
House, J.N. Medical College A.M.U., Aligarh (India), were conditioned to animal 
house environment prior to the experiment, diet and water was given ad libitum. 
The rats were housed in a light-controlled isolator in which the dark period was 
maintained from 3.00 a.m. to 3.00 p.m. two weeks before the killing. The rats were 
sacrificed at sixth hour of dark cycle at the peak of diurnal rh>'thm of HMG-CoA 
reductase (Edwards et al., 1977). 
2.1J Diet 
The rats were given pelleted rat chow and water ad libitum unless otherwise 
stated. For the induction of hyperlipidemia, rats were given an atherogenic diet 
consisting of 5% hydrogenated fat, 0.5% cholic acid and 1% cholesterol. The 
atherogenic diet, which was given in addition to the pelleted rat chow, was 
administered as a suspension through gastric intubation in two divided doses 
(morning and evening) of 0.5 ml each/rat/day. TRF was also administered through 
gastric intubation in two equal doses of 0.5 ml in saline/rat/day. 
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METHODS 
2.2.1 Isolation and Purification of Tocotrienol Rich Fraction from Crude 
and Refined Edible Grade Rice Bran Oil 
2.2.1.1 Procurement of rice bran and extraction of crude rice bran oil 
Raw and parboiled paddies of different cultivars, namely Basmati (long grain) and 
Saket-4 (short grain) and Mansuri (medium grain) of rice were procured. The 
brans from these cultivars of rice, representative of different rice growing zones of 
UP. (India), were obtained by Sheller milling method. Rice brans obtained from 
each raw and parboiled paddies of Basmati and Saket-4 were soaked in haxane 
(7 ml/g bran) within 24 h of milling. The crude rice bran oil (RBO) was extracted 
in hexane for 72 h with intermittent stirring. The crude RBO fraction was obtained 
by evaporating hexane under vacuum in a rotary evaporator. 
2.2.1.2 Extraction of tocotrienol rich fraction from crude and refined rice 
bran oil 
Tocotrienol rich fraction (TRF) from crude and refmed RBO was extracted in 
methanol by stirring in a container for 1 h. The minimum amount of methanol 
essential for extraction of maximum amount of TRF had been worked out to be 
7 ml per gram of RBO. Methanol layer containing TRF was evaporated at 65 °C 
under vacuum in a rotary evaporator and crude TRF was recovered. 
2 21.3 Isolation of purified tocotrienol rich fraction 
The procedure for purification of TRF from crude TRF was based on the method 
reported previously (He et al, 1996) with following modifications. 100 g silica gel 
(230-400 mesh) was soaked in hexane and layered on a 500 ml scintered glass 
fimnel connected to a water aspirator tube for generating a mild vacuum. The silica 
gel was washed with 500 ml of hexane and then loaded with 0.5 g of crude TRF in 
20 ml of hexane. The gel was washed with 1.5 lit of hexane in order to remove 
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non-tocotrienol and tocopherol components such as triacylglycerols, sterols, etc. 
Purified mixtures of tocotrienol (T3) and tocopherol (T) was then rapidly eluted 
with diethyl ether. The elution was speeded by the application of vacuum 
produced by water aspirator. The solvent was evaporated under vacuum in order to 
obtain purified mixture of T3 and T. The silica gel was regenerated by tiioroughly 
washing with methanol, which removes all the bound components and reused 
again for the purification of crude TRF. 
2.2.1.4 Analytical HPLC of crude and purified tocotrienol rich fraction 
The analytical HPLC system that was used consisted of Beckman System Gold 
127 Progranmiable Solvent Module (127 Pump) and 166 Programmable Detector 
Module. Samples (20 }il) were injected into Beckman Ultrasphere Silica Column 
(4.6 mm x 25 cm) using a 20 jil loop. The mobile phase consisted of 0.3% 
isopropanol in hexane at a flow rate of 1 ml/min and the eluent was monitored at 
290 nm by UV detector. The chromatogram obtained were monitored on a 
HP 3395 integrator. The crude and purified TRF were characterized by comparing 
the retention time of each peak with the standard TRF. The concentration of 
individual tocopherols and tocotrienols was calculated fi"om the area under each 
peak. 
2.2.2 Experimental Design 
Z2.2.1 Studies in rats 
For investigating the hypolipidemic effect of TRF, purified TRF, the experiments 
were carried out in different sets. Male albino rats were divided in the following 
groups in each set as described below: 
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2.2.2.1.1 Experimental Group No. I 
=> Normalipidemic Control (NLP-C) 
Five rats were given 0.5 ml saline through gastric intubation for two week. 
=> Normolipidemic Treated-! (NLP-Tl) 
Five rats in this group were given 125 mg TRF /kg/day for two weeks. 
=> Normolipidemic Treated-2 (NLP-T2) 
Five rats in this group were given 81.25 purified TRF /kg/day for two weeks. 
2.2.2.1.2 Experimental Group No. II 
=^ Normolipidemic Control (NLP-C) 
Three rats were given 0.5 ml saline through gastric intubation for three weeks. 
=^ Normolipidemic Treated (NLP-T) 
Three rats in this group were given 65 mg purified TRF /kg/day for three weeks. 
=> Hyperlipidemic Control (HLP-C) 
Three rats in this group were given an atherogenic diet for three weeks. 
=> Hyperlipidemic Treated-1 (HLP-Tl) 
Three rats in this group were given 65 mg purified TRF/kg/day alongwith an 
atherogenic diet for three weeks. 
=^ Hyperlipidemic Untreated-1 (HLP-UI) 
Three rats in this group were given an atherogenic diet for three weeks and then 
kept on pelleted rat chow for an additional 5 days. 
=^ Hyperlipidemic Treated-1 (HLP-Tl) 
Three rats in this group, after giving atherogenic diet for three weeks, were given 
16.25 mg purified TRF/kg/day for 5 days. 
=> Hyperlipidemic Treated-2 (HLP-T2) 
Three rats in this group, after giving atherogenic diet for three weeks, were given 
32.50 mg purified TRF/kg/day for 5 days. 
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=^ Hyperlipidemic lIntreated-2 (HLP-U2) 
Three rats in this group were given an atherogenic diet for three weeks and then 
kept on pelleted rat chow for an additional 7 days. 
=> Hyperlipidemic Treated-3 (HLP-T3) 
Three rats in this group, after giving atherogenic diet for three weeks, were given 
16.25 mg purified TRF/kg/day for 7 days. 
=^ Hyperlipidemic Treated-4 (HLP-T4) 
Three rats in this group, after giving atherogenic diet for three weeks, were given 
32.50 mg purified TRP/kg/day for 7 days. 
2.2.2.1.3 Experimental Group No. Ill 
=> Normolipidemic Control (NLP-C) 
Three rats were given 0.5 ml saline through gastric intubation for three weeks. 
=> Normolipidemic Treated-] (NLP-Tl) 
Three rats in this group were given 4 mg TRF /kg/day for three weeks. 
=^ Normolipidemic Treated-2 (NLP-T2) 
Three rats in this group were given 8 mg TRF /kg/day for three weeks. 
=> Normolipidemic Treated-3 (NLP-T3) 
Three rats in this group were given 12 mg TRF /kg/day for three weeks. 
=> Normolipidemic Treated-4 (NLP-T4) 
Three rats in this group were given 4 mg purified TRF/kg/day for three weeks. 
^> Normolipidemic Treated-5 (NLP-T5) 
Three rats in this group were given 8 mg purified TRF/kg/day for three weeks. 
=^ Normolipidemic Treated-6 (NLP-T6) 
Three rats in this group were given 12 mg purified TRF/kg/day for three weeks. 
=> Hyperlipidemic Control (HLP-C) 
Three rats in this group were given an atherogenic diet for three weeks. 
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=> Hyperlipidemic Untreated (HLP-U) 
Three rats in this group were given an atherogenic diet for three weeks and then 
kept on pelleted rat chow for an additional 7 days. 
=^ Hyperlipidemic Treated-J (HLP-T-1) 
Three rats in this group, after giving atherogenic diet for three weeks, were given 
2.6 mg purified TRF/kg/day for 7 days. 
=> Hyperlipidemic Treated-2 (HLP-T-2) 
Three rats in this group, after giving atherogenic diet for three weeks, were given 
5.2 mg purified TRF/kg/day for 7 days. 
=> Hyperlipidemic Treated-3 (HLP-T-3) 
Three rats in this group, after giving atherogenic diet for three weeks, were given 
7.8 mg purified TRP/kg/day for 7 days. 
2.2.2.1.4 Experimental Group No IV 
=> Normolipidemic Control (NLP-C) 
Four rats were given 0.5 ml saline through gastric intubation for three weeks. 
=^ Hyperlipidemic Control (HLP-C) 
Four rats in this group were given an atherogenic diet for three weeks. 
=> Hyperlipidemic Untreated (HLP-U) 
Four rats in this group were given an atherogenic diet for three weeks and then 
kept on pelleted rat chow for an additional 7 days. 
=^ Hyperlipidemic Treated-] (HLP-T-1) 
Four rats in this group, after giving atherogenic diet for three weeks, were given 
1.67 mg purified TRF/kg/day from Basmati for 7 days. 
=> Hyperlipidemic Treated-2 (HLP-T2) 
Four rats in this group, after giving atherogenic diet for three weeks, were given 
3.35 mg purified TRF/kg/day from Basmati for 7 days. 
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=> Hyperlipidemic Treated-S (HLP-T3) 
Four rats in this group, after giving atherogenic diet for three weeks, were given 
1.17 mg purified TRF/kg/day from Saket-4 for 7 days. 
=> Hyperlipidemic Treated-4 (HLP-T4) 
Four rats in this group, after giving atherogenic diet for three weeks, were given 
2.34 mg purified TRF/kg/day from Saket-4 for 7 days. 
2.2.2.2 Studies in Human Subjects 
2.2.2.2.1 Studies in a familial hypercholesterolemic patient 
A 5 year boy presented with a classical case of familial hypercholesterolemia to 
J.N.Medical college OPD, including a severe rapidly growing skin xanthomas on 
buttocks extending to thighs, moderately on elbows and couple of them on the 
knee. Based on above characterization the patient can be categorized as familial 
hypercholesterolemic. Considering the rare availability of such type of patients, 
the child was started on low fat, cholesterol free diet, with 8 mg TRF/kg/day for 
100 weeks. Ten ml overnight fasted blood sample was collected at the entry point 
(0 week) and after 8, 20, 60 and 100 weeks of TRF treatment. Plasma was isolated 
and stored at -20 ^C for analysis. 
2.2.2.2.2 Studies in normolipidemic subjects 
For investigating the hypolipidenic effect of RBO, five apparently healthy female 
volunteers were involved in the study with an average age of 39.8 ± 12.1 years and 
average weight of 48.8 ± 9.8 kg. Each volunteer took 0.2 g RBO/kg/day for 4 weeks At 
the end of the feeding trial, an interview was conducted to see if the volunteers complied 
to the feeding schedule. Ten ml overnight fasted blood was taken from each individual at 
the entry point of the study and after 2 and 4 weeks of RBO intake. Plasma was isolated 
and stored at -20 °C for analysis. 
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2.2 J Analytical Procedures 
2.2.3.1 Collection of blood 
At the end of the treatment, the rats in all groups were anaesthetized and blood 
draAvn by cardiac puncture. The blood from each rat in a given group was collected 
using heparin as anticoagulant. Blood was mixed gently by inversion 2 or 3 times 
and immediately cooled to 2-4 °C in an ice bath. The samples were centrifiiged for 
30 min at 2,500 rpm. Plasma was aliquoted in micro-centrifiige tubes and stored at 
-20 °C. 
2.2.3.2 Fractionation of plasma lipoproteins 
Lipoproteins were fractionated from plasma by precipitation as described by 
Kastener (1976). Isolation of HDL-cholesterol and VLDL-cholesterol + LDL-
cholesterol was done by using phosphotungstate and magnesium chloride. The 
following solutions were used: 
• 9.7 mM phosphotungstic acid 
• 0.4 M magnesium chloride 
0.2 volume of 1:1 mixture of phosphotungstic acid and magnesium chloride 
was added to 1 volume of plasma. The samples were mixed immediately, allowed 
to stand for 5 min at room temperature and then centrifiiged for 10 min at 12,000 
rpm at room temperature. The clear supernatant was used for the analysis of HDL-
cholesterol as well as for the fractionation of HDLs-cholesterol and HDL2-
cholesterol. The precipitate was dissolved in 1 volume of freshly prepared 0.1 M 
sodium citrate and used for the analysis of VLDL-cholesterol + LDL-cholesterol 
Fractionation of HDL-cholesterol subfraction and VLDL-cholesterol was 
done by precipitation method described by Bachorik and Albers (1986). The 
following solutions were used for the fractionation of HDL-cholesterol: 
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• Dextran sulfate (Mr 50,000) 40 gm/L, pH 7.0. 
• MgCl2.6H20, 2 M, pH 7.0. 
• Reagent 'X' was prepared by mixing 1 volume of 40 gm/'L dextran sulfate 
with 3 volumes of 2 M MgCl2.6H2Q. 
For HDL-cholesterol fractionation, 0.1 volume of reagent 'X' was added to 
1 volume of HDL-cholesterol sample and mixed immediately. The samples were 
allowed to stand at room temperature for 15 min and then centrifv^ed at 5,000 rpm 
for 30 min at 4 °C. Aliquots of clear supernatant were used for HDLs-cholesterol 
analysis. HDL2-cholesterol were then calculated as the difference between HDL-
cholesterol and HDLs-cholesterol. 
For the isolation of VLDL, 0.075 volume of 10% SDS solution was added 
to 1 volume of plasma. After mixing them well, the samples were incubated for 2 h 
at 37 °C. These were then centrifiiged at 10,000 rpm for 10 minutes at room 
temperature. The VLDL pellicle floats at the top of the tube. The subnatant was 
carefully removed with a hypodermic syringe and discarded. The pellicle residue 
was dissolved in 1 volume of 1% SDS by warming at 37 °C for 15 minutes. 
2.2.3.3 Determination of cholesterol 
Total, free and esterified cholesterol were estimated in plasma and lipoproteins as 
described by Annino and Giese (1976). To glass centrifuge tubes, containing 4.8 
ml of isopropanol, were added 0.2 ml of the test sample or 0.2 ml of the standard 
cholesterol (200 mg/100 ml isopropanol). The contents were mixed, allowed to 
stand for 5 min and centrifiiged at 3,000 rpm for 10 min. 
For the determination of cholesterol in plasma and subfractions, 1.0 ml of 
the supernatant was taken in glass test tubes and treated with 2.0 ml of ferric 
chloride reagent (70 mg of ferric chloride hexahydrate/lOO ml of glacial acetic 
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acid), mixed immediately, followed by the addition of 2.0 ml of sulphuric acid 
with thorough mixing. For reagent blank, 1.0 ml of isopropanol was used instead 
of supernatant. After 5 min, the absorbance was read at 550 nm in a Beckman 
DU 640 spectrophotometer. 
For the determination of free cholesterol and cholesterol ester, 1.0 ml of the 
above supernatant was treated with 2.0 ml of acetone and 1.0 ml of digitonin 
solution (1.0 g of digitonin dissolved in 60 ml of absolute ethanol, diluted to 
100 ml with distilled water and mixed well). The tubes were allowed to stand in an 
ice bath for 30 min and then centrifiiged for 10 min at 4,000 rpm. The supernatant 
was decanted completely. The precipitate was again washed with 3.0 ml of 
acetone and dissolved in 1.0 ml of isopropanol. At the same time, 1.0 ml 
isopropanol was taken in a clean tube to serve as blank. To all the tubes, 2.0 ml of 
ferric chloride reagent and 2.0 ml sulphuric acid were added and the contents were 
mixed well. After 5 min, the absorbance was read at 550 nm in a Beckman 
DU 640 spectrophotometer. 
Calculations: Total, free and esterified cholesterol were calculated as follows : 
Total cholesterol (mg/dl) = Absorbance of test sample x 200 
Absorbance of standard 
Free cholesterol (mg/dl) = Absorbance of test sample x 200 
Absorbance of standard 
Cholesterol ester (mg/dl) = Total cholesterol - Free cholesterol. 
2.2.3.4 Determination of triglycerides 
Triglycerides were determined by using enzymatic kit purchased from Pointe 
Scientific, Inc. (USA). The method uses a modified Trinder colour reaction to 
produce a fast, linear, end point reaction (Trinder, 1969). 
A Jt 
4 \ Ace. N o ) //' 5R 
- // 
Principle: 
Lipase 
Triglycerides ^ Glycerol + Fatty acids 
Glycerol kinase 
Glycerol + ATP • G3P + ADP 
Glycerophosphate oxidase 
G3P + O2 • DAP + H2O2 
Peroxidase 
H2O2 + 4-AAP + TBHB • Quinoneimine D>'e ^ 2H2O 
Triglycerides in the sample are hydrolyzed by lipase to glycerol and fatty 
acids. The glycerol is then phosphorylated by adenosine-5-triphosphate (ATP) to 
glycerol-3-phosphate (G3P) and adenosine-5-diphosphate (ADP) in a reaction 
catalyzed by glycerol kinase. Glycerol-3-phosphate is then converted to 
dihydroxyacetone phosphate (DAP) and hydrogen peroxide (H2O2) by 
glycerophosphate oxidase. The hydrogen peroxide then reacts with 4-amino-
antipyrine (4-AAP) and 3-hydroxy-2,4,6-tribomobenzoic acid (TBHB) in a 
reaction catalyzed by peroxidase to yield a red coloured quinoneimine dye. The 
intensity of the colour produced after incubation is directly proportional to the 
concentration of triglycerides in the sample when measured at 540 nm. 
Calculations: Triglycerides in a plasma sample were calculated as follows: 
Triglycerides (mg/dl) = OP Sample x n 
OD Standard 
[ n = standard concentration (200 mg/dl)] 
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2.2.3.5 Determination ofapoA-1 and apoB 
ApoA-1 and apoB were deteraiined in plasma samples by using Idt from Spectrum 
(New Delhi). This test system permits the quantitative determination of apoAl and 
apoB in plasma samples by turbidimetric analysis. 
The reaction is based on the precipitation of antigen-antibody complexes 
provided from die monospecific antibody in determined quantity and the antigen, 
tiie apoA-1 or apoB present in the sample. The formation of this insoluble 
immuno-complex is accelerated in presence of polyethylene glycol buffer. The 
reaction is started by the addition of plasma containing the antigens. The optical 
density measured after incubation at 340 imi is proportional to the quantity of 
antigen present in the sample. 
Calculations: ApoA-1 and apoB concentrations were determined by utilizing the 
optical density of each sample on a calibration curve constructed by using apoA-1 
and apoB standards. The results were expressed as mg/dl. 
2.2.3.6 Determination of lipid peroxidation in rat liver microsomes 
Lipid peroxidation was induced by the method of Kamat et al. (1997) by using 
ascorbate-Fe^^ system. The incubation mixture (0.5 ml) contained i) 0.35 ml of 
Tris-HCl, pH 7.4 containing 1 mM KH2PO4; ii) 50 i^l FeS04 in 0.1 mM HCl (final 
cone. 50 \xM); iii) 50 \i\ microsomes; and iv) 50 fil ascorbic acid to give a final 
concentration of 0.4 mM. Incubation was carried out at 37 °C for 10 min in a 
shaker water bath. After incubation, the peroxidation product formed was 
measured as thiobarbituric acid reactive substances (TBARS) as described by 
Pushpendran et al. (1993). For estimating TBARS, the reactants were boiled for 
15 min in a water bath with thiobarbituric acid reagent (0.5% 2-thiobarbituric 
acid/10% trichloro acetic acid/6 mM EDTA/0.63 M hydrochloric acid). After 
cooling, the precipitate formed was removed by centrifiigation at 1,000 g for 10 
57 
min. The absorbance of the sample was determined at 532 mn against blank that 
contained all the reagents minus the microsomes. 
Calculations: The values were calculated on the basis of molar extinction 
coefficient(MEC) of malondehyde (1.56 x lO' XT'cm'). 
TBARS cone. = Absorbance 
MEC X Protein cone. 
mnole/min/mg protein 
Absorbance = Absorbance per min 
2.2.3.7 Determination ofLDL oxidation in plasma 
2.2.3.7.1 Isolation ofLDLfrom plasma 
Plasma LDL were isolated by a precipitation method described by Wieland and 
Seidel (1983). The precipitation buffer consisted of 64 mM trisodium citrate 
adjusted to pH 5.05 with 5 N HCl, and contained 50,000 lU/L heparin. Before 
precipitation of LDL, plasma samples and precipitation reagents were allowed to 
equilibrate to room temperature. One milliliter of the sample was added to 7.0 ml 
of the heparin-citrate buffer. After mixing with a vortex mixer, the suspension was 
allowed to stand for 10 min at room temperature. The insoluble lipoproteins were 
then sedimented by centrifugation at 1,000 g for 10 min. The pellet was 
resuspended in 1.0 ml of 0.1 M Na-phosphate buffer, pH 7.4, containing 0.9% of 
NaCl. 
2.2.3.7.2 Oxidation of LDL 
LDL oxidation was induced by ascorbate-Fe^^-system (Kamat et al., 1997). The 
incubation mixture contained 0.35 ml of Tris-HCl, pH 7.4 containing 1 mM 
KH2PO4; 50 nM FeS04 in 0.1 mM HCl; 50 i^l of LDL and 0.4 mM of ascorbic 
acid. Incubation was carried out at 37 °C for 10 min in a shaker water bath. The 
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oxidation products formed were measured by the metiiod of Buege and Aust 
(1978). The amount of conjugated dienes formed during LDL oxidation was 
assayed by measuring the absorbance of LDL at 234 nm against a buffer blank 
containing all tiie constituents except LDL. 
Calculations: The amount of conjugated dienes formed were calculated on the 
basis of MEC of conjugated dienes (2.52 x 10 M" cm" ). 
Cone, of conjugated dienes = O.D. 
MEC X Vol. of LDL 
nmole/min/ml plasma 
O.D. = Change in optical density per min 
2.2.3.8 Determination of HMG-CoA reductase activity in rat liver microsomes 
2.2.3.8.1 Isolation of microsomes 
Rat liver microsomes were isolated by the method of Edwards and Gould (1972) 
with minor modifications. Livers were homogenized at 4 °C in buffer A containing 
0.04 M potassium phosphate, pH 7.2, 0.05 M KCl, 0.03 M potassium EDTA, 
0.1 M sucrose (2.0 ml/g of hver) in a warring blender. The homogenate was 
centrifiiged at 10,000 g for 20 min. The post-mitochondrial supernatant was 
centrifuged at 100,000 g for 1 h at 4 °C. The microsomal pellet was stored frozen 
a t - 2 0 T . 
2.2.3.8.2 Solubilization ofHMG-CoA reductase 
For optimal solubilization of the HMG-CoA reductase, method of Edwards et al. 
(1979) was used. The frozen microsomes were allowed to thaw either at room 
temperature or at 37 °C before addition of an equal volume of 50% glycerol in 
buffer B (buffer A plus 20 mM PME) preheated to 37 °C. The suspension was 
rehomogenized with 10 downward passes of a hand driven, all glass Potter-
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Elvejhem homogenizer and then incubated at 37 °C for 60 min. The suspension 
was diluted three fold with buffer B preheated to 37 T to a final glycerol 
concentration of 8.3%, rehomogenized with 10 downward passes of the glass 
homogenizer pestle and centrifuged at 100,000 g for 1 h at 25 °C. The supernatant 
containing solubilized HMG-CoA reductase was removed and stored at -20 C^ for 
fiiture use. 
2.2.3.8.3 Assay ofHMG-CoA reductase 
HMG-CoA reductase activity in solubilized fractions (above) was assayed 
spectrophotometrically by the method of Kleinsek et al. (1977) with minor 
modifications. The activity of the solubilized HMG-CoA reductase was 
determined at 37 °C in a total volume of 0.25 ml using Beckman DU 640 spectro-
photometer. Assay was carried out in buffer C containing 0.16 M potassium 
phosphate, pH 6.8, 0.2 M KCl, 0.004 M EDTA and 0.02 M PME. The reaction 
cell contained 100-200 ^g protein, 0.2 mM NADPH and 0.1 mM HMG-CoA, 
whereas, control cell contained only 100-200 |ig protein and 0.2 mM NADPH. 
Before the addition of HMG-CoA, the tubes were pre-incubated for 15 min. The 
reaction was stopped in cold water bath at 4 °C after incubation for 5 min at 37 °C. 
The change in absorbance fi"om zero time was monitored at 340 nm against blank 
containing all the reagents except NADPH. The rate of oxidation of NADPH 
obtained in the linear range in control cell was subtracted fi^om the rate obtained in 
the reaction cell. 
One unit of enzyme activity is defined as the amount required to oxidize 
2 nmole NADPH per min. Hence, one unit is equivalent to the synthesis of 
1 nmole mevalonate per min. 
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Calculations: 
Specific activity = OP- x F 
Protein cone. 
nmole of mevalonate/min/mg protein 
O.D. = Change in optical density per min 
F = Factor 
2.2.3.9 Determination ofHMG-CoA reductase protein mass by enzyme-linked 
immunosorbant assay (ELISA) 
HMG-CoA reductase protein mass was determined by the method of Duckworth et 
al. (1991) with minor modifications. Assay was performed in % well maxisorp E 
plates (Nalgene NUNC). Plates were coated with 100 i^l of microsomal enzyme 
(1-6 [ig protein) diluted in 0.05 M carbonate-bicarbonate-coating buffer. pH 9.6. 
This was allowed to sit overnight at 4 °C. The protein solution was removed, and 
the wells were filled with 100 jil of 5% non-fat dry milk in Tris-buffered saline 
(TBS). This blocking solution was allowed to incubate for 3-4 h at room 
temperature. The blocking solution was removed and the plates were washed three 
times, for 2 min each, with 100 fil of Tween-Tris-buffered saline (TTBS) (20 mM 
Tris, pH 7.5, 500 mM NaCl, 0.05% Tween-20). The plates were then incubated 
with 50 nl of rat hepatic HMG-CoA reductase antibody for 2 h at 37 °C. The wells 
were again washed two times with TTBS. The secondary antibody consisted of 
50 i^l of goat anti-rabbit IgG conjugated with horseradish peroxidase (1:1000). 
This was allowed to incubate on the plates for 1-2 h. The wells were again washed 
two times with TTBS. Plates were developed by the addition of 100 )il of the 
3,3',5,5'-tetramethyl benzidine peroxidase system. The colour reagent remained on 
the plates for 30 min, and the development was terminated by the addition of 
100 nl of 1 M phosphoric acid. The absorbance was read at 450 nm on an 
automatic microplate reader. 
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Calculations: HMG-CoA reductase protein mass was calculated by utilizing the 
known amount of purified HMG-CoA reductase protein. 
HMG-CoA protein mass = Absorbance of Unknown x n 
Absorbance of Purified 
(xg/g of microsomal protein 
[n = Protein mass of purified HMG-CoA reducatse] 
2.2.3.10 Protein estimation 
The protein was determined by the method of Bradford (1976), using bovine 
serum albumin as standard. Aliquots of liver, brain, colon, pancreas and mammary 
gland homogenates and post-mitochondrial supematants, microsomal suspension 
and solubilized HMG-CoA reductase fi-actions were first precipitated with 20% 
trichloroacetic acid. The protein pellets were dissolved in IN NaOH and suitable 
aliquots were used for protein determination. 
2.2.3.11 Statistical analysis 
Statistical analysis of data was done by employing two tailed student t-test (Bennet 
and Franklin, 1967). P values less than 0.05 were considered significant. 
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^suCts 
3.1 Percent Yield of Oil From Brans of Basmati and Saket-4 Cultivars and 
Percent Yield of Tocotrienol Rich Fraction (TRF) Isolated From These 
Oils and From Refined Edible Grade Rice Bran Oil 
As seen in Table 1, the percent yield of crude rice bran oil (RBO) isolated 
from raw and parboiled of Basmati was 15% and 17%, respectively, whereas the 
percent yield of RBO from raw and parboiled Saket-4 was 12% and 14%, 
respectively. The yield of tocotrienol rich fraction (TRF) isolated from refined 
edible grade RBO was 4.3%, whereas yield of TRF from raw and parboiled 
Basmati and Saket-4 was approximately 6.9%. After purification of TRF on silica 
gel bed, the yield of purified TRF of commercial refined edible grade RBO was 
reduced from 4.3% to 2.8% due to removal of non-tocotrienol and non-tocopherol 
contaminants. The TRF and purified TRF, however, may be contaminated with 
minor amounts of oryzanol, polyphenols and/or steroids/terpenes. The average 
percent yield of purified TRF for raw and parboiled Basmati was 4.7%, whereas 
for Saket-4 it was 4.6%. These results demonstrate that yield of oil from parboiled 
cultivars of rice was shghtly higher than the yield from the raw cultivars. The 
results also indicate that yield of TRF and purified TRF from crude RBO of 
Basmati and Saket-4 was approximately 68% higher than the TRF yield obtained 
from commercial refined edible grade RBO. 
3.2 Quantification of Types and Content of Tocotrienols (T3) and 
Tocopherols (T) by HPLC, Present in TRF and Purified TRF Isolated 
from Refined Edible Grade Rice Bran Oil and from Crude RBO of Two 
Cultivars of Rice 
Table 2, represent the type and percent content of tocotrienols (T3) and 
tocopherols (T) in TRF isolated from RBO, procured commercially and from 
Basmati and Saket-4, as determined by HPLC. The results were calculated from 
each peak area of the chromatogram of HPLC and are representative of the percent 
of the amount of sample loaded. The combined amount of T3 in TRF and purified 
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TABLE 1 
PERCENT YIELD OF OIL, TOCOTRIENOL RICH FRACTION (TRF) AND 
PURIFIED TRF ISOLATED FROM TWO CULTTVARS OF RICE, AND YIELD 
OF TRF AND PURIFIED TRF FROM REFINED EDIBLE GRADE RICE BRAN 
OIL (RBO) 
Type % Yield of Oil* % Yield of TRF % Yield of Purified 
TRF 
Refined RBO - 4J±0.27 2.8 ±0.26 
RawBasraati 14.9 ±0.21 7.2 ±0.18 4.9 ±0.12 
Parboiled Basmati 17.3 ±0.29 6.6 ±0.15 4.5 ±0.10 
RawSaket-4 12.4 ±0.35 7.1 ±0.15 4.8 ±0.15 
Parboiled Saket-4 13.6 ±0.37 6.7 ±0.11 4.3 ±0.13 
* Values are mean (g/100 g) ± SD of 3 separate determinations. 
TABLE 2 
QUANTIFICATION OF TYPES AND CONTENT OF TOCOTRIENOLS AND 
TOCOPHEROLS BY HPLC, PRESENT IN TRF AND PURIFIED TRF 
ISOLATED FROM REFINED EDIBLE GRADE RBO AND FROM CRUDE RBO 
OF TWO CULTIVARS OF RICE 
Type 
Tocotrienols 
a-T3 
P-T3 
Y-T3 
5-T3 
Refined RBO 
TRF 
14.6 
2.2 
6.2 
6.2 
Purified TRF 
20.6 
2.3 
9.7 
9.6 
Basmati 
Raw 
20.0 
-
5.0 
17.2 
Parboiled 
15.9 
-
9.7 
19.0 
Saket-4 
Raw 
14.1 
-
24.9 
6.9 
Parboiled 
16.2 
-
19.3 
12.9 
Total 29.2 42.2 42.2 44.6 45.9 48.1 
Tocopherols 
a-T 
P-T 
Y-T 
8-T 
Total 
14.7 
10.6 
3.1 
10.7 
39.1 
20.6 
16.1 
4.8 
16.4 
57.9 
20.1 
10.1 
17.9 
9.7 
57.8 
21.7 
9.3 
12.2 
12.2 
55.4 
24.2 
29.9 
-
54.1 
19.4 
22.1 
3.5 
6.6 
51.6 
TRF from refined edible grade RBO was 29% and 42%, respectively, whereas that 
of T was 39% and 58%, respectively. Purified TRF from RBO of raw Basmati 
contained 42% T3 and 59*'/o T, whereas, purified TRF from RBO of parboiled 
Basmati contained 45% T3 and 55% T. Purified TRF from raw Saket-4 contained 
46% T3 and 54% T, whereas, purified TRF from parboiled Saket-4 contained 48% 
T3 and 52% T. The combined content of y- and 5-T3 in TRF from refined RBO 
was approximately 12%, whereas, y- and 5-T3 content in purified TRF from 
refined RBO was around 19%. The yield of y- and 6-T3 in purified TRF obtained 
from RBO of raw and parboiled Basmati was 22% and 29%, respectively. The 
total content of y- and 5-T3, in purified TRF isolated from RBO of raw and 
parboiled Saket-4 was 32% and 32%, respectively, (Table 2). These results 
demonstrate that TRF content as well as the individual type and quantity of T3 and 
T vary from cultivar to cultivar of raw as well as parboiled rice. 
3J Effect of Tocotrienol Rich Fraction and Purified Tocotrienol Rich 
Fraction (TRF) on Plasma Lipids, Plasma Lipoprotein Lipids, ApoB, 
ApoA-1, Activity and Protein Mass of HMG-CoA Reductase, 
Microsomal Lipid Peroxidation and Plasma LDL Oxidation in 
Normolipidemic Rats After Two Weeks of Treatment 
In the experiments described below, the lipid lowering as well as 
antioxidant property of TRF and purified TRF was investigated in normolipidemic 
rats after two weeks of administration. The dose of purified TRF (81.25 mg/kg/ 
day) from refined RBO was adjusted to the dose calculated for TRF (125 mg/kg/ 
day) after removing the non-tocotrienol and non-tocopherol contaminants, which 
were approximately 35%. 
3.3.1 Effect on plasma lipids 
As shown in Table 3, administration of TRF (NLP-Tl) and purified TRF 
(NLP-T2) to normolipidemic rats was associated with a significant decline in lipid 
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TABLE 3 
EFFECT OF TRF AND PURIFIED TRF ON TMGLYCERIDES, TOTAL, 
ESTERIFIED AND FREE CHOLESTEROL IN NORMOLIPIDEMIC RATS 
AFTER TWO WEEKS OF TREATMENT 
Parameters NLP-C NLP-Tl NLP-T2 
Triglycerides 47.9 ±2.1* 33.2 ±1.3 33.0 ±L6 
(-30.7%V (-31.1%)* 
Total cholesterol 73.4 ±2.8 65.2 ±2.1 64.4 ±2.2 
(-11.2%f (-12.3%f 
Esterified cholesterol 54.1 ± 0.9 47.1 ± 1.9 46.4 ± 1.4 
(-12.9%)* (-14.5%)* 
Free cholesterol 19.3 ± 1.1 18.1± 0.9 18.0 ± 0.6 
(-6.2%) (-6.7%) 
'^ Values are mean (mg/dl) ± SD from plasma of 5 individual rats in each group. 
NLP-C, saline-fed control; NLP-Tl & NLP-T2, given 125 mg TRF and 81.25 mg purified 
TRF/kg/day, respectively, for 2 weeks. 
Significantly different from NLP-C at *p<0.001, *p<0-01 & V<0-05-
parameters. Plasma triglycerides showed a highly significant decline of 
approximately 31% whereas the decrease in total cholesterol was 12% in both the 
treated groups. Esterified cholesterol decreased by 13% and 15% in NLP-Tl and 
NLP-T2, respectively, whereas a decrease of approximately 6% in the free 
cholesterol was not significant (Table 3). These results demonstrate that TRF 
significantly reduces the plasma lipids in normohpidemic rats. 
3.3.2 Impact on plasma lipoprotein lipids, apoB and apoA-1 
As seen in Table 4 there was a significant decline in VLDL-C, LDL-C and 
HDL3-C after two weeks of treatment of TRF and purified TRF. VLDL-C 
decreased by approximately 35% whereas the decline in LDL-C was 34-35% in 
NLP-Tl and NLP-T2. Although TRF and purified TRF did not affect HDL-C 
levels, HDL-C subfractions, HDL3-C decreased by 11% and 15% in NLP-Tl and 
NLP-T2, respectively. In contrast, a significant increase of 31% and 38% in 
HDL2-C was seen in NLPT-1 and NLP-T2, respectively, after two weeks of TRF 
and purified TRF administration. ApoB showed a considerable decrease and the 
decline was same in both the treated groups (19%) with no significant change in 
apoA-1 levels (Table 4). These results demonstrate that hypolipidemic impacts of 
TRF and purified TRF in normohpidemic rats were similar, apparently due to high 
dose of TRF (125 mg/kg/day) and purified TRF (81.25 mg/kg/day) used in these 
experiments. 
3.3.3 Regulation of en:ymatic activity and Protein Mass of solubilised 
Microsomal HMG-CoA reductase 
In order to find out the mechanism of hypohpidemic action of TRF in 
normal rats, effect of TRF and purified TRF on hepatic HMG-CoA reductase 
activity as well as protein mass was investigated. The specific activity of HMG-
CoA reductase was significantiy reduced to 3.0 and 2.9 units/mg in NLP-Tl and 
NLP-T2, respectively, from 7.4 units/mg of saline-fed control rats (Table 5). 
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TABLE 4 
IMPACT OF TRF AND PURIFIED TRF ON VLDI^C, LDL-C, HDL-C, HDLj-C, 
HDL3-C, ApoB AND ApoA-1 IN NORMOLIPIDEMIC RATS TREATED FOR 
TWO WEEKS 
Parameters NLP-C NLP-Tl NLP-T2 
VXDL-cholesterol 7.6^0.5* 5.0 ±0.4 4.9 ±0.2 
(-34.2%)*' (-35.5%)*' 
LDL-cholesterol 22.1 ± 1.4 14.6 ±0.9 14.3 ±0.6 
(-33.9%)* (-35.3%)' 
HDL-cholesteroI 43.7 ±1.6 45.3 ±1.2 45.4 ±1.7 
(+3.7%) (+3.9%) 
HDL2-cholesterol 15.6^0.8 20.4 + 0.9 21.5 ±0.8 
(+30.8%)* (+37.8%)* 
HDLj-cholesterol 28.1 + 1.1 24,9 ±1.1 23.9 ±1.1 
(-11.4%)* (-14.9%)* 
ApoB 14.0 ±0.5 11.4 ±0.7 11.4 ±0.6 
(-18.6%)* (-18.6%)* 
ApoA-1 92.9 ±3.6 92.4 ± 2.3 92.5 ± 3.1 
(-0.5%) (-0.4%) 
*Values are mean (mg/dl) ± SD from plasma of 5 individual rats in each group. 
NLP-C, saline-fed control; NLP-Tl & NLP-T2, given 125 mg TRF and 81.25 mg purified 
TRF/kg/day, respectively, for 2 weeks. 
Significantly different from NLP-C at *p<0.001 <& *p<0.01. 
TABLE 5 
IN VIVO MODULATION OF ACTIVITY AND PROTEIN MASS OF HEPATIC 
HMG-CoA REDUCTASE IN NORMOLIPIDEMIC RATS TREATED WITH TRF 
AND PURIFIED TRF FOR TWO WEEKS 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
NLP-C 
NLP-Tl 
NLP-T2 
^Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**VaIues are mean (^g/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, saline-fed control: NLP-Tl & NLP-T2, given 125 mg TRF and 81.25 mg purified 
TRF/kg/day, respectively, for 2 weeks. 
Significantly different from NLP-C at ^p<0.001. 
7.4 ± LO 
3.0 ± 0.7 
(-59.4%)* 
2.9 ± 0.5 
(-60.8%)* 
212 ±14 
96 ± 8 
(-54.7%) 
91 ± 6 
(-57.1%) 
Feeding of TRF (NLP-Tl) and purified TRF (NLP-T2) caused a significant 
decline in the protein mass of HMG-CoA reductase by 55% and 57% respectively. 
These results demonstrate that TRF mediated decrease in lipid parameters of 
normolipidemic rat is due to decline in hepatic HMG-CoA reductase activity, 
which is due to reduction in its protein mass. 
3.3.4 Impact on microsomal lipid peroxidation and plasma LDL oxidation 
As shown in Table 6 TRF and purified TRF administration to 
normolipidemic rats significantly prevented microsomal lipid peroxidation and 
LDL oxidation measured in vitro. There was a significant decrease of 23% and 
29% in thiobarbituric acid reactive substances (TEARS) formation, in NLP-Tl 
and in NLP-T2, respectively, when compared to untreated control rats. Whereas, 
formation of conjugated dienes, a reflection of plasma LDL oxidation was 
significantiy decreased by approximately 42% in both the treated groups. These 
results demonstrate that TRF acts as a potent antioxidant in normolipidemic rats. 
3.4 Effect of Purified Tocotrienol Rich Fraction on Plasma Lipids, Plasma 
Lipoprotein Lipids, ApoB, ApoA-1, Activity and Protein Mass of HMG-
CoA Reductase, Microsomal Lipid Peroxidation and Plasma LDL 
Oxidation in Normolipidemic and Hyperlipidemic Rats Treated for 
Three Weeks 
In the experiments described below the lipid lowering effect of purified 
TRF at dose of 65 mg/kg/day, which is equivalent to dose of 100 mg TRF/kg/ 
day, in normolipidemic rats was investigated after three weeks of administration. 
The efficacy of purified TRF in preventing the increase in lipid parameters was 
also investigated by administering the same dose of 65 mg purified TRF/kg/day 
along with the atherogenic diet. 
TABLE 6 
EFFECT OF TRF AND PURIFIED TRF ON MICROSOMAL LIPID 
PEROXIDATION AND PLASMA LDL OXIDATION IN NORMOLIPIDEMIC 
RATS TREATED FOR TWO WEEKS 
Group TBARS* Conjugated Diene** 
NLP-C 1.88 ± 0.06 5.42 ± 0.22 
NLP-Tl L44 ± 0.10 3.12 ± 0.27 
(-23.4%)* (-42.4%)* 
NLP-T2 1.34 ±0.10 3.10 ±0.19 
(-28.7%)* (-42.8%)* 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, saline-fed control; NLP-Tl & NLF-T2, given 125 mg TRF and 81.25 mg purified 
TRF/kg/day, respectively, for 2 weeks. 
Significantly different from NLP-C at *p<0.001. 
3.4.1 Impact on plasma lipids 
When normolipidemic rats were treated with 65 mg purified TRF/kg/day 
for three weeks, a significant reduction in lipid parameters, lipoprotein lipids. 
HMG-CoA reductase activity and its mass was observed. As shown in Table 7, 
triglycerides reduced by 34%, whereas, the total, esterified and fi^ee cholesterol 
levels showed a significant decline of 15%, 17% and 10%, respectively, when 
compared to saline-fed control rats. 
Feeding of atherogenic diet to rats (HLP-C) for three weeks, caused a 
substantial increase in all the lipid parameters. Triglycerides, total, esterified and 
fi-ee cholesterol increased fi^om 48, 75, 54 and 20 mg/dl, respectively in NLP-C to 
168, 185, 145 and 40 mg/dl in HLP-C, respectively. Administration of 65 mg 
purified TRF along with atherogenic diet to rats (HLP-T), significantly prevented 
the increase in lipid parameters when compared to HLP-C. The increase in 
triglycerides, total, esterified and free cholesterol was 191%, 81%, 89% and 61%, 
respectively in HLP-T, respectively, was significantly lower than an increase of 
252%, 148%, 166% and 100%, respectively, in HLP-C (Table 7). These resuhs 
demonstrate that purified TRF caused significant decline of plasma lipids in 
normolipidemic rats after three weeks of treatment, whereas, in hyperlipidemic 
rats purified TRF significantly prevented the increase in lipid parameters. 
3.4.2 Effect on plasma lipoprotein lipids, apoB and apoA-1 
As shown in Table 8 purified TRF administration to normolipidemic rats 
for three weeks caused a significant reduction in VLDL-C, LDL-C and HDL3-C by 
47%, 35% and 18%, respectively, with no significant effect on HDL-C. HDL.-C 
was significantly increased by 35%. ApoB level was significantly decreased by 
21% when compared to saline-fed control rats, whereas apoA-1 level remained 
unaffected. 
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TABLE 7 
EFFECT OF PURIFIED TRF ON TRIGLYCERIDES, TOTAL, ESTERIFIED 
AND FREE CHOLESTEROL IN NORMOLIPIDEMIC AND HYPERLIPIDEMIC 
RATS AFTER THREE WEEKS OF TREATMENT 
Parameters 
Triglycerides 
Total cholesterol 
Esterified cholesterol 
Free cholesterol 
NLP-C 
47.8^2.1* 
74.5 ± 3.1 
54.4 ± L7 
20.1 ± 0.7 
NLP-T 
31.7 ±1.0 
(-33.7%y 
63.0 ± 1.9 
(-15.4%)^ 
44.9 ± 1.9 
(-17.5%)^ 
18.1 ± 0.7 
(-9.9%y 
HLP-C 
168.3 ± 5.2 
(+252.1%)* 
185.0 ± 6.5 
(+148.3%)' 
144.7 ± 5.7 
(+166.0%)' 
40.2 ± 1.6 
(+100.0%)' 
HLP-T 
139.0 ± 4.4 
(+190.8%)' 
135.2 ± 3.7 
(+81.5%)' 
102.8 ± 3.3 
(+89.0%)' 
32.3 ± 0.6 
(+60.7%)' 
* Values are mean (mg/dl) ± SD from plasma of 3 individual rats in each group. 
NLP-C, saline-fed control; NLP-T, given 65 mg purified TRF/l^day for 3 weeks; HLP-C, 
hyperlipidemic control; HLP-T, given 65 mg purified TRF/I^day alongwith the atherogenic 
diet for 3 weeks. 
Significantly different from NLP-C at 'p<0.001 & *p<0.01. 
TABLE 8 
IMPACT OF PURIFIED TRF ON VLDL-C, LDL-C, HDL-C, HDL2-C, HDL3-C, 
ApoB AND ApoA-1 IN NORMOLIPIDEMIC AND HYPERLIPIDEMIC RATS 
TREATED FOR THREE WEEKS 
Parameters 
VLDL-cholesterol 
LDLrcholesterol 
HDL-cholesterol 
HDL;-cholesterol 
HDL3-cholesterol 
ApoB 
ApoA-1 
NLP-C 
8.0 ± 0.4* 
23.0 ± 1.2 
43.5 ±1.5 
15.3 ± 0.7 
28.2 ±1.1 
14.6 ± 0.6 
92.5 ± 3.4 
NLP-T 
4.2 ± 0.3 
(-47.5%)* 
15.0 ± 0.8 
(-34.8%)* 
43.8 ± 1.1 
(+0.7%) 
20.7 ± 0.5 
(+35.3%)* 
23.1 ± 0.8 
(-18.1%)* 
11.5 ±0.6 
(-21.2%)* 
92.4 ± 2.6 
(-0.1%) 
HLP-C 
16.0 ± 0.4 
(+100.0%)* 
104.0 ± 4.3 
(+352.2%)* 
64.9 ± 2.4 
(+49.2%)* 
23.0 ± 0.9 
(+50.3%)* 
41.9 ±1.2 
(+48.6%)* 
62.2 ± 2.0 
(+326.0%)* 
107.9 ± 3.9 
(+16.6%)* 
HLP-T 
11.4 ±0.4 
(+42.5%)* 
68.5 ± 1.2 
(+197.8%)* 
55.0 ±1.1 
(+26.4%)* 
23.0 ± 0.9 
(+50.3%)* 
32.0 ±1.1 
(+13.5%)* 
42.9 ±1.4 
(+193.8%)* 
101.6 ±3.1 
(+9.8%)' 
^Values are mean (mg/dl) ± SD from plasma of 3 rats in each group. 
NLP-C, saline-fed control; NLP-T, given 65 mg purified TRF/kg/day for 3 weeks; HLP-C, 
hyperlipidemic control; HLP-T, given 65 mg purified TRF/kg/day alongwith the atherogenic 
diet for 3 weeks. 
Significantly different from NLP-C at *p<0.001 & *p<0.01. 
Plasma lipoprotein lipids, apoB and apoA-1 levels were significantly 
increased on feeding atherogenic diet for three weeks. This increase was 
significantly arrested by administration of 65 mg purified TRF along with 
atherogenic diet. The increase in VLDL-C was 100% in HLP-C whereas an 
increase of only 43% was observed in purified TRF treated (HLP-T) group 
(Table 8). Similarly, purified TRF prevented the increase of LDL-C, HDL-C and 
HDLrC substantially. The increase in LDL-C, HDL-C and HDL3-C levels was 
198%, 26% and 13%, respectively, in HLP-T, compared to an increase of 352%, 
49°'o and 49%, respectively, in HLP-C rats, whereas no effect was seen on 
HDL2-C level. ApoB and apoA-1 levels increased by 326% and 17%, respectively, 
in HLP-C whereas an increase of 194% and 10%, respectively, was observed in 
HLP-T, after three weeks of TRF feeding (Table 8). These results demonstrate that 
purified TRF caused the significant decline in VLDL-C, LDL-C and apoB levels 
with no significant affect on HDL-C and apoAl levels in normoUpidemic rats after 
3 weeks of TRF treatment. Feeding of purified TRF along with atherogenic diet 
for 3 weeks significantly prevented the increase in lipoprotein lipids including 
apoB. 
3.4.3 Regulation of enzymatic activity and Protein Mass of solubilized 
Microsomal HMG-CoA reductase 
As depicted in Table 9, HMG-CoA reductase activity and protein mass was 
significantly decreased by 54% and 49%, respectively, in normolipidemic rats 
treated with TRF (NLP-T) for 3 weeks in comparison to saline-fed control rats. 
Feeding of atherogenic diet caused a suppression of HMG-CoA reductase activity 
and protein mass. The specific activity of HMG-CoA reductase in HLP-C was 2.1 
units/mg as compared to 7.4 units/mg in NLP-C, indicating a suppression of 72%. 
Similarly, a reduction of 49% in protein mass was observed in HLP-C. Purified 
TRF feedii^ along with atherogenic diet caused a fiirther decrease in the 
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TABLE 9 
REGULATION OF ACTIVITY AND PROTEIN MASS OF HEPATIC HMG-CoA 
REDUCTASE IN NORMOLIPIDEMIC AND HYPERLIPIDEMIC RATS 
TREATED WITH PURIFIED TRF FOR THREE WEEKS 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
NLP-C 
NLP-T 
HLP-C 
HLP-T 
*Values are mean (nmoles of mevalonate fortned/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean {\ig/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, saline-fed control; NLP-T, given 65 mg purified TRF/kg/day for 3 weeks; HLP-C, 
hyperlipidemic control; HLP-T, given 65 mg purified TRF/kg/day alongwith the atherogenic 
diet for 3 weeks. 
Significantly different from NLP-C at ^p<0.001. 
7.4 ± 0.8 
3.4 ± 0.5 
(-54.0%)* 
2.1 ± 0.4 
(-7L6%)* 
L8 ± 0.2 
(-75.7%)* 
247 ± 3 
126 ± 4 
(-49.0%)* 
125 ± 3 
(-49.4%)* 
9 6 ± 4 
(-61.1%)* 
\ [ Ace. No )^] 
enzymatic activity (76%) and protein mass (61%) of HMG-CoA reductase 
(Table 9). These results demonstrate that decrease in lipid parameters of 
normolipidemic rat is due to decline in hepatic HMG-CoA reductase activity, 
which is due to reduction in its protein mass. Feeding of atherogenic diet caused a 
significant decrease in HMG-CoA reductase activity and protein mass, which was 
further declined when purified TRF was administered along with atherogenic diet. 
3.4.4 Impact on microsomal lipid peroxidation and LDL oxidation 
As shown in Table 10, a significant decrease of 34% in TBARS formation 
was observed in normolipidemic rats treated with purified TRf. The formation of 
conjugated dienes was significantly decreased by 44% after three weeks of 
purified TRF administration to normolipidemic rats. Feeding of atherogenic diet 
caused an increase in TBARS and conjugated dienes formation by 96% and 79%, 
respectively, as compared to values obtained from NLP-C rats. Administration of 
purified TRF along with atherogenic diet (HLP-T) for 3 weeks significantly 
blocked the increase in TBARS and conjugated dienes formation by 62% and 
66%. respectively (Table 10). These results demonstrate that purified TRF 
significantly prevented the lipid peroxidation and oxidation of LDL in normo-
lipidemic rats. The results also demonstrate that the induction of hyperlipidemia in 
rats is associated with a significant increase in the microsomal lipid peroxidation 
as well as plasma LDL oxidation, which is significantly prevented by the 
administration of purified TRF. 
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TABLE 10 
IMPACT OF PURIFIED TRF ON MICROSOMAL LIPID PEROXIDATION AND 
PLASMA LDL OXIDATION IN NORMOLEPIDEMIC AND HYPERLIPIDEMIC 
RATS TREATED FOR 3 WEEKS 
Group TBARS* Conjugated Diene* 
NLP-C L94±0.08 5.50 ± 0.26 
NLP-T 1.27 ±0.10 3.10 ±0.29 
(-34.5%)^ (-43.6%)* 
HLP-C 3.81 ± 0.13 9.85 ± 0.28 
HLP-T 1.46 ± 0.14 3.39 ± 0.23 
(-61.7%)^ (-65.6%)* 
^Values are mean (nmole/min/mg) ± SO of 4 separate assay in each group. 
**Values arc mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, saline-fed control; NLP-T, given 65 mg purified TRF/kg/day for 3 weeks; HLP-C, 
hyperlipidemic control; HLP-T, given 65 mg purified TRFA(g/day alongwith the atherogenic 
diet for 3 weeks. 
Significantly different from respective controls, NLP-C and HLP-C at *p<0.001. 
3.5 Effect of Purified Tocotrienol Rich Fraction on Plasma Lipids, Plasma 
Lipoprotein Lipids, ApoB, ApoA-1, Activity and Protein Mass of HMG-
CoA Reductase, Microsomal Lipid Peroxidation and Plasma LDL 
Oxidation in Hyperlipidemic Rats Treated for 5 Days After Withdrawal 
of Atherogenic Diet 
As expected, the efficacy in terms of lipid lowering property of TRF at 
125 mg/kg/day and purified TRF at an equivalent dose of 81.25 mg/kg/day was 
quite similar in normolipidemic rats after two weeks of administration. In order to 
find out the impact of purified TRF on cholesterol dynamics in experimentally 
induced hyperlipidemic rats, a dose of 16.25 and 32.50 mg purified TRF/kg/day, 
equivalent to 25 and 50 n^ TRF/kg/day, respectively, was administered for 
5 days. 
3.5.1 Effect on plasma lipids 
As seen in Table 11, feeding of an atherogenic diet for three weeks caused 
an increase in plasma lipids and lipoproteins. However, 5 days after the 
withdrawal of atherogenic diet, a decrease in these parameters was observed in 
HLP-UC group. The decrease in these parameters was more marked when 16.25 
(HLP-Tl) and 32.50 mg (HLP-T2) purified TRF was given for 5 days. There was 
significant decline in triglycerides and total cholesterol levels by 11% and 18%, 
respectively, in both the treated groups, when compared to HLP-UC 1. Esterified 
cholesterol decreased by 20% (HLP-Tl) and 19% (HLP-T2), whereas free 
cholesterol decreased by approximately 13% in both the treated groups (Table 11). 
These results demonstrate a significant TRF-mediated decline in lipid parameters 
after 5 days of administration to hyperlipidemic rats. 
3.5.2 Effect on plasma lipoprotein lipids, apoB and apoA-1 
As shown in Table 12, there was an insignificant decline of 4% in 
VLDL-C in HLP-Tl, but VLDL-C decreased (10%) significantly in HLP-T2, 
whereas a significant decline of 21% was observed in LDL-C in both the TRF 
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TABLE 11 
EFFECT OF PURIRED TRF ON TRIGLYCERIDES, TOTAL, ESTERIFIED 
AND FREE CHOLESTEROL IN HYPERLIPIDEMIC RATS TREATED FOR 
5 DAYS 
Parameters HLP-C HLP-UCl HLP-Tl HLP-T2 
Triglycerides 168.3 ±5.2* 151.8 ±6.1 135.6 ±4.5 135.7 ±6.1 
(-10.7%)' (-10.6%)' 
Total cholesterol 185.0 ±6.5 159.6 ±6.2 130.8 ±5.2 130.7 ±4.6 
(-18.0%)* (-18.1%)* 
Esterified cholesterol 144.7 ±5.7 122.2 ±4.9 98.1 ±3.5 98.4 ±3.4 
(-19.7%)* (-19.5%)* 
Free cholesterol 40.2 ±1.6 37.4 ±1.3 32.7 ±1.7 32.3 ± 1.4 
(-12.6%)' (-13.6%)* 
* Values are mean (mg/di) ± SD from plasma of 3 individual rats in each group. 
HLP-C, hyperlipidemic control; HLP-UCl, saline-fed control; HLP-Tl & HLP-T2, given 
16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 5 days. 
Significantly different from HLP-UCl at *p<0.001 & *p<0.01. 
TABLE 12 
IMPACT o r PURIFIED TRF ON VLDL-C, LDL-C, HDL-C, HDLj-C, HDL3-C, 
ApoB AND ApoA-1 IN HYPERLEPIDEMIC RATS AFTER 5 DAYS OF 
TREATMENT 
Parameters HLP-C HLP-UCl HLP-Tl HLP-T2 
VLDL-cholesterol 16.0 ±0.4* 13.7 ±0,4 13.1 ± 0.6 12.3 ±0.9 
(-4.4%) (-10.2%f 
LDI^cholesterol 104.0 ±4.3 8S.6±2.2 67.6 ±3.0 67.5 ±2.1 
(-21.0%)^ (21.1%)* 
HDL-cholesterol 64.9 ±2.4 60.0 ±1.2 50.0 ±1.9 50.7 ±1.8 
(-16.7%)* (-15.5%)* 
HDL2-cholesterol 23.0 ± 0.9 24.7 ± 0.7 18.2 ± 0.7 19.3 ± 1.0 
(-26.3%)* (-21.9%)* 
HDLa-cholesterol 41.9 ±1.2 35.3 ±0.8 31.8 ±1.5 31.4 ±1.7 
(-9.9%)* (-11.0%)* 
ApoB 62.2 ±2.0 53.4 ±2.0 42.0 ±1.1 42.6 ±2.1 
(-21.3%)* (-20.2%)* 
ApoA-1 107.9 ±3.9 104.6 ± 4.1 100.2 ± 2.9 100.7 ± 2.1 
(-4.2%) (-3.7%) 
^Values are mean (mg/di) ± SD from plasma of 3 individual rats in each group. 
HLP-C, hyperlipidemic control; HLP-UCl, saline-fed control; HLP-Tl & HLP-T2, given 
16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 5 days. 
Significantly different from HLP-UCl at *p<0.001, ^ p<0.01 & ^p<0.05. 
treated groups. The levels of HDL-C, HDL2-C and HDL3-C were decreased by 
17% , 26% and 10% in HLP-Tl, respectively, and the decrease in HLP-T2 was 
15%, 22% and 11% respectively, as compared to HLP-UCl after 5 days of 
treatment. ApoB levels were significantly decreased by 20% to 21% in both the 
treated groups, with no significant change in apoA-1 levels (Table 12). These 
results demonstrate that feeding of atherogenic diet causes a significant increase 
of VLDL-C, LDL-C and apoB levels. As can be seen, administration of purified 
TRF to hyperlipidemic rats for 5 days substantially decrease the above lipid 
parameters including apoB. 
3.5.3 Modulation ofHMG-CoA reductase activity and its protein mass 
HMG-CoA reductase activity and its protein mass was decreased by 47% 
and 31%, respectively, in HLP-Tl as compared to HPL-UCl after 5 days of 
purified TRF treatment as shown in Table 13. The level of reduction in HMG-CoA 
reductase activity and protein mass in HLP-T2 was similar to HLP-Tl. These 
results indicate that feeding of exogenous cholesterol or purified TRF to rats 
decrease the synthesis of endogenous cholesterol via decrease in HMG-CoA 
reductase activity which in turn is mediated by the decrease in its protein mass. 
However, withdrawal of atherogenic diet relieves this inhibition which is evident 
from the increase in HMG-CoA reductase activity as well as its protein mass. 
3.5.4 Impact on microsomal lipid peroxidation and LDL oxidation 
As shown in Table 14, formation of TBARS in microsomes was increased 
from 1.94 imits/mg in NLP-C to 3.81 unit&''mg in HLP-C, whereas LDL oxidation 
in plasma increased from 5.50 units/ml in NLP-C to 9.85 units/ml in HLP-C, after 
feeding atherogenic diet for three weeks. These values were reduced to 
3.09 units/mg and 8.26 units/ml in HLP-UCl after 5 days of the withdrawal of 
atherogenic diet, but tiie decrease was enhanced significantly in purified TRF 
treated hyperlipidemic rats for 5 days. Lipid peroxidation in microsomes decreased 
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TABLE 13 
IN VIVO MODULATION OF ACTIVITY AND PROTEIN MASS OF HEPATIC 
HMG-CoA REDUCTASE IN HYPERLIPIDEMIC RATS TREATED WITH 
PURIFIED TRF FOR 5 DAYS 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
HLP-C 
HLP-UCl 
HLP-Tl 
HLP-T2 
*Values are mean (nmoles of mevalonate formed/min/ing protein) ± SD from three separate 
assay in each group. 
**Values are mean (ng/g of microsomal protein) ± SD from three separate assay in each 
group. 
HLP-C, byperlipidemic control; HLP-UCl, saline-fed control; HLP-Tl & HLP-T2, given 
16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 5 days. 
Significantly different from HLP-UCl at *p<0.001. 
2.1 ± 0.4 
3.8 ± 0.3 
2.0 ± 0.2 
(-47.4%)^ 
2.0 ± 0.3 
(-47.4%)^ 
125 ± 3 
142 ± 5 
98 ± 3 
(-31.0%) 
95 ± 4 
(-33.1%) 
TABLE 14 
IMPACT OF PURIFIED TRF ON MICROSOMAL LIPID PEROXIDATION AND 
PLASMA LDL OXIDATION IN HYPERLIPIDEMIC RATS AFTER 5 DAYS OF 
TREATMENT 
Group TBARS* Conjugated Diene* 
NLP-C L94±0.08 5.50 ±0.26 
HLP-C 3.81 ± 0.13 9.85 ± 0.28 
HLP-UCl 3.09 ±0.12 8.26 ±0.26 
HLP-Tl 1.61 ± 0.11 4.55 ± 0.24 
(-38.5%)* (-42.8%)* 
HLP-T2 1.55 ±0.11 4.40 ±0.18 
(-41.2%)* (-44.4%)* 
•Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
HLP-C, hyperlipidemic control; HLP-UCl, saline-fed control; HLP-Tl & HLP-T2, given 
16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 5 days. 
Significantly different from HLP-UC2 at ^ p<0.001. 
by 39%, and 41% in HLP-Tl and HLP-T2, respectively, whereas formation of 
conjugated dienes in plasma was reduced by approximately 43%, in both the 
treated groups. (Table 14). These results demonstrate that the induction of 
hyperlipidemia in rats is associated with a significant increase in the microsomal 
lipid peroxidation as well as plasma LDL oxidation, which is significantly 
prevented by the administration of purified TRF. 
3.6 Effect of Purified Tocotrienol Rich Fraction on Plasma Lipids, Plasma 
Lipoprotein Lipids, ApoB, ApoA-1, Activity and Protein Mass of HMG-
CoA Reductase, Microsomal Lipid Peroxidation and Plasma LDL 
Oxidation in Hyperlipidenuc Rats Treated for 7 Days After Withdrawal 
of Atherogenic Diet 
In experiments described below, the impact of purified TRF on cholesterol 
dynamics in experimentally induced hyperlipidemic rats was investigated. A dose 
of 16.25 and 32.50 mg purified TRF/kg/day, equivalent to 25 and 50 mg 
TRF/kg/day, was administered for 7 days. 
3.6.1 Effect on plasma lipids 
As shown in Table 15, a highly significant decrease of 34% in triglycerides 
concentration was observed in hyperlipidemic rats treated with 16.25 mg 
(HLP-T3) and 32.50 mg (HLP-T4) of purified for 7 days when compared to 
HPL-UC2, the saline-fed untreated control rats. Similarly, total, esterified and free 
cholesterol levels showed a significant reduction of 36%, 38% and 33%, respec-
tively, in HLP-T3, whereas, the reduction in HLP-T4 was approximately same as 
in HLP-T3 (Table 15). These results demonstrate that reduction in lipid parameters 
was achieved at a faster rate when treated with TRF as compared to untreated 
hyperlipidemic control group. 
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TABLE 15 
EFFECT OF PURIFIED TRF ON TRIGLYCERIDES, TOTAL, ESTERIFIED 
AND FREE CHOLESTEROL IN HYPERLIPIDEMIC RATS TREATED FOR 
7 DAYS 
Parameters HLP-C HLP-UC2 HLP-T3 HLP-T4 
Triglycerides 
Total cholesterol 
Esterified cholesterol 
Free cholesterol 
168.3 ± 5.2* 134.0 ± 6.0 
185.0 ± 6.5 
144.7 ± 5.7 
40.2 ± 1.6 
129.7 ± 6.3 
97.8 ± 5.2 
31.9 ±1.1 
88.5 ± 3.3 
(-34.0%)* 
82.4 ± 3.6 
(-36.5%)* 
60.9 ± 2.6 
(-37.7%)^ 
21.5 ±1.1 
(-32.6%)* 
88.6 ± 3.1 
(-33.8%)* 
83.7 ± 2.2 
(-35.5%)* 
62.0 ± 2.1 
(-36.6%)* 
21.7 ± 1.4 
(-32.0%)* 
^Values are mean (mg/dl) ± SD from plasma of 3 individual rats in each group. 
HLP-C, hyperiipidemic control; HLP-UC2, saline-fed control; HLP-T3 & HLP-T4, given 
16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC2 at *p<0.001. 
3.6.2 Effect on plasma lipoprotein lipids, apoB and apoA-I 
VLDL-C decreased significantly by approximately 23% in HLP-T3 and 
HLP-T4 when compared to HLP-UC2 after 7 days of treatment (Table 16). The 
decline in LDL-C was approximately 58% in HLP-T3 and in HLP-T4 rats. 
Reduction in HDL-C and HDL2-C was approximately same in both the treated 
groups, i.e. 9.0% and 16.0%, respectively, with no significant change in HDL3-C 
concentration. ApoB levels showed a significant decline of 53% in both the treated 
groups as compared to HLP-UC2 group, whereas apoA-I levels were not affected 
after 7 days of purified TRF treatment (Table 16). These results demonstrate that 
decline in total cholesterol was due to a significant decrease in VLDL-C and 
LDL-C. In addition, a reduction in apoB levels, which is associated with LDL was 
also seen. 
3.6.3 Regulation of hepatic HMG-CoA reductase activity and protein mass 
As seen in Table 17, after 7 days of purified TRF treatment, HMG-CoA 
reductase activity and protein mass was decreased by 60% and 52%, respectively, 
in HLP-T3 as compared to HLP-UC2 group. Similarly a decrease of 59% and 53% 
in enzymatic activit>^ and protein mass of HMG-CoA reductase was observed in 
HLP-T4. (Table 17). These results demonstrate that reduction in HMG-CoA 
reductase activity and protein mass at the two doses of purified TRF is almost 
similar. 
3.6.4 Impact on microsomal lipid peroxidation and LDL oxidation 
As shown in Table 18, formation of TEARS in microsomes was increased 
fi^om 1.94 units/mg in NLP-C to 3.81 units/mg in HLP-C, whereas LDL oxidation 
in plasma increased from 5.50 units/ml in NLP-C to 9.85 units/ml in HLP-C, after 
feeding atherogenic diet for three weeks. These values were reduced to 
2.21 units/mg and 6.40 units/ml in HLP-UCl after 7 days of the withdrawal of 
atherogenic diet, but the decrease was enhanced significantly in purified TRF 
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TABLE 16 
IMPACT OF PURIFIED TRF ON VLDL-C, LDL-C, HDL-C, HDLrC HDL3-C, 
ApoB AND ApoA-1 IN HYPERLIPIDEMIC RATS AFTER 7 DAYS OF 
TREATMENT 
Parameters HLP-C HLP-UC2 HLP-T3 HLP-T4 
VXDL-cholesteroi 16.0 ±0.4* 11.4 ±0.9 8.9 ±0,8 8.7 ±0.5 
(-21.9%)* (-23.7%)* 
LDL-cholesterol 104.0 ±4.3 66.8 ±2.2 27.1 ±2.4 28.6 ±1.4 
(-59.4%)* (-57.2%)* 
HDL-choIesterol 64.9 ± 2.4 50.9 ± 1.8 46.3 ± 1.2 46.4 ± 1.4 
(-9.0%)^ (-8.8%)* 
HDL-cholesterol 23.0 ±0.9 20.0^0.8 16.8 ± 1.01 16.9 ± 1.0 
(-16.0%)^ (-15.5%)* 
HDL3-cholesterol 41.9 ±1.2 30.9 ±1.2 29.5 ±3.6 29.5 ±2.1 
(-4.5%) (-4.5%) 
ApoB 62.2 ± 2.0 44.4 ± 1.4 20.9 ± 0.7 20.5 ± 1.5 
(-52.9%)* (-53.8%)* 
ApoA-1 107.9 ±3.9 100.7 ± 4.7 94.5 ±4.1 95.2 ± 3.8 
(-6.1%) (-5.5%) 
*VaIues are mean (mg/dl) ± SD from plasma of 3 individual rats in each group. 
HLF-C, hyperlipidemic control; HLP-UC2, saline-fed control; HLP-T3 & HLP-T4, given 
16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC2 at *p<0.001 & V<0.01. 
TABLE 17 
REGULATION OF ACTIVITY AND PROTEIN MASS OF HEPATIC HMG-CoA 
REDUCTASE IN HYPERLIPIDEMIC RATS TREATED WITH PURIFIED TRF 
FOR 7 DAYS 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
HLP-C 
HLP-UC2 
HLP-T3 
HLP-T4 
^Values are mean (nmoies of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (p-g/g of microsomal protein) ± SD from three separate assay in each 
group. 
HLP-C, hjperlipidemic control; HLP-IIC2, saline-fed control; HLP-T3 & HLP-T4, given 
16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC2 at ^p<0.001. 
2.1 ± 0.4 
6.5 ± 0.5 
2.6 ± 0.3 
(-60.0%)* 
2.7 ± 0.3 
(-58.5%)* 
125 ± 3 
219 ± 5 
105 ± 5 
(-52.0%) 
104 ± 3 
(-52.5%) 
TABLE 18 
IMPACT OF PURIFIED TRF ON MICROSOMAL LIPID PEROXIDATION AND 
PLASMA LDL OXIDATION IN HYPERLIPIDEMIC RATS AFTER 7 DAYS OF 
TREATMENT 
Group TBARS* Conjugated Diene' 
NLP-C 1.94 ± 0.08 5.50 ± 0.26 
HLP-C 3.81 ±0.13 9.85 ±0.28 
HLP-UC2 2.21 ±0.16 6.40 ±0.31 
HLP-T3 1.36 ± 0.10 3.66 ± 0.19 
(-38.5%)* (-42.8%)* 
HLP-T4 1.30 ± 0.10 3.56 ± 0.22 
(-41.2%)* (-44.4%)* 
^Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
** Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
HLP-C, hyperlipidemic control; HLP-UC2, saline-fed control; HLP-T3 & HLP-T4, given 
16.25 mg and 32.50 mg purified TRF/kg/day, respectively, for 7 days. 
Significantly different from HLP-UC2 at *p<0.001. 
treated hyperlipidemic rats for 7 days. Lipid peroxidation in microsomes decreased 
by 39%, and 41% in HLP-T3 and HLP-T4, respectively, whereas formation of 
conjugated dienes in plasma was reduced by approximately 43%, in both the 
treated groups. (Table 18). These results demonstrate that the induction of 
hyperlipidemia in rats is associated with a significant increase in the microsomal 
lipid peroxidation as well as plasma LDL oxidation, which is significantly 
prevented by the administration of purified TRF. 
3.7 Dose-Dependent Impact of Tocotrienol Rich Fraction on Plasma Lipids, 
Plasma Lipoproteins, ApoB, ApoA-1, Activity and Protein Mass of 
HMG-CoA Reductase and Microsomal Lipid Peroxidation and Plasma 
LDL Oxidation in Normolipidemic Rats After 3 Weeks of Treatment 
It is evident fi-om the above combined results that efficacy in terms of lipid 
lowering property of TRF and purified TRF in normolipideic rats at the doses of 
81.25 mg or 65 mg for 2 and 3 weeks respectively was quite similar. Therefore, in 
order to find out the optimal dose of TRF in terms of its maximal hypolipidemic 
activity, 4, 8 and 12 mg TRF/kg/day was administered to normolipidemic as well 
as hyperlipidemic rats. 
3.7.1 Impact on plasma lipids 
Data presented in Table 19, demonstrate that administration of 4, 8 and 
12 mg TRF/kg/day for 3 weeks resulted in the decrease of lipid parameters. At 
4 mg TRF the decrease in triglyceride was 25% whereas a decrease of 33% and 
35% was observed at 8 and 12 mg TRF/kg/day. The decline in total cholesterol 
content was not significant at 4 mg TRF. However, a significant decline of 8% 
and 10% was observed at 8 and 12 mg TRF. Esterified cholesterol was 
insignificantly reduced by 7% at 4 and 8 mg TRF, but significantly decreased by 
10% at 12 mg TRF. Three doses of TRF did not influence die fi-ee cholesterol 
level after 3 weeks of treatment. (Table 19). These results demonstrate that there is 
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TABLE 19 
DOSE-DEPENDENT EFFECT OF TRF ON TRIGLYCERTOES, TOTAL, 
ESTERIFIED AND FREE CHOLESTEROL W NORMOLIPIDEMIC RATS 
AFTER 3 WEEKS TREATMENT 
Parameters NLP-C NLP-Tl NLP-T2 NLP-T3 
Triglycerides 5L2±2.79* 38.6 ±1.55 34.1 i L20 33.1 ± 1.80 
(-24.6%)* (-33.4%)' (-35.3%)* 
Total cholesterol 72.8 ± 1.76 69.3 ± 1.48 66.6 ± 1.60 65.8 ± 1.90 
(-4.8%) (-8.5%)^ (-9.6%)' 
Esterified cholesterol 53.0 ±2.29 49.1 ± 1.65 49.3 ±0.83 47.8 ±0.95 
(-7.3%) (-7.0%) (-9.8%)^ 
Free cholesterol 19.9 ±1.20 20,2 ±0.36 17.3 ±1.12 18.0 ±1.10 
(+1.5%) (-13.1%) (-9.5%) 
* Values are mean (mg/dl) ± SD from plasma of 3 individual rats in each group. 
NLP-C, saline-fed control; NLP-Tl, NLP-T2 & NLP-T3, given 4 mg, 8 mg and 12 mg 
TRF/kg/day, respectively, for 3 weeks. 
Significantly different from NLP-C at ^p<0.001, V<0.01 & '^ p<0.05. 
a differential decrease in lipid parameters at 3 doses of TRF with a maximum 
affect observed at 8 mg TRF/kg/day. 
3.7.2 Effect on plasma lipoprotein lipids, apoB and apoA-1 
As shown in Table 20, VLDL-C level was insignificantly reduced by 9% 
and 14% at 4 and 8 mg of TRF treatment, respectively. However, a significant 
reduction of 19% was observed at 12 mg of TRF treatment for 3 weeks when 
compared to saline-fed control. LDL-C showed a significant decline of 7%, 15% 
and 17% at 4, 8 and 12 mg of TRF treatment, respectively. No effect was seen on 
HDL-C levels at 3 doses of TRF, whereas HDL2-C increased significantly by 
approximately 27% at 4, 8 and 12 mg of TRF administration. The decrease in 
HDL3-C levels after 4, 8 and 12 mg of TRF treatment was 15%, 19% and 19%, 
respectively. ApoB levels showed a significant reduction of 23%, 25% and 25% 
at 4, 8 and 12 mg of TRF administration, respectively, whereas apoA-1 levels did 
not register any significant decrease at the 3 doses of TRF (Table 20). These 
results demonstrate that reduction in total cholesterol was due a significant 
decrease in LDL-C. 
5.7.3 Regulation of hepatic HMG-CoA reductase activity and protein mass 
Both HMG-CoA reductase activity and protein mass were significantly 
reduced, with a maximum decrease at 8 mg TRF (Table 21). Enzyme activity was 
decreased significantly by 48% at 4 mg TRF, 61% at 8 mg TRF and 62% decrease 
at 12 mg TRF. Similarly, protein mass of HMG-CoA reductase was reduced by 
35%, 60% and 63% at 4, 8 and 12 mg TRF, respectively, when compared to 
saline-fed control (Table 21). These results demonstrate a differential effect of 
TRF at 3 doses of TRF on HMG-CoA reductase activity and protein mass with a 
optimal effect at 8 of TRF mg/kg/day. 
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TABLE 20 
DOSE-DEPENDENT IMPACT OF TRF ON VLDL-C, LDL-C, HDL-C, HDLrC, 
HDL3-C, ApoB AND ApoA-1 IN NORMOLIPIDEMIC RATS TREATED FOR 
3 WEEKS 
Parameters NLP-C NLP-Tl NLP-T2 NLP-T3 
VLDL-cholesterol 8.6 ±0.6* 7.8 ±0.7 7.4 ± 0.5 7.0 ±0.4 
(-9.3%) (-13.9%) (-18.6%)' 
LDL-cholesterol 19.9 ±0.7 18.5 ±0.5 17.0 ±0.7 16.5 ±0.5 
(-7.0%)' (-14.6%)* (-17.1%)^ 
HDL-cholesterol 43.9 ±0.9 43.1 ±0.5 42.6 ±0.8 42.2 ±0.5 
(-1.8%) (-3.0%) (-3.9%) 
HDL2-cholesterol 15.0 ±0.7 18.9 ±0.6 19.2 ± 0.6 19.0 ±0.7 
(+26.0%)* (+28.0%)* (+26.7%)* 
HDLj-cholesterol 28.8 ±0.3 24.5 ±0.4 23.4 ±0.2 23.2 ± 0.2 
(-14.9%)* (-18.7%)* (-19.4%)* 
ApoB 15.4 ±0.6 11.9 ±0.2 11.6 ±0.6 11.6 ±0.4 
(-22.7%)* (-24.7%)* (-24.7%)* 
ApoA-1 90.7 ± 1.2 92.4 ± 1.7 93.2 ± 1.6 92.1 ± 2.3 
(+1.9%) (+2.7%) (+1.5%) 
'Values are mean (mg/dl) ± SD from plasma of 3 individual rats in each group. 
NLP-C, saline-fed control; NLP-Tl, NLP-T2 & NLP-T3, given 4 mg, 8 mg and 12 mg 
TRF/kg/ day, respectively, for 3 weeks. 
Significantly different from NLP-C at *p<0.001, V<0.01 & 'p<0.05. 
TABLE 21 
DOSE-DEPENDENT REGULATION OF ACTIVITY AND PROTEIN MASS OF 
HEPATIC HMG-CoA REDUCTASE IN NORMOLIPIDEMIC RATS TREATED 
WITH TRF FOR 3 WEEKS 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
NLP-C 
NLP-Tl 
NLP-T2 
NLP-T3 
*Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (p.g/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, saline-fed control; NLP-Tl, NLP-T2 & NLP-T3, given 4 mg, 8 mg and 12 mg 
TRF/kg/ day, respectively, for 3 weeks. 
Significantly different from NLP-C at *p<0.001. 
7.88 ± 0.20 
4.13 ±0.16 
(-47.6%)^ 
3.04 ± 0.19 
(-61.4%)* 
2.96 ± 0.18 
(-62.4%)* 
239 ± 10 
156 ± 22 
(-34.7%)* 
96 ± 4 
(-59.8%)* 
89 ±11 
(-62.8%)* 
3.7.4 Impact on microsomal lipid peroxidation and LDL oxidation 
As shown in Table 22 TRF administration to nonnolipidemic rats 
significantly prevented microsomal lipid peroxidation and LDL oxidation 
measured in vitro in a dose dependent manner. There was a significant decrease of 
26% and 40% and 42% at 4, 8 and 12 mg TRF/kg/day in thiobarbitmic acid 
reactive substances (TBARS) formation, in NLP-Tl, NLP-T2 and NLP-T3, 
respectively, when compared to untreated control rats. Whereas, formation of 
conjugated dienes, a reflection of plasma oxidation was significantly decreased by 
approximately 15%, 32% and 36% in NLP-Tl, NLP-T2 and NLP-T3 respectively. 
Table 22. These results demonstrate that TRF caused a dose-dependent antioxidant 
impact in normolipidemic rats with a maximum effect observed at 8 mg 
TRF/kg/day. 
3.8 Dose-Dependent Impact of Purified Tocotrienol Rich Fraction on 
Plasntt Lipids, Plasma Lipoproteins, ApoB, ApoA-1, Activity and 
Protein Mass of HMG-CoA Reductase and Microsomal Lipid 
Peroxidation and Plasma LDL Oxidation in Normolipidemic Rats After 
3 Wedis of Treatment 
In the experiments described below a dose-dependent effect of purified 
TRF on cholesterol dynamics in normolipidemic rats was investigated. Doses of 
2.6, 5.2 and 7.8 mg purified TRF/kg/day was administered to nonnolipidemic 
rats, which is equivalent to 4, 8 and 12 mg of TRF/kg/day, isolated from refined 
edible grade RBO. 
3.8.1 Impact on plasma lipids 
As depicted in Table 23, triglyceride concentration was decreased 
significantly by 23%, 30% and 34% at 2.6, 5.2 and 7.8 mg of purified TRF, 
respectively, after 3 weeks of treatment when compared to saline-fed normal 
control. No significant decrease in total cholesterol level at 2.6 mg of purified TRF 
was observed. However, a significant decline of 7% and 10% was seen at 5.2 and 
97 
TABLE 22 
DOSE-DEPENDENT IMPACT OF TRF ON MICROSOMAL LIPID 
PEROXIDATION AND PLASMA LDL OXIDATION IN NORMOLIPIDEMIC 
RATS TREATED FOR 3 WEEKS 
Group TBARS* Conjugated Diene' 
NLP-C 2.23 ± 0.15 5.26 ± 0.45 
NLP-Tl 1.65 ± 0.13 4.49 ± 0.37 
(-26.0%)' (-14.6%)* 
NLP-T2 1.33 ±0.12 3.60 ±0.31 
(-40.3%)* (-31.5%)* 
NLP-T3 1.30 ± 0.09 3.36 ± 0.30 
(-41.7%)* (-36.1%)* 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, saline-fed control; NLP-Tl, NLP-T2 & NLP-T3, given 4 mg, 8 mg and 12 mg 
TRF/kg/ day, respectively, for 3 weeks. 
Significantly different from NLP-C at *p<0.001 and *p<0.01. 
TABLE 23 
DOSE-DEPENDENT EFFECT OF PURIFIED TRF ON TRIGLYCERIDES, 
TOTAL, ESTERIFIED AND FREE CHOLESTEROL IN NORMOLIPIDEMIC 
RATS AFTER 3 WEEKS OF TREATMENT 
Parameters NLP-C NLP-T4 NLP-T5 NLP-T6 
Triglycerides 5L2 ± 2.79* 39.5 ± 1.86 35.7 ± 1.2 34.0 ± 1.70 
(-22.8%)^ (-30.3%)* (-33.6%)* 
Total cholesterol 72.8 ± 1.76 69.4 ± .65 67.4 ± 1.4 65.7 ± 1.82 
(-4.7%) (-7.4%)^ (-9.7%)^ 
EsteriHed cholesterol 53.0 ±2.29 48.6 ±1.45 49.3 ±1.1 48.3 ±2.3 
(-8.3%) (-7.0%) (-8.9%) 
Free cholesterol 19.9 ±1.20 20.7 ±0.71 18.1 ± 0.4 17.4 ±0.6 
(+4.0%) (-9.0%) (-12.6%)' 
^Values are mean (mg/dl) ± SD from plasma of 3 individual rats in each group. 
NLP-C, saline-fed control; NLP-T4, NLP-T5 & NLP-T6, given 2.6 mg, 5.2 mg and 7.8 mg 
purified TRF/kg/day, respectively, for 3 weeks. 
Significantly different from NLP-C at *p<G.00l, *p<0.01 & ^p<0.05. 
7.8 mg purified TRF, respectively. There was no significant effect on esterified 
cholesterol at all 3 doses of purified TRF. Free cholesterol did not show any 
significant change at 2.6 and 5.2 mg of purified TRF, but a significant decline of 
13% at 7.8 mg of purified TRF treatment was observed (Table 23). These results 
demonstrate that three doses of purified TRF caused a differential decrease in lipid 
parameters after 3 weeks of treatment to normohpidemic rats. 
3.8.2 Effect on plasma lipoprotein lipids, apoB and apoA-l 
As shown in Table 24, administration of 2.6, 5.2 and 7.8 mg of purified 
TRF/kg/day was associated with no significant decline in VLDL-C, whereas 
LDL-C was decreased insignificantly by 6%, significantly by 16% and 18% at the 
above three doses of purified TRF, respectively. There was no change in HDL-C 
at all the 3 doses, whereas HDL2-C showed a significant increase of 22%, 29% 
and 29% at 2.6, 5.2 and 7.8 mg purified TRF treatment, respectively. HDL3-C 
subfraction was decreased significantly by 14%, 17% and 19%, at 2.6, 5.2 and 
7.8 mg of purified TRF respectively, after 3 weeks of treatment. ApoB levels were 
significantly declined by 20%, 27% and 28% at 2.6, 5.2 and 7.8 mg of purified 
TRF treatment, receptively. No significant change in apoA-1 levels was observed 
(Table 24). These results demonstrate a significant decline in LDL-C and apoB 
levels at 2.6, 5.2 and 7.8 mg purified TRF/kg/day with a significant increase in 
HDL2-C levels. In addition, a maximal hypoUpidemic impact of TRF was obtained 
at 5.2 mg of purified TRF/kg/day which is equivalent to 8 mg of TRF/kg/day. 
3.8.3 Regulation of hepatic HMG-CoA reductase activity and protein mass 
Purified TRF showed a dose-dependent decline in HMG-CoA reductase 
activity and protein mass as shown in Table 25. Activity was decreased by 45%, 
58% and 60% at 2.6, 5.2 and 7.8 mg purified TRF treatment, respectively, when 
compared to saline-fed control after 3 weeks. Similarly, protein mass was 
decreased by 41%, 57% and 60% at 2.6, 5.2 and 7.8 mg of purified TRF, 
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TABLE 24 
DOSE-DEPENDENT IMPACT OF PURIFIED TRF ON VLDL-C, LDL-C, HDL-C, 
HDLrC, HDL3-C, ApoB AND ApoA-1 IN NORMOLIPIDEMIC RATS AFTER 3 
WEEKS OF TREATMENT 
Parameters 
VLDL-cholesteroI 
LDL-cholesterol 
HDL-cholesterol 
HDLz-cholesterol 
HDL3-cholesteroi 
ApoB 
ApoA-1 
NLP-C 
8.6 ± 0.6* 
19.9 ± 0.7 
43.9 ± 0.9 
15.0 ± 0.7 
28.8 ± 0.3 
15.4 ± 0.6 
90.7 ± 1.2 
NLP-T4 
7.9 ± 0.8 
(-8.1%) 
18.8 ±0.7 
(-5.5%) 
43.1 ± 0.7 
(-1.8%) 
18.3 ±0.6 
(+22.0%)^ 
24.7 ± 0.2 
(-14.2%)* 
12.4 ± 0.6 
(-19.5%)* 
92.3 ± 1.7 
(+1.8%) 
NLP-T5 
7.1 ± 0.5 
(-17.4%)^ 
16.7 ± 0.6 
(-16.1%)^ 
43.3 ± 0.8 
(-1.4%) 
19.4 ± 0.5 
(+29.3%)^ 
23.9 ± 0.3 
(-17.0%)* 
11.2 ±0.5 
(-27.3%)* 
92.8 ± 1.8 
(+2.3%) 
NLP-T6 
7.6 ± 0.4 
(-11.6%) 
16.4 ± 0.6 
(-17.6%)* 
42,7 ± 0.6 
(-2.7%) 
19.3 ± 0.6 
(+28.7%)* 
23.4 ± 0.6 
(-18.7%)' 
11.1 ±0.7 
(-27.9%)* 
91.7 ±1.5 
(+1.1%) 
* Values are mean (mg/dl) ± SD from plasma of 3 individual rats in each group. 
NLP-C, saline-fed control; NLP-T4, NLP-T5 & NLP-T6, given 2.6 mg, 5.2 mg and 7.8 mg 
purified TRF/kg/day, respectively, for 3 weeks. 
Significantly different from NLP-C at *p<0.001, *p<0.01 & 'p<0.05. 
TABLE 25 
DOSE-DEPENDENT IN VIVO MODULATION OF ACTIVITY AND PROTEIN 
MASS OF HEPATIC HMG-CoA REDUCTASE IN NORMOLIPIDEMIC RATS 
TREATED WITH PURIFIED TRF FOR 3 WEEKS 
Group HMG-CoA reductase 
Specific activity* Protein mass** 
NLP-C 
NLP-T4 
NLP-T5 
NLP-T6 
*Values are mean (nmoles of mevalonate fonned/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (ng/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, saline-fed control; NLP-T4, NLP-T5 & NLF-T6, given 2.6 mg, 5.2 mg and 7.8 mg 
purified TRF/kg/day, respectively, for 3 weeks. 
Significantly different from NLP-C at *p<0.001. 
7.88 ± 0.20 
4.37 ± 0.52 
(-44.5%)^ 
3.30 ± 0.19 
(-58.1%)* 
3.13 ± 0.24 
(-60.3%)* 
239 ± 10 
140 ±12 
(-41.4%)* 
103 ± 9 
(-56.9%)* 
96 ± 9 
(-59.8%)* 
respectively, after 3 weeks of treatment (Table 25). These results demonstrate that 
reduction in HMG-CoA reductase activity is due to decrease in its protein mass. 
The results also indicate that maximal reduction in HMG-CoA reductase activity 
and protein mass was mediated by 5.2 mg of purified TRF or 8 mg of TRf/kg/day. 
3.S.4 Impact on microsomal lipid peroxidation and LDL oxidation 
As shown in Table 26 TRF administration to normolipidemic rats 
significantly prevented microsomal lipid peroxidation and LDL oxidation 
measured in vitro in a dose dependent manner. There was a significant decrease of 
28% and 42% and 43% at 2.6, 5.2 and 7.8 mg purified TRF/kg/day in 
thiobarbituric acid reactive substances (TBARS) formation, in NLP-T4, NLP-T5 
and NLP-T6, respectively, when compared to untreated control rats. Whereas, 
formation of conjugated dienes, a reflection of plasma oxidation was significantly-
decreased by approxmiately 17%, 36% and 38% in NLP-T4, NLP-T5 and 
NLP-T6 respectively, Table 22. These results demonstrate that TRF caused a dose-
dependent antioxidant impact in normolipidemic rats with a maximum effect 
observed at 5.2 mg purified or 8 mg of TRF/kg/day. 
3.9 Dose-Dependent Impact of Purified Tocotrienol Rich Fraction on 
Plasma Lipids, Plasma Lipoproteins, ApoB, ApoA-1, Activity and 
Protein Mass of HMG-CoA Reductase and Microsomal Lipid 
Peroxidation and Plasma LDL Oxidation in Hyperlipidemic Rats 
Treated For 7 Days 
As evident from the above combined results, the hypolipidemic impact of 
purified TRF in experimentally induced hyperlipidemic rats at the doses of 16.25 
and 32.50 mg/kg/day, which is equivalent to 25 and 50 mg TRF/kg/day, after 
5 and 7 days of treatment was quite similar. Therefore, to find out the optimal dose 
of purified TRF in terms of its cholesterol lowering efificiency, 2.6, 5.2 and 7.8 mg 
of purified TRF/kg/day, which is equivalent to 4, 8 and 12 mg TRF/kg/day, was 
administered to experimentaUy induced hyperlipidemic rats. 
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TABLE 26 
DOSE-DEPENDENT IMPACT OF PURIFIED TRF ON MICROSOMAL LIPID 
PEROXIDATION AND PLASMA LDL OXIDATION IN NORMOLIPIDEMIC 
RATS TREATED FOR 3 WEEKS 
Group TEARS* Conjugated Diene* 
NLP-C 2.23 ±0.15 5.26 ± 0.45 
NLP-T4 L60±0.11 4.36 ±0.30 
(-28.2%)' (-17.1%)^ 
NLP-T5 L29 ± 0.11 3.38 ± 0.31 
(-42.1%)^ (-35.7%)* 
NLP-T6 L27 ± 0.08 3.24 ± 0.28 
(-43.0%)* (-38.4%)* 
*Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, saline-fed control; NLP-T4, NLP-T5 & NLP-T6, given 2.6 mg, 5.2 mg and 7.8 mg 
purified TRF/kg/day, respectively, for 3 weeks. 
Significantly different from NLP-C at *p<0.001 and *p<0-01. 
3.9.1 Effect on plasma lipids 
Atherogenic diet had a profound impact on the hpid parameters of the 
hyperlipidemic rats in comparison to the normal rats. As seen in Table 27, 
triglycerides, total cholesterol, esterified cholesterol and free cholesterol were 
increased from 51, 73, 53 and 20 mg/dl, respectively in NLP-C to 156, 175, 141 
and 34 mg/dl in HLP-C, respectively. Seven days after the withdrawal of 
atherogenic diet a significant decrease in triglycerides, total cholesterol, esterified 
cholesterol and free cholesterol levels to 139, 139, 109 and 29 mg/dl, respectively, 
in HLP-UC was observed. However, administration of 2.6, 5.2 and 7.8 mg of 
purified TRF /kg/day for 7 days significantly reduced these parameters at a faster 
rates. When compared to saline-fed hyperlipidemic control (HLP-UC), 
triglycerides decreased by 26%, 30% and 32% in HLP-Tl, HLP-T2 and HLP-T3, 
respectively. Compared to HLP-UC, total cholesterol was reduced by 10% at 
2.6 mg purified TRF, whereas it was reduced by 24% and 30% at 5.2 and 7.8 mg 
purified TRF, respectively. Similarly, esterified cholesterol showed a decline of 
11% in HLP-Tl, 27% in HLP-T2 and 31% in HLP-T3. Free cholesterol was 
insignificantly reduced by 5% in HLP-Tl, whereas it was significantly declined by 
14% and 27% in HLP-T2 and HLP-T3, respectively (Table 27). These results 
demonstrate that maximal anticholesterol effect on plasma lipids of hyperlipidemic 
rats was exerted at 5.2 mg of purified TRF, which is equivalent 8 mg TRF/kg/da>'. 
3.9.2 Impact on plasma lipoproteins lipids, apoB and apoA-1 
As shown in Table 28, all the plasma lipoproteins along with apoB and 
apoA-1 were increased on feeding atherogenic diet for three weeks. However, a 
reduction in these parameters was observed 7 days after the withdrawal of 
atherogenic diet. VLDL-C, LDL-C and apoB levels were affected most after the 
administration of TRF for 7 days. When compared to saline-fed hyperlipidemic 
control (HLP-UC), HLP-Tl, HLP-T2 and HLP-T3 showed a significant decline in 
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VLDL-C by 18%, 29.0% and 31%, whereas LDL-C was reduced by 16%, 37% 
and 48%, respectively. HDL-C, HDL2-C, HDL3-C levels were not affected 
significantly in HLP-Tl, HLP-T2 and HLP-T3. ApoB also showed a significant 
decrease of 25%, 55% and 54%, whereas apoA-1 showed no significant effect at 
2.6 mg and 5.2 mg but a significant decline of 4.3% (p<0.05) at 7.8 mg of purified 
TRF in HLP-Tl, HLP-T2 and HLP-T3, respectively, when compared to HLP-UC 
(Table 28). These results demonstrate that the increase in the total cholesterol by 
feeding an atherogenic diet for three weeks is due to the significant increase of 
VLDL-C and LDL-C. As expected, feeding of atherogenic diet also results in an 
increase of apoB associated with LDL. However, administration of purified TRF 
was associated with a significant decrease in these lipoprotein lipids including 
apoB, with an optimal effect at 5.2 mg purified TRF, which is equivalent to 8 mg 
TRF/kg/day. 
3.9.3 Regulation of hepatic HMG-CoA reductase activity and protein mass 
As seen in Table 29, there was a significant reduction in both HMG-CoA 
reductase activity and protein mass in HLP-C as compared to NLP-C. The specific 
activity of HMG-CoA reductase in NLP-C was 7.88 units/mg, whereas it was 
decreased to 1.97 units/mg in HLP-C. Similarly, protein mass was decreased from 
239 fxg/g of microsomal protein in NLP-C to 102 |ig/g of microsomal protein in 
HLP-C. Seven days after the withdrawal of the atherogenic diet, however, resulted 
in the increase in both the activity as well as the protein mass of HMG-CoA 
reductase. Administration of purified TRF to hyperlipidemic rats for 7 days 
resulted in further decrease of HMG-CoA reductase activity and protein mass by 
36% and 15% in HLP-Tl, 54% and 45% in HLP-T2 and 57% and 49% in 
HLP-T3, respectively (Table 29). These results demonstrate that feeding of 
atherogenic diet to normolipidemic rats significantly decrease the HMG-CoA 
reductase activity by negative feed-back regulation mediated via decrease in 
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TABLE 29 
DOSE-DEPENDENT REGULATION OF ACTIVITY AND PROTEIN MASS OF 
HEPATIC HMG-CoA REDUCTASE DV HYPERLIPIDEMIC RATS AFTER 7 
DAYS OF PURIFIED TRF ADMINISTRATION 
Group HMG-CoA Reductase 
NLP-C 
HLP-C 
HLP-UC 
HLP-Tl 
HLP-T2 
HLP-T3 
*Yalues are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (^ .g/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-Tl, HLP-T2 & HLP-T3, given 2.6 mg, 5.2 mg and 7.8 mg purified TRF/kg/day, 
respectivdy, for 7 days. 
Significantly different from HLP-UC at *p<0.001. 
Specific activity* 
7.88 ± 0.20 
L97 ± 0.19 
5.74 ± 0.22 
3.69 ± 0.27 
(-35.7%)* 
2.65 ± 0.15 
(-53.8%)* 
2.48 ± 0.28 
(-56.8%)* 
Protein mass** 
239 ± 10 
102 ±11 
165 ± 15 
140 ±6 
(-15.1%) 
91 ±9 
(-44.8%)* 
85 ±8 
(-48.5%)* 
HMG-CoA reductase protein mass. Feeding of TRF causes a further decline in 
HMG-CoA reductase activity by enhancing the decrease in its protein mass. 
3.9.4 Effect on microsomal lipid peroxidation and plasma LDL oxidation 
As shown in Table 30, formation of TBAR5 in microsomes was increased 
from 2.23 units/mg in NLP-C to 3.98 units/mg in HLP-C, whereas LDL oxidation 
in plasma increased from 5.26 units/ml in NLP-C to 9.35 units/ml in HLP-C, after 
feeding atherogenic diet for three weeks. These values were reduced to 
2.49 units/mg and 7.45 units/ml in HLP-UC after 7 days of the withdrawal of 
atherogenic diet, but the decrease was enhanced significantly in purified TRF 
treated hyperlipidemic rats for 7 days. Lipid peroxidation in microsomes decreased 
by 26%, 39% and 40% in HLP-Tl, HLP-T2 and HLP-T3, respectively, whereas 
formation of conjugated dienes in plasma was reduced by 38%, 50% and 53%, 
respectively (Table 30). These results demonstrate that the induction of 
hyperlipidemia in rats is associated with a significant increase in the microsomal 
hpid peroxidation as well as plasma LDL oxidation, which is significantly 
prevented by the administration of purified TRF. 
Based on the above combined results and similar investigations related to 
hypolipidemic action of TRF in hypercholesterolemic patients carried out in our 
laboratory, an optimal dose of 8 mg TRF/kg/day and a 4.3% TRF yield of refined 
edible grade RBO, intake of an equivalent amount of 186 mg dietary refined 
RBO/kg/day should exert similar hypolipidemic impacts. 
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TABLE 30 
DOSE-DEPENDENT IMPACT OF PURIFIED TRF ON MICROSOMAL LIPID 
PEROXIDATION AND PLASMA LDL OXIDATION IN HYPERLIPIDEMIC 
RATS TREATED FOR 7 DAYS 
Group TEARS* Conjugated Diene* 
NLP-C 2.23 ±0.15 5.26 ± 0.45 
HLP-C 3.98 ± 0.17 9.35 ± 0.63 
HLP-UC 2.49 ± 0.16 7.45 ± 0.54 
HLP-Tl L83 ± 0.13 4.61 ± 0.25 
(-26.5%)' (-38.1%)* 
HLP-T2 1.54 ±0.13 3.72 ± 0.28 
(-38.5%)* (-50.1%)* 
HLP-T3 1.49 ± 0.14 3.54 ± 0.29 
(-40.2%)* (-52.5%)* 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-Tl, HLP-T2 <& HLP-T3, given 2.6 mg, 5.2 mg and 7.8 mg purified TRF/kg/day, 
respectively, for 7 days. 
Significantly different from HLP-UC at *p<:0.001 and V<0-01. 
3.10 Dose-Dependent Effect of Purified Tocotrienol Rich Fraction Isolated 
from the Raw Bran of Basmati on Plasma Lipids, Plasma Lipoproteins, 
ApoB, ApoA-1, Activity and Protein Mass of HMG-CoA Reductase and 
Microsomal Lipid Peroxidation and Plasma LDL Oxidation in 
Hyperiipidemic Rats After 7 Days of Treatment 
Earlier reports indicated that rice bran or rice bran oil (RBO) vary in their 
hypocholesterolemic activity and some have shown that neither rice bran nor RBO 
lowered cholesterol levels. These findings may be explained by other reports that 
some, but not all, rice cultivars contain tocotrienols (T3), which exert a powerful 
hypocholesterolemic action. Because of these variation in types and content of T3, 
one finds variation in the cholesterol lowering effects of RBO isolated from 
different cultivars of rice. Out of a-, P-, y- and 5-T3. 5-form was most potent in 
terms of cholesterol lowering effect, followed by y-form. a- Tocotrienol has very 
low effect, whereas, P-form has no anti-cholesterol activity. Based on the above 
optimal dose of 8 mg TRF/kg/day, we have investigated the hypolipidemic impacts 
of purified TRF isolated from two cultivars of rice, raw basmati and saket-4, in a 
linear range of 3 and 6 mg TRF/kg/day. As seen in Table 31, the combined percent 
content of y- and 5-T3 in each cultivar was adjusted equivalent to that present in 
3 and 6 mg of TRF isolated from refmed edible grade RBO. Hence, based on 
12.4% of combined conce itration of y- and 5-T3 quantified in TRF of refined 
RBO, equivalent calculated doses of purified TRF from raw Basmati, containing 
22.2% of y- and 5-T3, was 1.67 and 3.35 mg. Similarly, equivalent calculated 
doses of purified TRF from raw Saket-4, containing 31.8% of y- and 5-T3, was 
1.17 and 2.34 mg (Table 31). Therefore, impact of 1.67 and 3.35 mg/kg/day of 
purified TRF from raw Basmati and 1.17 and 234 n^/kg/day of purified TRF 
from raw Saket-4 was investigated in hyperiipidemic rats after 7 days of treatment. 
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TABLE 31 
CALCULATED EQUIVALENT DOSE OF PURIFIED TRF, FROM TWO 
CULTIVARS OF RICE, BASED ON OPTIMAL ANHCHOLESTEROL 
ACTrVTFY OF y- AND 6-TOCOTRIENOLS PRESENT BV TRF ISOLATED 
FROM EDIBLE GRADE REFINED RBO 
Type Y-
Reflned RBO 
Raw Basmati 
Raw Saket-4 
Parboiled Mansuri 
and 6-T3 
12.4 
22.2 
3L8 
16.2 
3mg TRF* 6 
3.00 
1.67 
1.17 
2.30 
mgTRF 
6.00 
3.35 
2.34 
4.60 
8 mgTRF 
8.00 
4.47 
3.12 
6.12 
* Values of equivalent doses are calculated on the basis of total content of 12.4% y- and 5-T3, 
present in TRF isolated from edible grade refined RBO. 
3.10.1 Impact on plasma lipids 
Table 32 shows the impact of purified TRF on plasma lipids of 
hyperlipidemic rats treated for 7 days. All the lipid parameters were significantly 
increased after the feeding of atherogenic diet for three weeks. Triglycerides 
increased fi^om 54 to 162 mg/dl, total cholesterol increased fi-om 73 to 183 mg/dl, 
esterified cholesterol increased fi-om 53 to 144 mg/dl and free cholesterol 
increased from 20 to 39 mg/dl. There was a decline in triglycerides, total 
cholesterol, esterified cholesterol and free cholesterol by 16%, 21%, 21% and 
20^0, respectively, in HLP-UC after 7 days of withdrawal of atherogenic diet, as 
compared to values in HLP-C. However, due to purified TRF treatment, a fiirther 
significant reduction in these lipid parameters was observed. Triglycerides were 
reduced by 21% and 27% in HLP-Tl and HLP-T2, respectively. Total cholesterol 
showed a decrease of 13% and 27% at 1.67 and 3.35 mg purified TRP, 
respectively, when compared to saline-fed hyperlipidemic control rats. Similarly, 
esterified cholesterol registered a decrease of 12% and 28% in HLP-Tl and 
HLP-T2, respectively. There was also a significant reduction of 14% and 20% in 
free cholesterol of HLP-Tl and HLP-T2. respectively (Table 32). These results 
indicate that purified TRP mediate a differential dose-dependent decrease in the 
levels of cholesterol. 
3.10.2 Effect on plasma lipoproteins, lipids, apoB and apoA-1 
As seen in Table 33, plasma lipoproteins along with apoB and apoA-I were 
also significantly elevated after the feeding of atherogenic diet. These parameters 
were decreased 7 days after the withdrawal of atherogenic diet. However, the 
decrease in VLDL-C (14%) and LDL-C (31%) was highly significant in purified 
TRF treated HLP-Tl and HLP-T2 groups, when compared to HLP-UC. LDL-C 
levels were reduced by 19% and 38% in HLP-Tl and HLP-T2, respectively. 
HDL-C, HDL2-C and HDL3-C levels did not show any significant change 
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compared to saline-fed control rats. ApoB was significantly reduced by 15% in 
HLP-Tl, but decreased highly significantly in HLP-T2 by 47%. Again, apoA-1 did 
not show any significant change (Table 33). These results demonstrate that feeding 
of atherogenic diet causes a significant increase of VLDL-C and LDL-C which in 
turn increase the level of total cholesterol. As evident, feeding of atherogenic diet 
also results in a concomitant increase of apoB which is associated with LDL. 
However, administration of purified TRF substantially decrease these lipid 
parameters including apoB. 
3.10.3 Modulation of hepatic HMG-CoA reductase activity and protein mass 
Feeding of atherogenic diet for three weeks to rats caused a significant 
decline in both enzyme activity as well as protein mass of HMG-CoA reductase. 
As shown in Table 34, specific activity was decreased from 8.20 units/mg in 
NLP-C to 1.90 units/mg in HLP-C, whereas protein mass decreased from 239 |ig/g 
of microsomal protein in NLP-C to 102 )ig/g of microsomal protein in HLP-C. 
These parameters were increased after the withdrawal of atherogenic diet. 
However, administration of purified TRF for 7 days prevented the increase in 
enzyme activity by 37% in HLP-Tl and 54% in HLP-T2, whereas enzyme mass 
was decreased by 28% and 38% in HLP-Tl and HLP-T2, respectively, when 
compared to HLP-UC (Table 34). These results indicate that feeding of exogenous 
cholesterol or purified TRF to rats decrease the synthesis of endogenous 
cholesterol via decrease in HMG-CoA reductase activity which in turn is mediated 
b) the decrease in its protein mass. However, withdrawal of atherogenic diet 
relieves this inhibition which is evident from the increase in HMG-CoA reductase 
activity as well as its protein mass. 
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TABLE 34 
DOSE-DEPENDENT IN VIVO MODULATION OF ACTIVITY AND PROTEIN 
MASS OF HEPATIC HMG-CoA REDUCTASE IN HYPERLIPIDEMIC RATS 
TREATED WFTH PURIFIED TRF ISOLATED FROM BRAN OF BASMATI 
AFTER 7 DAYS OF ADMINISTRATION 
Group HMG-CoA Reductase 
NLP-C 
HLP-C 
HLP-UC 
HLP-Tl 
HLP-T2 
*Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Values are mean (fxg/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-Tl & HLP-T2, given 1.67 mg and 3.35 mg of purified TRF/kg/day, respectively, for 
7 days. 
Significantly different from HLP-UC at ^ p<0.001, p<0-01 & ^p<0.05. 
Specific activity* 
8.20 ± 0.32 
1.90 ±0.15 
5.91 ± 0.25 
3.75 ± 0.21 
(-36.5%)* 
2.74 ± 0.18 
(-53.6%)* 
Protein mass** 
239 ± 10 
102 ±11 
165 ± 15 
119±6 
(-27.9%)* 
103 ± 4 
(-37.6%)* 
3.10.4 Effect on microsomal lipid peroxidation and plasma LDL oxidation 
As shown in Table 35, formation of TEARS in microsomes was increased 
from 2.41 units/mg in NLP-C to 4.14 units/mg in HLP-C, whereas LDL oxidation 
in plasma increased from 5.31 units/ml in NLP-C to 10.17 units/ml in HLP-C, 
after feeding atherogenic diet for three weeks. These values were reduced to 
2.81 units/mg and 7.78 units/ml in HLP-UC after 7 days of the withdrawal of 
atherogenic diet, but the decrease was enhanced significantly in purified TRP 
treated hyperlipidemic rats for 7 days. Lipid peroxidation in microsomes decreased 
by 35% and 47% in HLP-Tl and HLP-T2, respectively, whereas formation of 
conjugated dienes in plasma was reduced by 36% and 46%, respectively 
(Table 35). These results demonstrate that the induction of hyperlipidemia in rats 
is associated with a significant increase in the microsomal lipid peroxidation as 
well as plasma LDL oxidation, which is significantly prevented by the 
administration of purified TRF. 
3.11 Dose-Dependent Impact of Purified Tocotrienol Rich Fraction Isolated 
from the Raw Bran of Saket-4 on Plasma Lipids, Lipoproteins Lipids, 
ApoB and ApoA-1, Activity and Protein Mass of HMG-CoA Reductase, 
Microsomal Lipid Peroxidation and Plasma LDL Oxidation in 
Hyperlipidemic Rats After 7 Days of Administration 
3.11.1 Effect on plasma lipids 
Similar to results summarized in Table 36, there was an increase in the lipid 
parameters of hyperlipidemic rats after the feeding of atherogenic diet for three 
weeks, which showed a substantial decline after 7 days of withdrawal of 
atherogenic diet. However, these parameters fiirther declined in rats treated with 
purified TRF, which was isolated from the bran of Saket-4. Compared to saline-
fed hyperlipidemic control (HLP-UC) rats, the decrease in triglycerides was 24% 
and 28% in HLP-T3 and HLP-T4, respectively. Total cholesterol showed a dose-
dependent decrease of 11% at 1.17 mg purified TRF and 24% at 2.34 mg purified 
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TABLE 35 
DOSE-DEPENDENT IMPACT OF PURIFIED TRF ISOLATED FROM 
BASMATI ON MICROSOMAL LIPID PEROXIDATION AND PLASMA LDL 
OXIDATION IN HYPERLIPIDEMIC RATS TREATED FOR 7 DAYS 
Group TEARS* Conjugated Diene** 
NLP-C 2.41 ± 0.15 5.31 ± 0.40 
HLP-C 4.14 ±0.23 10.17 ±0.58 
HLP-UC 2.81 ± 0.18 7.78 ± 0.43 
HLP-Tl 1.82 ± 0.13 5.02 ± 0.27 
(-35.2%)' (-35.5%)^ 
HLP-T2 1.50 ± 0.11 4.18 ± 0.33 
(-46.6%V (-46.3%)^ 
* Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-Tl & HLP-T2, given 1.67 mg and 3.35 mg of purified TRF/I^day, respectively, for 
7 days. 
Significantly different from HLP-UC at ^ p<0.001 and *p<0.01. 
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TRP/kg/day. Similarly, esterified cholesterol decreased by 9% and 26% in 
HLP-T3 and HLP-T4, respectively, when compared to HLP-UC. Free cholesterol 
also showed a marked decline of 13% and 15% in HLP-T3 and HLP-T4. 
respectively (Table 36). These results demonstrate that purified TRF mediate a 
dose-dependent linear decrease in total and esterified cholesterol with a non-linear 
decrease in the levels of triglycerides and fi"ee cholesterol. 
3.11.2 Impact on plasma lipoproteins lipids, apoB and apoA-1 
As shown in Table 37, a significant increase in the plasma lipoprotein lipids 
as well as apoB and apoA-1 was observed after the induction of hyperlipidemia in 
rats fed atherogenic diet for three weeks. Seven days after the withdrawal of 
atherogenic diet a significant decline in these parameters were observed. However, 
the reduction was significantly greater in VLDL-C, LDL-C and apoB in purified 
TRF treated rats. In comparison to HLP-UC. VLDL-C decreased by 36% in 
HLP-T3 and 25% in HLP-T4. LDL-C showed a dose-dependent decrease of 15% 
at 1.17 mg purified TRF and 36% at 2.34 mg purified TRF /kg/day. HDL-C. 
HDL2-C and HDL3-C did not show any significant change after the administration 
of purified TRF. ApoB was reduced by 12% in HLP-T3, whereas it declined b\ 
39% in HLP-T4. On the other hand, apoA-1 showed no decline in HLP-T3 and a 
significant decrease of 6% (p<0.05) in HLP-T4, when compared to saline-fed 
hyperlipidemic control rats (Table 37). These results indicate that purified TRF 
has a significant effect on the levels of VLDL-C, LDL-C and apoB in 
hyperlipidemic rats. On the other hand, it does not affect the levels of HDL-C or 
its sub-fractions, HDL2-C and HDL3-C. 
3.11.3 Modulation of hepatic HMG-CoA reductase activity and protein mass 
As seen in Table 38, consistent with the data presented in Table 30, a 
severe decline in the activity and protein mass of HMG-CoA reductase in HLP-C 
rats was observed, which began to increase 7 days after the removal of atherogenic 
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TABLE 38 
DOSE-DEPENDENT REGULATION OF ACTIVITY AND PROTEIN MASS OF 
HEPATIC HMG-CoA REDUCTASE IN HYPERLIPIDEMIC RATS TREATED 
WITH PURIFIED TRF ISOLATED FROM BRAN OF SAKET-4 FOR 7 DAYS 
Group HMG-CoA Reductase 
NLP-C 
HLP-C 
HLP-UC 
HLP-T3 
HLP-T4 
^Values are mean (nmoles of mevalonate formed/min/mg protein) ± SD from three separate 
assay in each group. 
**Va]ues are mean (|j.g/g of microsomal protein) ± SD from three separate assay in each 
group. 
NLP-C, normal control; HLP-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T3 & HLP-T4, given 1.17 mg and 2.34 mg of purified TRF/kg/day, respectively, for 
7 days. 
Significantly different from HLP-UC at ^ p<0.001, V<0.01 & V<0.05. 
Specific activity* 
8.20 ± 0.32 
L90±0.15 
5.91 ± 0.25 
3.85 ± 0.19 
(-34.8%)* 
2.81 ± 0.21 
(-52.4%)* 
Protein mass** 
246 ±17 
102 ± 6 
173 ± 12 
138 ± 6 
(-20.2%)* 
94 ± 5 
(-45.7%)* 
diet. However, administration of purified TRF to these hyperlipidemic rats for 
7 days resulted in a further decrease in enzyme activity as well as protein mass of 
HMG-CoA reductase. HMG-CoA reductase activity remained decreased by 35% 
and 52% in HLP-T3 and HLP-T4, respectively, whereas protein mass was 
significantly reduced by 20% and 46% as compared to saline-fed hyperlipidemic 
control (Table 38). These results show that purified TRF mediate its action via 
decrease in HMG-CoA reductase protein mass which in turn results in decreased 
enzyme activity and cholesterol production. 
3.1L4 Effect on microsomal lipid peroxidation and plasma LDL oxidation 
As shown in Table 39, formation of TBARS in microsomes was increased 
fi-om 2.41 units/mg in NLP-C to 4.14 units/mg in HLP-C, whereas LDL oxidation 
in plasma increased from 5.31 units/ml in NLP-C to 10.17 units/ml in HLP-C, 
after feeding atherogenic diet for three weeks. These values were reduced to 
2.81 units/mg and 7.78 units/ml in HLP-UC after 7 days of the withdrawal of 
atherogenic diet, but the decrease was enhanced significantly in purified TRF 
treated hyperlipidemic rats for 7 days. Lipid peroxidation in microsomes decreased 
by 29% and 43% in HLP-T3 and HLP-T4, respectively, whereas formation of 
conjugated dienes in plasma was reduced by 33% and 46%, respectively, 
(Table 35). These results demonstrate that the induction of hyperlipidemia in rats 
is associated with a significant increase in the microsomal lipid peroxidation as 
well as plasma LDL oxidation, which is significantly prevented by the 
administration of purified TRF. 
The combined results demonstrate that hypolipidemic efficiency of purified 
TRF from raw Basmati (at 1.67 and 3.35 mg/kg/day) and raw Saket-4 (at 1.17 and 
2.34 mg/kg/day) was comparable with the anticholesterol impact of TRF from 
refined RBO (at 4 and 8 mg/kg/day). These results also indicate that differential 
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TABLE 39 
DOSE-DEPENDENT IMPACT OF PURIFIED TRF ISOLATED FROM SAKET-4 
ON MICROSOMAL LIPID PEROXIDATION AND PLASMA LDL OXIDATION 
IN HYPERLIPIDEMIC RATS TREATED FOR 7 DAYS 
Group TBARS* Conjugated Diene** 
NLP-C 2.41 ± 0.15 5.31 ± 0.40 
HLP-C 4.14 ± 0.23 10.17 ± 0.58 
HLP-UC 2.81 ± 0.18 7.78 ± 0.43 
HLP-T3 1.99 ± 0.12 5.22 ± 0.42 
(-29.2%)^ (-32.5%)* 
HLP-T4 1.60 ± 0.13 4.23 ± 0.39 
(-43.1%)* (-45.6%)* 
*Values are mean (nmole/min/mg) ± SD of 4 separate assay in each group. 
**Values are mean (nmole/min/ml) ± SD of 3 separate assay in each group. 
NLP-C, normal control; HLF-C, hyperlipidemic control; HLP-UC, saline-fed control; 
HLP-T3 & HLP-T4, given 1.17 mg and 2.34 mg of purified TRF/kg/day, respectively, for 
7 days. 
Significantly different from HLP-UC at *p<0.001 and ^p<0.01. 
hypolipidemic impacts of TRF on cholesterol dynamics is directly related to the 
total content of y- and 5-T3 present in TRF isolated from a given cultivar of rice. 
Based on the above results and the presence of y- and 6-T3 content in a 
given cultivar of rice, one can calculate the optimal dose of TRF in terms of its 
maximal cholesterol lowering efficiency. For example, as shown in Table 31, the 
combined content of y- and 6-T3 in parboiled Mansuri is 16.2%. Based on this 
value, the equivalent doses at 3 and 6 mg TRF/kg/day will be 2.30 and 4.60 mg 
purified TRF/kg/day, respectively. Similarly, an optimal dose of TRF in terms of 
its cholesterol lowering efficiency, equivalent to 8 mg TRF/kg/da>', will be 
6.12 mg purified TRF/kg/day. 
The combined results indicate that variety of edible oils lacking in 
Tocotrienols can be supplemented with an optimal dose of TRF for its therapeutic 
benefits. Based on strong hypolipidemic action of TRF in normolipidemic and 
hyperlipidemic rats, daily intake of TRF, RBO or edible oils supplemented with 
TRF by normal population will prevent the occurrence of hypercholesterolemia 
and cardiovascular disease. 
3.12 Impact of TRF on Plasma Cholesterol and Triglycerides VLDL-C, 
LDL-C, HDL-C, HDL2-C, HDL3-C, ApoB and ApoA-1 and on the 
Ratios of LDL-C/HDL-C, HDL-C/TC and ApoB/ApoA-1 in a Faimlial 
Hypercholesterolemic Patient With Severe Xanthomas After Different 
Duration of Treatment 
3.12.1 Effect on plasma lipids 
As shown in Table 40, the plasma total cholesterol (TC) concentrations 
were significantly decreased by 19%, 12%, 9% and 7% after 8, 20, 60 and 
100 weeks of TRF (8 n^/kg/day) treatment, respectively, when compared to zero-
time (entry point of the study) value. The plasma triglycerides level were 
decreased by 20%, 15%, 18% and 16% after 8, 20, 60 and 100 weeks of TRF 
treatment, respectively. These results indicate that TRF-mediated decrease of total 
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cholesterol and triglycerides was higher during initial phase of TRF treatment i.e., 
after 8 and 20 weeks. The results also indicate that the decline in triglycerides was 
more marked e\en at 60 and 100 weeks of TRF treatment than the decrease in TC 
levels. 
3.12.2 Impact on plasma lipoproteins lipids, apoB and apoA-1 
As seen in Table 41 plasma LDL-cholesterol levels decreased by 25%, 
23%, 16% and 14% after 8, 20, 60 and 100 weeks of TRF treatment, respectively, 
with a concomitant decrease in apoB levels, by 24%, 20%, 16% and 15%, 
respectively. \XDL-C levels decreased by 44%, after 8 weeks and increased by 
31%, after 20 weeks but again decreased by 10% and 25% after 60 and 100 weeks 
of TRF treatment, respectively. Whereas, HDL-C showed an increase of 39%, 
232%, 151% and 158% after 8, 20, 60 and 100 weeks of TRF treatment. ApoA-1 
levels were increased by 39%, 190%, 164% and 166%, respectively, during the 
same period of TRF treatment. The HDL sub-fi^ctions, HDL2-C was substantially 
increased by 170%, 284%, 598% and 608%, respectively, whereas, HDL3-C was 
moderately increased by 14%, 213%, 55% and 68%, respectively, after 8, 20, 60 
and 100 weeks of TRF treatment, (Table 41). These results indicate that LDL-C 
and its apoprotein apoB, which are directly correlated with premature coronary 
artery disease (CAD) decreased after the treatment with TRF. The decline in 
LDL-C was more pronounced during initial phase of treatment. The result also 
indicate that the levels of HDL-C and its sub-fi-actions HDL2-C and HDL3-C 
which are inversely correlated to the incidence of CAD, were significantiy 
increased due to TRF treatment. 
3.12.3 Impact on the ratios of LDL-C/HDL-C, HDL-C/TC and ApoB/ApoA-1 
As seen in Table 42, the LDL-C/HDL-C ratio declined by 46%, 77%, 65% 
and 67%, after 8, 20, 60 and 100 weeks of TRF treatment, respectively, as 
compared to zero-time value. Similar to LDL-C/HDL-C ratio, ApoB/ApoA-1 ratio 
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decreased by 47%, 73%, 69% and 69%, respectively at the above duration of TRP 
treatment. The HDL/TC ratio increased by 73%, 274%, 166% and 176% after 8, 
20, 60 and 100 weeks of TRF treatment, respectively, when compared to the 
values at the entr>' point of the study. These results indicate that LDL-C/HDL-C 
ratio and the ratio of their apoproteins, ApoB/ApoA-1, which are considered as a 
better predictor for CAD risks, were significantly reduced from an initial 7.5 fold 
increase to a 2.5 fold increase after TRF treatment. The HDL/TC ratio was 
increased from a low 3.5% to 9.7% after 100 weeks of TRF treatment when 
compared to a normal value of 20% and above. 
3.12.4 Regression of xanthomas, localized over the buttocks extending to thighs, 
elbows and knee after 20 weeks of TRF treatment of a familial 
hypercholesterolemic (FH) boy 
Fig. 3.1 (Panel A and B), depicts the skin xanthomas on his buttocks 
extending to thighs before ( entry point. Panel A) and after 20 weeks of TRF 
treatment (8 mg/kg/day) (Panel B) of the FH patient. It is evident that TRF 
treatment for 20 weeks caused a significant regression of xanthomas on his 
buttocks extending to thighs. Fig. 3.2 (Panel A and B) shows the stasus of skin 
xanthomas on left elbow before (entry point. Panel A) and after 20 weeks of TRF 
treatment (Panel B). Consistent with strong hypolipidemic property of TRF, a 
significant regression of xanthomas on patient's left elbow was observed following 
TRF treatment. As seen in Fig. 3.3 (Panel A and B), 20 weeks of TRF treatment of 
the FH patient was associated with a significant regression of xanthomas on his 
right elbow (Panel B), when compared to the severity of xanthomas at the entry 
point of the treatment (Panel A). Fig. 3.4 (Panel A and B) depicts the impact of 20 
weeks of TRF treatment of the FH patient, which is associated with a significant 
regression of both the xanthomas located on his knee (Panel B), in comparison to 
the size of xanthomas before die TRF treatment (Panel A). The combined results 
demonstrate that the regression of cholesterol deposition in tissues at the above 
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Pig. 3.1 Panel A. Photograph showing skin xanthomas on buttocks, extending to 
thighs of FH patient at the entry point, before initiation of TRF 
treatment. 
Panel B. Photograph showing regression of skin xanthomas after 20 weeks 
of TRF treatment. 
Panel A 
Panel B 
Fig. 3.2 Panel A. Photograph depicting skin xanthomas on left elbow of FH patient 
at the entry point, before initiation of TRF treatment. 
Panel B. Photograph depicting regression of skin xanthomas after 20 weeks 
of TRF treatment. 
Panel A 
Panel B 
Fig. 3.3 Panel A. Photograph showing skin xanthomas on right elbow of FH patient 
at the entry point, before initiation of TRF treatment. 
Panel B. Photograph showing regression of skin xanthomas after 20 weeks 
of TRF treatment. 
Panel A 
Panel B 
Fig. 3.4 Panel A. Photograph depicting skin xanthomas on the knee of FH patient 
at the entry point, before initiation of TRF treatment. 
Panel B. Photograph depicting regression of skin xanthomas after 20 weeks 
of TRF treatment. 
Panel A 
Panel B 
three locations, is apparently due to a reduction in plasma triglycerides, total 
cholesterol. LDL-C and a concomitant increase in HDL levels, after 20 weeks of 
TRF treatment. 
3.13 Impact of Rice Bran Oil on Plasma Cholesterol, VLDL-C, LDL-C and 
HDL-C and on the Ratios of LDL-C/HDL-C, HDL-C/TC in Normolipi-
demic Humans After Tv/o and Four Weeks of Intake 
3.13.1 Impact on Plasma Cholesterol, VLDL-C, LDL-C and HDL-C 
As seen in Table 43, intake of refined edible grade RBO (0.2 g/kg/day), 
rich in tocotrienols for 2 weeks caused an insignificant decline (4%) in plasma 
total cholesterol level, whereas a significant decline of 10% in total cholesterol 
level was observed after 4 weeks of RBO intake. LDL-C levels decreased 
significantly by 13% and 26% after 2 and 4 weeks of RBO intake, respectively. 
WTiereas. after 2 and 4 weeks of RBO intake HDL-C was significantly increased 
by 21 and 41%, respectively. VLDL-C levels after 2 and 4 weeks of RBO intake 
were not affected. The resuhs demonstrate that intake of RBO equivalent to 8 mg 
TRF/kg/day by normolipidemic subjects caused a significant decline in lipid 
parameters, indicating a role of RBO in the prevention of atherogenesis. 
3.13.2 Impact on the Ratios of LDL-C/HDL-C, HDL-C/TC 
As shown in Table 44, LDL-C/HDL-C ratio was significantly declined by 
47% after 4 weeks of RBO intake. HDL-C/TC ratio was significantly increased by 
27% and 55% after 2 and 4 weeks of RBO intake, respectively. These results 
indicate that a 4 week intake of RBO by normal himians caused a significant 
improvement in the aheady normal ratios of LDL-C/HDL-C and HDL-C/TC, 
which are known to be associtaed with the development of CAD. 
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TABLE 43 
IMPACT OF RICE BRAN OIL (RBO) ON PLASMA TOTAL CHOLESTEROL 
AND LIPOPROTEIN LIPIDS IN NORMOLIPIDEMIC HUMANS AFTER 2 AND 
4 WEEKS OF INTAKE 
Parameters 
Total cholesterol 
LDL-cholesterol 
HDL-cholesterol 
VLDL-cholesterol 
OTime 
197.6 ±22.1* 
129.5 ±23.7 
36.4 ± 6.7 
25.2 ± 4.9 
2 Weeks 
189.1 ± 18.2 
(-4.3%) 
113.3 ±14.9 
(-12.5%)' 
44.2 ± 8.0 
(+21.4%)* 
26.6 ±5.4 
(+5.6%) 
4 Weeks 
178.8 ±16.8 
(-9.5%)* 
95.8 ±8.2 
(-26.0%)^ 
51.3 ± 9.3 
(+41.0%)* 
27.3 ± 7.8 
(+8.3%) 
*Values are expressed as mean ± SD from three different determinations. 
Significantly different from zero-time at *p<0.001,^ p<0.01 & 'p<0.05. 
TABLE 44 
IMPACT OF RICE BRAN OIL (RBO) ON THE RATIOS OF LDL-C/HDL-C, 
HDL-C/TC IN NORMOLIPIDEMIC HUMANS AFTER 2 AND 4 WEEKS OF 
INTAKE 
Parameters OTime 2 Weeks 4 Weeks 
LDL-C/HDL-C 3.62 ± 0.66* 2.59 ± 0.31 
(-28.2%)* 
L93 ± 0.19 
(-46.5%)* 
HDL/TC% 18.4 ± 0.9 23.3 ± 1.3 
(+26.9%)* 
28.5 ± 1.7 
(+55.4%)* 
*\'alues are expressed as mean ± SO from three different determinations. 
Significantly different from zero-time at *p<0.001 
Norma] Values : LDL/HDL ratio is 3.2 to 3.6 or below, HDL/TC% ratio is 20% or above 
(Discussion 
The results presented in tiie thesis describe a rapid, efficient, and cost-
effective method for the isolation of tocotrienol and tocopherol rich fraction (TRF) 
from rice bran, crude rice bran oil (RBO) or refined edible grade RBO. Previously 
reported methods for the isolation of TRF involve time consuming multiple steps, 
including saponification of the oil (Sharma and Rukmini, 1987; Shin and Godber, 
1994). Our method simply involves the extraction of TRF from rice bran/RBO in 
methanol (Beg et al, 1996a). Precaution is taken that within 24 h of milling, brans 
from raw paddies are soaked in hexane. This is essential because during milling, 
lipase enzyme is activated which hydrolyzes triglycerides to free fatty acids 
(Migura, 1989). Free fatty acid rise in raw bran is very rapid, 6-10% in 24-48 h of 
milling, whereas only 2-3% in 48 h in case of parboiled bran, where lipase enzyme 
is apparently partially inactivated by parboiling. The yield of TRF isolated from 
refined edible grade RBO is 4.3*^ 0. which is consistent with the values reported 
earlier (Sharma and Rukmini, 1987). However, the percent yield of TRF isolated 
from crude RBO from brans of raw and parboiled Basmati and Saket-4 cultivars 
varied between 6.6 and 7.2. The variation in the percent yield of TRF is indicative 
of the fact that types, a-, p-, y- and 5-tocotrienols (T3) and tocopherols (T) and 
their quantity may vary in the raw and parboiled brans representative of two 
cultivars of rice. The TRF content of refmed edible grade RBO isolated by the 
above methodology was significantly lower, 4.3%, suggesting the possibility of 
some removal of T3/T during refining procedures of the commercial edible grade 
RBO. The TRF, tiius obtained, is purified involving a single step purification 
procedure. The yield of piuified TRF from TRF of crude RBO from raw and 
parboiled cultivars, was in the range of 4.3-4.9%, which is on an average ~ 62% 
higher than ~ 2.8% yield of purified TRF obtained from TRF of refined edible 
grade RBO. The combined resuJts demonstrate tiiat the isolation of purified TRF 
from crude RBO by employing tihe above methods yields a significantly higher 
quantity of value-added products, tocotrienols and tocopherols, in comparison to 
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purified TRF isolated fi"om refined edible grade RBO. In addition, the cost 
involved in the isolation of TRF fi-om crude RBO derived fi-om brans of different 
cultivars of rice is far less than the cost involved in the isolation of TRF fi-om 
commercially procured refined edible grade RBO. 
The combined content of a-, 3-, y- and 6-tocotrienols and tocopherols, as 
quantified by HPLC, in TRF isolated from refined edible grade RBO was 29.2% 
and 39.1%, respectively, whereas, for purified TRF the total content of Tj and T 
was 42.2% and 51.9%. The increase in percent content of the combined T3 and T 
in purified TRF was consistent with -35% of the non-Ts and T contaminants 
removed during the purification of TRF. Therefore, increase in combined percent 
yield of T3 and T in purified TRF of two cultivars of rice was in agreement with 
the ~35% contaminants associated with TRF. Since, it is known that y and 5-T3, 
are most potent in terms of their in vivo hypolipidemic, (Pearce et ai, 1992; 
Qureshi and Qureshi, 1993), ex vivo and in vitro antioxidant, (Suama et al, 1993; 
Kamat and Devasagayam, 1995; Kamat et al., 1997) and in vivo and in vitro anti-
tumour (Goh et ai, 1994; Nesaretnam et al, 1995; Guthrie et al, 1997; 
Nesaremam et al, 1998) activities, the combined percent content of 6- and y-Ts 
present in purified TRF of Basmati and Saket-4 was significantly different than 
fliat of purified TRF obtained from refined edible grade RBO. 
A detailed investigation of TRF and purified TRF, as isolated above, on 
cholesterol dynamics of normolipidemic and hyperUpidemic rats has been carried 
out. Feeding of tocotrienol as TRF, isolated from refined edible grade RBO to 
normal rats for two weeks was associated with a significant decline in plasma and 
lipoprotein lipids. It is interesting to note that both TRF and purified TRF 
mediated a significant decline in total and esterified cholesterol levels, with no 
significant change in free cholesterol. The results demonstrate that decrease in 
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plasma total cholesterol level is apparently due to a significant decrease in 
VLDL-C and LDL-C levels. Administration of TRF or purified TRF caused a 
significant decline in plasma apolipoprotein B associated with LDL. Although no 
significant change in HDL-C was observed, but its sub-fi-action, HDL2-C, which is 
considered to be a strong predictor of presence and extent of coronary artery 
disease (CAD) (Drexel et al., 1992), was significantly increased. Consistent with 
no change in HDL-C, its apolipoprotein A-1 level was not affected. 
In order to find out the minimum dose to exert a maximal hypolipidemic 
effect, we investigated the impacts of 4, 8 and 12 mg TRF/kg/day and 2.6, 5.2 and 
7.8 mg purified TRF/kg/day on cholesterol dynamics in normolipidemic rats for 
3 weeks. The combined results indicate that administration of TRF and purified 
TRF to normolipidemic rats was associated widi a significant decline in plasma 
levels of triglycerides, total cholesterol, LDL-C and apoB in a dose-dependent 
manner. No effect on HDL-C and apoA-1 was observed, whereas, HDL sub-
fi^ction, HDL2-C was significantly increased with a decline in HDL3-C. In 
general, our results are consistent with several scattered reports indicating 
hypolipidemic action of tocotrienols, in normoUpidemic animal and human 
models, administered as RBO, palm oil, barley oil or TRF isolated fi-om either 
RBO or palm oil. Feeding of a diet containing 5-20% RBO to normal rats was 
associated with a significant decline in serum total cholesterol, LDL-C and 
VLDL-C (Sharma and Rukmini, 1986; Pmnshothama et al, 1995), whereas 
triglycerides and HDL-C levels were not significantly changed (Sharma and 
Rukmini, 1986). Earlier fmdings fi-om our laboratory (Beg et al, 1996b) related to 
hypolipidemic action of TRF in normolipidemic humans are consistent with the 
results reported in the thesis. Our results are also consistent with a decline in 
plasma cholesterol in hamsters fed 9% RBO for 3 weeks (Kahlon et al, 1992). 
Diet containing 35% RBO when fed to normolipidemic monkeys also resulted in a 
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significant decline in total cholesterol, LDL-C and apoB, with no change in 
HDL-C (Nicolosi et ai, 1991). Feeding of TRF (50 ng/g of diet) for 6 and 8 weeks 
to normolipidemic swines was associated with a significant decline in total 
cholesterol, LDL-C and apoB with no change in HDL-C and apoA-I levels 
(Qureshi et al, 1991c). Consistent with tiie hypocholesterolemic action of TRF in 
rats reported here, Pearce et al. (1992) have demonstrated a significant 
hypolipidemic effect of a-, y- and 6-T3 in normolipidemic chickens. Feeding of 
a-, y- and 6-T3 (20 i^g/g of diet) to normolipidemic chickens for 4 weeks resulted 
in the significant decline in serum total cholesterol and LDL-C levels with no 
change in HDL-C level. As expected, hypolipidemic impact of a-Ts was lower 
than y- and 5-T3 (Qureshi and Qureshi, 1993). Feeding of dietary palm oil 
(15-20%) to normolipidemic rats resulted in varied effects on triglycerides, total 
cholesterol, LDL-C, HDL-C and HDL-C/total cholesterol ratio (Pereira et al., 
1990; Sundram et al, 1990; Osim et al, 1996). Similar results were observed 
when 70% dietary palm oil was fed to normolipidemic humans (Sundram et al., 
1992). However, feeding of one capsule/day of 18 mg tocopherols and 42 mg 
tocotrienols in 240 mg of palmolein for 30 days to normolipidemic humans, 
resulted in a significant decline in total cholesterol and LDL-C with inconsistent 
change in triglycerides and HDL-C levels (Tan et al, 1991). Similarly, feeding of 
barley oil to normolipidemic chickens significantly reduced the levels of plasma 
total cholesterol and LDL-C with no change in triglycerides and HDL-C levels 
(Qureshi e/a/., 1986). 
Next, we investigated the role of purified TRF in the prevention of 
experimental hyperlipidemia in rats. In addition, the efficacy of purified TRF as an 
anticholesterol drug in the treatment of experimental hyperlipidemia was also 
investigated. Feeding of 65 mg purified TRF/kg/day along with an atherogenic diet 
to rats for 3 weeks, significantly prevented the increase in triglycerides, total 
cholesterol including esterified and fi-ee cholesterol, VLDL-C, LDL-C and apoB 
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concentrations when compared to rats fed only atherogenic diet. Increase in 
apoA-1, HDL-C and its sub-fraction HDL3-C levels, observed apparently due to 
feeding of an atherogenic diet, significantly decreased due to supplementation of 
purified TRF. However, no preventive action of TRF was seen in HDLrC level. 
Administration of 65 mg purified TRF/kg/day to normolipidemic rats for 3 weeks 
exerted hypoUpidemic effects consistent with the data discussed above, where 
81.25 mg purified TRF/kg/day was fed to normal rats for 2 weeks. The results 
demonstrate that 5 and 7 days after tiie withdrawal of atherogenic diet, plasma 
triglycerides, total cholesterol including esterified and free cholesterol, VLDL-C, 
LDL-C including apoB, HDL-C and its sub-fraction, HDL2-C and HDL3-C levels 
were significantly reduced. Apo A-1 level was reduced insignificantly. Feeding of 
16.25 and 32.50 mg of purified TRP/kg/day to hyperlipidemic rats for 5 and 7 days 
resulted in fiulher significant reduction in the above mentioned plasma and 
lipoprotein lipids including apoB in comparison to untreated hyperhpidemic 
control. The significant decline in total cholesterol level mediated by TRF is due 
to a significant decrease in VLDL-C and LDL-C levels. The combined results 
demonstrate that hypolipidemic impacts at a dose of 16.25 and 32.50 mg purified 
TRf/kg/day for 5 and 7 days were similar, indicating that an optimal dose of 
purified TRF may be significantly lower than 16.25 mg/kg/day. 
In order to find out the minimum dose which can exert maximal 
hypolipidemic effect, we also investigated the impacts of 2.6, 5.2 and 7.8 mg 
purified TRF/kg/day on cholesterol dynamics in hyperlipidemic rats for 7 days. 
Administration of 2.6, 5.2 and 7.8 mg purified TRF/kg/day to hyperlipidemic rats 
for 7 days was associated with a dose-dependent decline in plasma triglycerides, 
total cholesterol including esterified and free cholesterol, VLDL-C, LDL-C and 
apoB. No affect on HDL-C and HDL3-C levels was observed at the 3 doses of 
purified TRF, whereas, slight change in the levels of HDL2-C and apo A-1 was 
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seen. The combined results demonstrate that a maximal hypolipidemic impact of 
purified TRF is exerted at a dose of 5.2 mg/kg/day in hyperlipidemic rats. These 
results also support the contention that a maximal efficacy of purified TRF in 
terms of its cholesterol lowering properties is obtained at 5.2 mg/kg/day which is 
similar to an optimal dose of 5.2 mg purified TRP/kg/day or 8 mg TRF/kg/day 
obtained in normolipidemic rats. 
Our results are supported by earlier studies where RBO (10%), TRF 
(0.2-0.4%) or y-T3 (50 ng/g of diet) were fed to rats along with cholesterol-rich 
diet for 6-8 weeks, which prevented significantly the increase in total cholesterol, 
LDL-C and VLDL-C. However, TRF did not affect significantly the HDL-C and 
triglycerides levels (Sharma and Rukmini, 1986 & 1987; Seetharamaiah and 
Chandrasekhara, 1989; Watkins et al, 1993). Similarly, feeding of tocotrienols 
together with atherogenic diet to rabbits for 12 weeks prevented significantly 
increase in serum total cholesterol and LDL-C (Teoh et al., 1994). Analogous to 
hypocholesterolemic impacts of TRF in experimental hyperiipidemic rats and 
rabbits, a significant decline in total cholesterol, LDL-C and apoB was observed in 
pigs, with inherited hyperlipidemia, fed TRF (50 jig/g of diet), isolated from palm 
oil, for 6 weeks. Similar to our results in rats, no affect on HDL-C and apoA-1 was 
observed in genetically hyperlipidemic pigs treated with TRF (Qureshi et al, 
1991c). Feeding of a diet supplemented with purified a-, y- and 5-T3 from palm oil 
(20 i^g/g of diet) to hypercholesterolemic chickens significantly reduced serum 
total cholesterol and LDL-C levels. Feeding of one capsule/day of 18 mg 
tocopherols and 42 mg tocotrienols in 240 mg of palmolein for 30 days to 
hyperlipidemic humans, resulted in a significant decline in total cholesterol and 
LDL-C with inconsistent change in triglycerides and HDL-C levels (Tan et al, 
1991). Consistent with our results, TRF/T3 exhibited more potent 
hypocholesterolemic action in inherited hyperlipidemic swines and experimental 
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hypercholesterolemic chickens comparison to normolipidemic swines and chickens 
(Qureshi et al., 1991c; Qureshi and Qureshi, 1993). The hypolipidemic effects of 
dietary RBO, TRF or Y-T3 in hyperUpidemic humans were consistent with our 
results observed in hyperlipidemic rats, and reported by others in rat (Sharma and 
Rukmini, 1986 & 1987; Seetharamaiah and Chandrasekhara, 1989; Watkins et al., 
1993), rabbit (Teoh ei al., 1994), pig (Qureshi et al., 1991c) and avian (Qureshi 
and Qureshi, 1993) models. Initial findings from our laboratory related to 
hypolipidemic effect of dietary RBO/TRF in hyperlipidemic rats (Beg et al., 
1996b) and humans (Khan et al., 1994; Beg et al., 1995 & 1996b) and repored by 
others in humans (Tan et al., 1991) are consistent with the results reported in the 
thesis and published, in part, elsewhere (Beg et al., 1997; Minhajuddin et al., 
1999). Intake of dietary RBO as cooking oil for 2 and 4 weeks by 
hypercholesterolemic humans resulted in a significant decrease of plasma 
triglycerides and total cholesterol levels (Raghuram et al., 1989). In another study, 
feeding of 200 mg TRF/day from palm oil or 200 mg y-T /^day for 4 weeks to 
hypercholesterolemic humans was associated with a significant decrease in total 
cholesterol, LDL-C and apoB levels, whereas, triglycerides, HDL-C and apoA-1 
levels were not affected (Qureshi et al., 1991a). Treatment of patients with 
hyperlipidemia and carotid stenosis with TRF (240-360 mg/day) isolated from 
pahn oil for 12 months revealed a significant apparent carotid atherosclerotic 
regression with no change in serum triglycerides, total cholesterol, LDL-C and 
HDL-C (Tomeo et al., 1995). 
The hypocholesterolemic action of TRF and purified TRF in normolipide-
mic and hyperUpidemic rats is mediated by a decrease in the enzymatic activity of 
HMG-CoA reductase, the rate-limiting en2yme in the biosynthetic pathway of 
cholesterol. A concomitant decline in immuno-reactive UMG-CoA reductase 
protein mass appears to be the reason for a decrease in enzyme activity and a 
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consequent decline in cholesterol production. Administration of TRF (125 mg/kg/ 
day) and purified TRF (81.25 mg/kg/day) for 2 weeks to normolipidemic rats was 
associated with a significant decrease in the enzymatic acti\it> of HMG-CoA 
reductase and its protein mass. Similar results were obtained in normolipidemic 
rats treated with 4, 8 and 12 mg TRF/kg/day or 2.6, 5.2 and 7.8 mg purified 
TRF/kg/day for 3 weeks in a dose-dependent manner. Feeding of cholesterol rich 
(atherogenic) diet to rats for 3 weeks resulted in a sharp decrease in the enzymatic 
activity and protein mass of HMG-CoA reductase. These results are consistent 
with the well knowTi negative feedback inhibition of HMG-CoA reductase 
mediated by feeding of high levels of cholesterol. Supplementation of purified 
TRF (65 mg/kg/day) with the atherogenic diet for 3 weeks further reduced the 
enzymatic activity and protein mass of HMG-CoA reductase, indicating the 
possibility of a different mechanism of cholesterol regulation than cholesterol 
itself. Five and seven days after the withdrawal of atherogenic diet in untreated 
hyperlipidemic rats, the enzymatic activity and protein mass of HMG-CoA 
reductase was significantly increased due to release of cholesterol feedback 
inhibition. However, the decline in total cholesterol and LDL-C levels by 
administering several doses of TRF or purified TRF for 5 and 7 days to 
hyperlipidemic rats is apparently mediated by a significant reduction in enzymatic 
activity of HMG-CoA reductase, which in turn is reduced by a decrease in its 
protein mass. Consistent with maximal hypolipidemic impacts of TRF, an optimal 
reduction in the enzymatic activity and protein mass of HMG-CoA reductase was 
obtained at 8 mg TRF/kg/day or 5.2 mg purified TRF/kg/day. The combined data 
provide sufficient evidence that tocotrienols present in TRF exert their 
hypolipidemic effects in normohpidemic as well as hyperlipidemic rats by a 
common mechanism involving the reduction in HMG-CoA reductase activity, 
which in turn is reduced by a decline in its protein mass. 
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The combined results presented here indicate that tocotrienols are highly 
effective in lowering blood cholesterol and LDL-C levels by repressing HMG-
CoA reductase. It has been established that the suppression of HMG-CoA 
reductase requires two regulators, cholesterol delivered by receptor-mediated 
uptake of LDL and non-sterol product derived from mevalonate. The former is 
expressed predominantly throu^ the changes in the rate of transcription of the 
HMG-CoA reductase gene, and the latter by modulating the efficiency of 
translation of HMG-CoA reductase mRNA or by the degradation of protein 
(Goldstein and Brown, 1990). The exact mechanism by which tocotrienols act in 
vivo at the cellular level has not been established. However, in normolipidemic and 
hyperlipidemic chickens, TRF/T3 have been shown to suppress the hepatic HMG-
CoA reductase activity (Pearce et al., 1992; Qureshi and Qureshi, 1993), whereas, 
enzymatic activity of HMG-CoA reductase in adipose tissue of normolipidemic 
and hypercholesterolemic swines was reduced after TRF treatment (Qureshi et al., 
1991a). Our results in normolipidemic and hyperlipidemic rats demonstrate that 
TRF suppresses the hepatic HMG-CoA reductase activity by reducing its protein 
mass. These studies represent an initial demonstration of the TRF mediated in vivo 
mechanism of suppression of HMG-CoA reductase activity involving a 
concomitant reduction in the protein mass. The decline in protein mass may be 
achieved by inhibition of HMG-CoA reductase synthesis and/or enhanced 
degradation. Similar to our in vivo results, Y-T3 has been shown to mediate the 
suppression of enzymatic activity and protein mass of HMG-CoA reductase in 
HepG2 cells, through decreased synthesis (57% of control) and enhanced 
degradation (2.4 fold versus control) of the enzyme (Parker et al., 1993). Thus, 
tocotrienols influence the mevalonate pathway in mammalian cells in vitro, by 
post-transcriptional suppression of HMG-CoA reductase, and appear to 
specifically modulate the intracellular mechanism for controlled degradation of the 
reductase protein (Parker et al., 1993). These activities of tocotrienols in HepG2 
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cells mirror the actions of the putative non-sterol feedback regulators derived from 
mevalonate in cultured cells (Goldstein and Brown, 1990). TRF mediated in vivo 
mechanism of inhibition of enzymatic activity and its protein mass of HMG-CoA 
reductase in normolipidemic and hyperlipidemic rats, as demonstrated in the 
present study, may be analogous to the mechanism shown in HepG2 cells (Parker 
et ai, 1993). Taken together, the available information indicate an association 
between the suppression of hepatic HMG-CoA reductase and cholesterogenesis, 
and the observed plasma cholesterol lowering activity of TRF in animal models. 
However, elucidation of precise in vivo mechanism(s) of TRF mediated inhibition 
of HMG-CoA reductase at molecular level remains to be investigated. 
A growing body of evidence has linked processes involving oxygen-derived 
free radicals with the initiation and propagation of atherosclerosis. In particular, 
the oxidative modification of LDL enhances its atherogenecity (Steinberg, 1988; 
Duthie et al, 1989; Palinski et ai, 1989). Recent studies have demonstrated that 
oxidized lipids, especially oxidized fatty acids and cholesterol in the diet are 
atherogenic (Staprans et al., 1998). An inadequate intake of foods containing 
antioxidant vitamins could result in the oxidation of LDL-C. Antioxidant, 
especially vitamin E (tocopherols), have recently received considerable attention 
as potential anti-atherogenic agents. Several studies have demonstrated the abihty 
of tocopherols to prevent ex vivo and in vitro LDL-C oxidation and significantly 
reduce the development of atherosclerotic lesions (Carew et al., 1987; Esterbauer 
et al., 1991; Mao et al., 1991), risk of coronary heart disease (CHD) (Rimm et al., 
1993; Stampfer et ai, 1993) and ischemic heart disease (Gey, 1995). As the TRF 
isolated from RBO is enriched with T3 and T, and tocotrienols are known to be 
more potent antioxidant than tocopherols (Suama et al., 1993; Kamat and 
Devasagayam, 1995; Kamat et al., 1997), we have investigated the antioxidant 
impacts of TRF in normolipidemic and hyperhpidemic rats. 
1 Ao 
Feeding of TRF and purified TRF to normolipidemic rats for 2 weeks was 
associated with a significant decline, in microsomal lipid peroxidation, quantified 
as thiobarbituric acids reactive substances (TEARS) and conjugated dienes of 
plasma LDL oxidation (conjugated dienes). Similarly, feeding of 4, 8 an 12 mg 
TRF/kg/day and 2.6, 5.2 and 7.8 mg purified TRF/kg/day for 3 weeks inhibited 
peroxidation of lipids and oxidation of LDL in a dose-dependent manner. Based 
on the combined results one can conclude that a dose of 8 mg TRF/kg/day or 
5.2 mg purified TRF/kg/day exerts a maximal hypolipidemic and antioxidant effect 
in normolipidemic rats. These results are consistent with earlier reports indicating 
an inhibition in the formation of TBARS and conjugated dienes by TRF or 
individual TT, and T when added in vitro in rat brain mitochondria (Kamat and 
Devasagayam, 1995) and in rat liver microsomes (Kamat et al, 1997). Indirect 
support to our results was obtained fi^om an earlier report indicating an inhibition 
in the formation of lipid hydroperoxides in rats and humans treated with a- and 
Y-T3(Suamae/a/., 1993). 
Since antioxidants may have a role in the prevention of h>'periipidemia and 
atherosclerosis, we also investigated the antioxidant impact of TRF on microsomal 
lipid peroxides (TBARS) and plasma LDL oxidation (conjugated dienes) in 
hyperlipidemic rats. Inhibition in the formation of lipid peroxides (TBARS) and 
LDL oxidation (conjugated dienes) in TRF treated (65 mg purified TRF) normal 
rats was similar to the antioxidant activity expressed by feeding 81.25 mg purified 
TRF for 2 weeks as shown in Table 6. In response to oxidative stress, evoked in 
experimental hyperlipidemia in rats, as reflected by increased (approximately 
2 fold) formation of TBARS and conjugated dienes, was substantially blocked by 
TRF feeding along with atherogenic diet. These results underline the importance 
of TRF as a potent antioxidant agent, because TRF suppressed the formation of 
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lipid peroxides (TBARS) and conjugated dienes during experimental hyperlipide-
mia, to a level lower than (24-38%) the observed values of normolipidemic rats. 
Treatment of h>'perlipidemic rats with 16.25 and 32.50 mg purified TRF/kg/day 
for 5 and 7 days not only caused significant decline in lipid peroxides and 
conjugated dienes in comparison to hyperlipidemic untreated control rats but 
further reduced these levels below normal values. In agreement with the above 
results, treatment of hyperlipidemic rats with 2.6, 5.2 and 7.8 mg purified 
TRF/kg/day caused a dose-dependent decline in lipid peroxides and diene 
conjugates below normal values. These results demonstrate that strong 
hypolipidemic impacts of TRF in conjunction with potent antioxidant property can 
provide additional therapeutic benefit in the prevention and treatment of 
atherogenesis. 
Our combined results demonstrating a strong antioxidant impacts of TRF 
(containing mixture of tocotrienols and tocopherols) in hyperlipidemic rats are in 
agreement with earlier reports indicating that feeding of atherogenic diet to rats, 
supplemented with y-Ts (50 ^g/g of diet) for 6 weeks caused a significant 
prevention in the formation of plasma lipid peroxides (TBARS). However, in order 
to get a similar level of preventive effect in the formation of Hpid peroxides 
(TBARS), feeding of ten fold higher concentration of a-T (500 i^g/g of diet) along 
with atherogenic diet was required, when compared to rats fed atherogenic diet 
alone. These results indicate that y-Ts exerts a significantly more potent 
antioxidant impact as compared to a-T (Watkins et al, 1993). Support to our 
results is also obtained from another study where feeding of a mixture of 
tocotrienols along with an atherogenic diet to rabbits was associated with a 
significant reduction in the formation of serum lipid peroxides (Teoh et al, 1994). 
Treatment of patients with hyperlipidemia and carotid stenosis with TRF (240-360 
mg/day), isolated from palm oil, for 8 months, caused a significant decrease in 
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TEARS, an ex vivo indicator of maximal platelet peroxidation (Tomeo ei al, 
1995). 
Vitamin E (tocopherols) is well accepted as the first line of defense against 
lipid peroxidation, protecting polyunsaturated fatty acids in cell membranes 
through its free radical quenching activity in bio-membranes at an early stage of 
free radical attack (Horwitt, 1986; Van Gossum et al, 1988; Packer, 1991). 
Studies in animal and human models have indicated that plasma a-T 
concentrations are highly correlated with plasma total lipid levels. In addition, 
vitamin E is transported in the plasma solely by lipoproteins; there are no other 
specific plasma transport proteins (Rubinstein et al, 1969; Carr et al, 1993). 
Similar to tocopherols, tocotrienols are also transported in the blood in association 
with circulating lipoproteins, as has been demonstrated in rats and human models 
(Suama et al, 1993). Therefore, it appears that TRF exerts its antioxidant effect on 
plasma LDL oxidation while being attached to LDL particle. 
Previously published scattered reports have shown that neither rice bran nor 
RBO lowered cholesterol levels. This discrepancy was explained by findings that 
some, but not all, rice cultivars contain tocotrienols which exert powerfiil 
hypolipidemic action (Qureshi et al, 1986; Qureshi et al, 1989). Because of 
these variation in the types and content of T3, one finds corresponding variation in 
the lipid lowering affects of RBO/TRF isolated from different cultivars of rice. 
Out of a-, P", y- and 6- forms of T3, y and 6- T3 have been found to be most potent 
in terms of their HMG-CoA reductase inhibition as well as cholesterol lowering 
effects. The efficiency of hypocholesterolemic action as well as the degree of 
inhibition of HMG-CoA reductase activity mediated by a-Ts was substantially 
lower than y and 5- T3 (Pearce et al, 1992). p-Form of T3 failed to exhibit any 
anticholesterol activity. Similarly, tocopherols fail to inhibit cholesterol synthesis 
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at the level of rate limiting enzyme, HMG-CoA reductase in chickens, rat liver 
hepatocytes and HepG2 cells (Pearce et al, 1992), hence do not lower cholesterol. 
Earlier studies in humans demonstrated that tocopherol supplementation to ones 
diet had no effect on serum cholesterol concentration (Isai et al, 1978; Schwartz 
and Rutherford, 1981; Ehnhohn et al, 1982; Kesaniemin and Grundy, 1982; 
Stampfer et al, 1983), or actually resulted in shght increase in serum cholesterol 
concentrations in some individuals (Chase et al, 1980; Howard et al, 1982). 
Similar observations were made in chickens, where administration of tocotrienols 
blended with increasing concentrations of tocopherols, significantly attenuated tfie 
inhibition of cholesterol biosynthesis (Qureshi et al, 1996). Therefore, tiie 
hypocholesterolemic effect of TRF (containing tocotrienols and tocopherols), 
isolated from palm oil, is exerted through the tocotrienols (Tan et al, 1991). 
Consistent with these reports and our results, the observed hypolipidemic impact 
of TRF, isolated from RBO, is apparently mediated by tocotrienols. In addition, 
our results indicate that the total percent content of tocopherols present in TRF is 
not sufficient to attenuate the anticholesterol action of tocotrienols. 
Based on our findings, indicating that 8 mg TRF/kg/day or 5.2 mg purified 
TRF/kg/day exerts a maximal hypohpidemic effect, we investigated die 
hypolipidemic impacts of purified TRF isolated from two cultivars of rice, raw 
Basmati and Saket-4, which differ in their y and 5- T3 content. Based on the total 
content of y and 5- T3 present in the purified TRF of each cultivar, hypolipidemic 
efficiencies at a dose of 1.67 and 3.35 mg purified TRF/kg/day from Basmati and 
1.17 and 2.34 mg purified TRF/kg/day from Saket-4 was investigated in 
hyperlipidemic rats for 7 days. The above calculated doses will be equivalent to 
combined concentration of y and 6- T3 present in 3 and 6 mg TRF from refined 
edible grade RBO. In addition, this calculation of TRF doses from two cultivars of 
rice is based on the observed maximal effect of 8 mg TRF/kg/day from refined 
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edible grade RBO. As expected, feeding of the above two doses of purified TRF 
fi-om each cultivar to hyperlipidemic rats for 7 days was associated with a 
significant decline in plasma triglycerides, total cholesterol including esterified 
and free cholesterol, VLDL-C, LDL-C, apoB and enzymatic activity and protein 
mass of HMG-CoA reductase. It is important to note that at 6 mg equivalent dose 
of purified TRF/kg/day fi-om both the cultivars, a twofold decrease in total 
cholesterol and LDL-C was observed in comparison to the hypolipidemic effect 
seen at 3 mg equivalent dose. In general, a dose-dependent impact of TRF on the 
above lipid parameters was observed. These results indicate that the hypolipidemic 
impacts of calculated doses fi-om purified TRF of two rice cultivars are consistent 
with the observed effects seen at 4 and 8 mg TRF/kg/day. The results also 
demonstrate that efficacy of hypolipidemic action of TRF or purified TRF is 
directly related to the total content of y and 6- T3 (Qureshi and Qureshi, 1993). The 
combined results also show that the TRF lowers plasma total cholesterol and 
LDL-C concentrations more effectively (twofold) in hyperlipidemic rats as 
compared to normolipidemic rats. Based on the combined results, one can 
calculate an optimal dose of TRF in terms of its maximal hypolipidemic effect in a 
given cultivar, which is proportional to the combined quantity y and 6- T3 
(Table 31). Consistent with earlier results, administration of 3 and 6 mg equivalent 
doses of purified TRF/kg/day fi"om two cultivars of rice to hyperlipidemic rats for 
7 days significantly reduced the formation of TBARS and conjugated dienes in a 
dose-dependent manner. Antioxidant effects of TRF coupled with its 
hypolipidemic property in normolipidemic and hyperlipidemic rats underline the 
importance of TRF in the prevention and treatment of hyperlipidemia and coronary 
heart disease. 
The combined results presented in the thesis provide considerable evidence 
that tocotrienol rich fi-action isolated fi-om rice bran oil as a non saponifiable 
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fraction exhibit a potent hypolipidemic and antioxidant activities in noimolipide-
mic as well as hyperlipidemic rats. Tocotrienol rich fraction used in the present 
investigation is rich in both tocotrienols and tocopherols. Previously published 
reports have suggested that tocotrienols mediate a potent hypohpidemic activity 
when administered in the diet to animals, including humans, (Pearce et ai, 1992; 
Qureshi et al., 1995), an attribute not observed with tocopherols (Kesaniemi and 
Grundy, 1982; Ehnhobn et al., 1982). Side-chain unsaturation, which is absent in 
tocopherols, is important for this activity of tocotrienols. In studies, directed 
toward a possible mechanism of action, Qureshi et al. (1986) observed that the 
plasma cholesterol lowering effect of TRF, from barley oil, in chickens and rats, 
was associated with decreased levels of hepatic HMG-CoA reductase activity. 
Furthermore, the structure-activity relationship for the hypocholesterolemic 
activity of T3 revealed that the natural and synthetic T3 lacking the 5-methyl ring 
substitution, viz. y-Ts and 8-T3 were highly active as suppressors of HMG-CoA 
reductase activity and cholesterol biosynthesis in primary rat hepatocytes and 
human hepatoma HepG2 cells (Pearce et al., 1992). In general, our results are in 
agreement with the reported frndings that presence of y- and 8-T3 in TRF is mainly 
responsible for the strong impact on cholesterol dynamics of normal and 
hyperlipidemic rats. In addition, our results demonstrate that efficacy of TRF in 
terms of cholesterol lowering activities varies due to the difference in the quantity 
of y- and 5-T3, which differ from cultivar to cultivar. Based on these observations, 
an optimal dose of 8 mg TRF/kg/day or 5.2 mg purified TRF/kg/day, fractionated 
from commercial refined edible grade RBO, which exerts a maximal hypolipide-
mic impact in normolipidemic and hyperiipidemic rats has been found. Similarly, 
based on the 22.2% and 31.8% combined content of y and 5- T3 in Basmati and 
Saket-4, respectively, an optimal dose of 4.47 and 3.12 mg purified TRF/kg/day 
was found in hyperlipidemic rats. In addition, based on the above results, and the 
combined content of y- and 5-T3 in a given cultivar, one can calculate a dose of 
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TRF for the maximal hypolipidemic activity of TRF. For example, an optimal dose 
of 6.12 mg purified TRF/kg/day has been calculated for Mansuri cultivar, based on 
total y- and 5-T3 content present in TRF (Table 31). 
Our combined results demonstrate a strong hypolipidemic action of TRF, 
when administered to normolipidemic and hyperlipidemic rats. In particular, total 
cholesterol, LDL-C and apoB, which are positively associated with coronary heart 
disease, were significantly reduced. Levels of plasma HDL-C and apoA-1, which 
are considered as anti-atherogenic, were not influenced in normal and 
hyperlipidemic rats treated with different doses of TRF or purified TRF. However, 
in normolipidemic rats treated with TRF, HDL2-C, which is considered as strong 
predictor of the presence and extent of CAD (Drexel et al., 1992), was 
significantly increased. Several epidemiological studies have demonstrated that 
elevated triglycerides level is associated with increased risk of CHD (Albrink and 
Man, 1959; Hulley et al, 1980; Aberg et al, 1985; Freedman et al, 1988; Austin, 
1991), a risk fliat is especially high in subjects with low HDL-cholesterol (Castelli, 
1986). However, the status of triglycerides as an independent risk for CAD 
continues to be controversial. In our studies, TRF and purified TRF also mediated 
a significant decline in plasma triglycerides level of both normolipidemic and 
hyperlipidemic rats. 
A five year old boy with severe skin xanthomas was referred to J.N. 
Medical College. Laboratory evaluation at entry point disclose that the child had a 
total cholesterol concentration of 440 mg/dl, a fasting triglycerides concentration 
of 211 mg/dl, LDL-C concentration of 392 mg/dl and a HDL-C concentration of 
15.6 mg/dl. HDL2-C was only 2.5 mg/dl, whereas HDL3-C level was 13.0 mg/dl. 
Consistent with high LDL-C level, the apoB level was 207 mg/dl, whereas apoA-1 
concentration was 28.3 mg/dl. The LDL-C/HDL-C ratio of the patient was 25.2, 
when ratio of normal humans is in the range of 3.2-3.6 or below. Similarly, 
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HDL-C/total cholesterol ratio at tfie entry point was 3.5% when compared to 
percent ratio of 20 or above in normal subjects. The child presented with classical 
case of familial hypercholesterolemia including a rapidly growing severe eruptive 
skin xanthomas on buttocks extending to thighs, less severe on elbows and couple 
of them on the knee. Based on above characterization the patient can be 
categorized as familial hypercholesterolemic. Considering the rare availability of 
such type of patients, the child was started on low fat, cholesterol-free diet, with 8 
mg TRF/kg/day for 100 weeks. With this regimen, his triglycerides, total 
cholesterol and LDL-C were reduced by 20-25% after 8 weeks of TRJF treatment. 
However, after 20 weeks, for unknown reasons, efficiency of TRf treatment in 
terms of its hypolipidemic action was lower than the initial phase of therapy, 
which was also reflected in the degree of regression of growing skin xanthomas. 
Since, in humans, FH is associated with an elevated plasma total and 
LDL-cholesterol and its apoB levels, data from several epidemiological studies 
document a significant and consistent relationship between elevated levels of 
plasma total cholesterol and LDL-C and increased incidence of CHD (Stamler et 
al., 1986; CasteUi et al., 1986; Martin et al., 1986) and atherosclerotic lesions 
(Solberg and Strong, 1983). A significant reduction in total cholesterol, LDL-C 
and apoB was seen in a FH patient following 100 weeks of TRF treatment. 
Numerous studies have also demonstrated an inverse relationship between plasma 
levels of HDL-C including apoA-1, CHD incidence (Goldbourt et al., 1985; 
Gordan et al., 1989; Goldbourt and Yaari, 1990) and coronary atherosclerosis 
(Solberg and Strong, 1983). Our results demonstrate a substantial increase in the 
levels of HDL-C (155%) and apoA-1 (166%) after 100 weeks of TRF treatment. 
There is a mounting evidence that lower levels of HDL-C predict CAD even when 
total cholesterol levels are not elevated (Brunner et al., 1987; Abbott et al., 1988; 
Miller et al., 1990). Case-control studies indicate that the inverse relationship with 
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CAD is mainly due to HDL subfraction, HDL2-C, which is the strongest predictor 
of both presence and extent of CAD (Drexel et al., 1992). Our results are 
consistent with these reported findings indicating a TRF mediated significant 
increase of 620% in HDL2-C level after 100 weeks of treatment, hitervention with 
repeated coronary arteriographies to monitor disease progression have consistently 
shown that ratios of LDL-C/HDL-C, apoB/apoA-1 and HDL-C/total cholesterol 
are independently associated witii growth of atherosclerotic lesion (Levy et al., 
1984; Amtzenius et al., 1985; Nikldla et al., 1994). Consistent with these findings, 
100 weeks of TRF treatment demonstrated that the above ratios have been 
substantially improved indicating the normalization of lipid parameters. Several 
epidemiological studies have demonstrated that elevated triglycerides is associated 
with increased risk of CHD (Albrink and Man, 1959; Hulley et al., 1980; 
Freedman et al., 1988). Our results demonstrate a significant decline in plasma 
triglyceride levels after 100 weeks of TRF treatment in a FH patient. In general, 
the hypolipidemic effect of TRF in FH patient is consistent with earlier reports, 
where RBO, TRF and y-tocotrienol administration to patient with hypercholestero-
lemia for 4 weeks was associated with the normalization of serum and lipoprotein 
lipids (Raghuram et al, 1989; Tan et a/., 1991; Qureshi et al., 1995; Khan et al., 
1994; Beg et al., 1995 & 1996). However, TRF treatment of FH patient upto 
100 weeks was not associated with the normalization of plasma and lipoprotein 
lipid parameters, which is due to inherited genetic defect. Consistent with the 
reduction in triglycerides, total cholesterol and LDL-C and an increase in HDL-C 
concentrations, after TRF treatment, the rapid growth of skin xanthomas was 
arrested. In addition, regression of xanthomas on buttocks, extending to thighs, 
elbows and knee was observed after 20 weeks of TRF treatment. 
Although treatment of FH patient with TRF is associated with a significant 
improvement in lipid profile including inhibition in the growth of skin xanthomas 
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with some regression, such patients generally require additional therapy to prevent 
or even reverse the damage resulting from tissue deposition caused by profoundly 
elevated LDL/HDL ratio. Diet plus a combination of niacin, an inhibitor of HMG-
CoA reductase, and bile acid sequestrant can reduce the total and LDL 
concentrations in hetrozygous FH by 35-50% (Witztum et a!., 1989; Illingworth, 
1990). Based on these findings, TRF in combination with cholestyramine will be 
more effective therapy for tfie FH patient described here. 
Consistent with the hypolipidemic properties of RBO (Sharma and 
Rukmini, 1986; Purushothama et al, 1995) or TRF in normolipidemic and 
hyperlipidemic rats (present study, Sharma and Rukmini, 1987; Seetharamaiah and 
Chandrasekhara, 1989; Watkins et al, 1993) and hyperhpidemic humans (Beg et 
al., 1997; Minhajuddin et al, 1999), daily intake of 0.2 g/kg/day RBO, 
(equivalent to 8 mg TRF/kg/day), upto 4 weeks by normolipidemic subjects was 
associated with a significant decline in plasma total cholesterol and LDL-C. These 
results are also in agreement v«th previously published report indicating a 
hypocholesterolemic effect of palm oil concentrate containing tocotrienols, in 
normal and hyperlipidemic human volunteers (Tan et al, 1991). Since high levels 
of HDL are known to be anti-atherogenic, intake of RBO (0.2 g/kg/day) by normal 
humans for 4 weeks caused a significant increase in HDL-C. These results are 
inconsistent with an earlier report (Tan et al, 1991), where intake of palm oil 
concentrate by normolipidemic and hyperlipidemic humans for 30 da\'S was not 
associated with any increase in HDL-C level. Since it has been established that 
LDL-C/HDL-C and HDL-C/TC (%) ratios are good predictors for the presence 
and severity of CAD, intake of RBO by normolipidemic subjects for 4 weeks 
resulted in a significant improvement in these ratios. 
In the Lipid Research Clinical (LRC) Trials, every 1% decrease in serum 
cholesterol resulted in a 2% reduction in the risk of CHD (Lipid Research Clinic 
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Program, 1984 a&b). Therefore, the decline of 20% in plasma total cholesterol of 
familial hypercholesterolemic (FH) patient treated with TRF for 8 weeks would 
indicate a 40% reduction in cardiovascular risk. Similarly, a 10% decrease in 
LDL-C was associated with 17% reduction in CHD incidence. Based on a 
reduction of 24% in LDL-C after 8 weeks of TRF treatment will reflect a 4 1 % 
reduction in CHD incidence. If the results of LRC Trials can be extrapolated to the 
present studies, dealing with hypolipidemic action of TRF in rats, a 25% decrease 
in plasma total cholesterol levels observed with TRF fed to hyperiipidemic rats for 
1-3 weeks would indicate a 50% reduction in cardiovascular risks. Increased 
triglycerides level are associated with increase risk of CHD (Aberg et al., 1985). In 
our study with FH patient, TRF treatment for 8 weeks significantly reduced the 
triglycerides level by 20%, thereby reducing the risk of CHD. 
Based on our combined results, and earlier reported fiidings in 
normolipidemic and hyperiipidemic animal models, the TRF mediated mechanism 
of hypolipidemic activity in subjects with hyperlipidemia or genetic hypercholes-
terolemia is shown in Fig. 4.1. Administration of TRF to hyperiipidemic subjects 
will inhibit HMG-CoA reductase which intum will reduce the synthesis of 
cholesterol. Reduced formation of cholesterol will decrease VLDL production, 
thereby reducing the conversion of VLDL to LDL, which will reduce total 
cholesterol, LDL-C and triglycerides concentrations in plasma. Based on a report 
(Parker et al., 1993) indicating an increase in LDL-receptor protein in HepG2 cells 
following incubation of y-Ta, an additional mechanism for the decreased total 
cholesterol, LDL-C and triglycerides levels may envoive upregulation of LDL 
receptors by TRF which intum would increase the removal and catabolism of 
LDL. In addition, in hyperlipidemia, TRF treatment triggers a substantial increase 
in HDL, which would enhance the removal of excess tissue cholesterol via liver 
involving a HDL mediated reverse cholesterol transport system (Fig. 1.4). 
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Fig. 4.1 Schematic representation for the mechanisms of hypolipidemic action of 
tocotrienols (TRF) mediated by inhibition of HMG-CoA reductase and/or 
upregulation of LDL receptors. 
In summary, the combined results presented in the thesis provide sufficient 
evidence that administration of TRF, isolated from RBO, to noimolipidemic and 
hyperlipidemic rats was associated with a significant decline in plasma and 
lipoprotein lipids including apoB. The hypolipidemic action of TRF is apparently 
mediated by a decrease in the enzymatic activity of HMG-CoA reductase, the rate-
limiting enzyme, which in turn is modulated by a reduction in its protein mass. 
Formation of hpid peroxides (TEARS) and conjugated dienes (LDL oxidation) 
were significantly reduced in TRF treated normolipidemic rats. In response to 
oxidative stress, evoked in experimental hyperlipidemia in rats, as reflected by 
increased formation of TBARS and conjugated dienes, was significantly prevented 
by TRF treatment. The hypolipidemic property of TRF is dependent on the percent 
content of 5- and y-tocotrienols present in TRF, which vary firom cultivar to 
cultivar. 
Long term (upto 100 weeks) TRF treatment of a FH patient with severe skin 
xanthomas was associated with a significant improvement in the ratios of 
LDL-C/HDL-C, apoB/apoA-1 and HDL-CA'C. In addition, the growth of skin 
xanthomas were significantly inhibited by TRF treatment. Based on the present 
study and previous studies in normolipidemic and hyperlipidemic humans from 
our laboratoiy, RBO or TRF (vitamin E), potent antioxidants, can be used in the 
prevention and treatment of hyperlipidemia and atherosclerosis. Daily intake of 8 
mg TRF/kg body weight will provide maximum therapeutic benefits. In addition, 
daily consumption of only 0.2 g or -0.2 ml RBO/kg/day, which is equivalent to an 
optimal dose of 8 mg TRF/kg/day, will prevent the occurrence of hyperhpidemia 
and cardiovascular diseases in normal subjects, whereas, it will be useful in the 
treatment of hyperlipidemia and CHD in subjects with lipid disorders. 
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Rice bran, an inexpensive milling by-product largely used as animal 
feedstock, is potentially an underutilized resource of value-added products. India is 
the major rice producing country in the world, but only a fraction of rice bran, rich 
in oil and several beneficial micronutrients, including tocotrienols and tocopherols 
(vitamin E), is utilized as health food. Only 0.5 million ton of RBO, corresponding 
to 8.5% of total vegetable oils, is consumed annually in India {Source: Central 
Organisation for Oil Industry and Trade, India, 1998). Based on TRF mediated 
dual therapeutic benefits, refined edible grade RBO, which has a fatty acid and 
glyceride composition similar to peanut oil, can be used as a major source of 
edible oil on daily basis. Daily use of RBO by normal population will prevent the 
occurrence of hyperlipidemia and cardiovascular diseases. Furthermore, daily 
consumption of RBO as cooking oil by subjects suffering from lipid abnormalities 
will be usefiil in the treatment of hyperlipidemia and CHD. In addition, based on 
avarage consumption/day/person, variety of other traditional edible oils such as 
mustard oil, peanut oil, soybean oil, com oil, safflower oil, sunflower oil, etc., 
which lack in tocotrienols, can be supplemented with an optimal dose of 8 mg 
TRF/kg/day for maximal therapeutic benefits. Use of TRF-supplemented vegetable 
oil on daily basis will provide all the health benefits without compromising ones 
oil of choice. Furthermore, use of RBO, TRF or TRF-supplemented other popular 
edible oils will be an excellent source of vitamin E with substantial antioxidant 
activity. 
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Summary 
India is the major rice producing country in the world, but only a fraction of 
rice bran, an inexpensive milling by-product, rich in oil and several beneficial 
micronutrients, including tocotrienols and tocopherols (vitamin E), is utilized as 
health food. Current worldwide interest in the use of tocotrienols (T3) as potential 
therapeutic agent, creates a need to develop a simple and cost-effective methodo-
logy for the isolation of tocotrienol/tocopherol rich fi:^ction (TRF) from rice 
bran/rice bran oil (RBO). We have developed a rapid, efficient, reproducible and 
cost-effective methodology for the isolation of TRF from rice bran, crude RBO or 
refined edible grade RBO. The TRF, thus obtained, is purified involving a single 
step purification procedure. The results further demonstrate that the isolation of 
TRF or purified TRF from crude RBO isolated from brans of two cultivars of rice, 
Basmati and Saket-4, was associated with a significantly higher yield of value-
added products, tocotrienols and tocopherols, in comparison to TRF or purified 
TRF isolated from refined edible grade RBO. 
Feeding of tocotrienols as TRF or purified TRF, isolated from refined 
edible grade RBO, to normal rats for two weeks was associated with a significant 
decline in plasma triglycerides, total cholesterol, LDL-C including apoB levels. 
HDL2-C, which is considered as strong predictor of the presence and extent of 
CAD was significantly increased in TRF treated normolipidemic rats. The efficacy 
of TRF in the prevention of experimental hyperlipidemia in rats has been shown 
by administration of TRF along with atherogenic diet for three weeks, TRF 
significantly prevented the increase in plasma triglycerides, total cholesterol, 
LDL-C, apoB, HDL-C, apoA-1 and HDL3-C levels in comparison to rats fed 
atherogenic diet alone. Five and seven days after the withdrawal of atherogenic 
diet all the plasma and lipoprotein Upid levels including apoB and apoA-1 were 
reduced. Treatment of hyperlipidemic rats with purified TRF resulted in a further 
significant reduction in the above parameters indicating the efficacy of TRF in the 
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treatment of experimental hyperlipidemia. The minimum dose of TRP or pmified 
TRF required to exert the maximum hypolipidemic effect in normolipidemic and 
hNnperlipidemic rats has been found to be 8 mg TRF or 5.2 mg purified 
TRF/kg/day. 
The resuhs provide evidence that administration of TRF or purified TRF to 
normolipidemic rats was associated with a significant decrease in en2ymatic 
activity of HMG-CoA reductase. Experimental hyperlipidemia in rats was 
associated with down-regulation of enzyme activity and protein mass of HMG-
CoA reductase. Administration of purified TRF along with atherogenic diet to rats 
was associated with further inhibition of enzymatic activity of HMG-CoA 
reductase and its protein mass, in comparison to hyperlipidemic controls, 
indicating the possibility of a different mechanism of HMG-CoA reductase 
inhibition by TRF. Five and seven days of purified TRF treatment to 
hyperlipidemic rats, after flie withdrawal of atherogenic diet, caused a further 
reduction in the activity and protein mass of HMG-CoA reductase, in comparison 
to untreated hyperlipidemic rats. A concomitant decline in immuno-reactive HMG-
CoA reductase protein mass represents an initial demonstration and indicates the 
involvement of long-term control by alteration in protein synthesis and/or 
degradation. Based on the combined results, it can be concluded that cholesterol 
lowering property of TRF in normolipidemic and hyperlipidemic rats is due to the 
suppression of enzymatic activit>' and protein mass of HMG-CoA reductase. 
Administration of TRF, enriched with tocotrienols and tocopherols, 
resulted in a significant decline in microsomal lipid peroxidation (TEARS) and 
plasma LDL oxidation (conjugated dienes) in normoUpidemic and hyperlipidemic 
rats. In response to oxidative stress, evoked in experimental hyperlipidemia in rats, 
as reflected by increased formation of TEARS and conjugated dienes, was 
substantially blocked by TRF feeding along with atherogenic diet, to a level lower 
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than the observed values of nonnolipidemic rats. Treatment of hyperhpidemic rats 
with purified TRF for 5 and 7 days not only caused significant decline in lipid 
peroxides and conjugated dienes in comparison to hyperhpidemic untreated 
control rats, but fiuther reduced these levels below normal values. These results 
underline tiie importance of TRF as a potent antioxidant agent. The combined 
results demonstrate that strong hypolipidemic impacts of TRF in conjunction with 
its potent antioxidant property can provide an additional therapeutic benefit in the 
prevention and treatment of hyperlipidemia and coronar>' heart disease. 
The results also demonstrate a differential hypolipidemic impact of purified 
TRF isolated fi^om two cultivars of rice, raw Basmati and Saket-4, due to the 
difference in their y- and 5-T3 content in hyperhpidemic rats. Based on the total 
content of y- and 6-T3 present in the purified TRF of each cultivar, hypoHpidemic 
efficiencies at a dose of 3 and 6 mg equivalent TRF/kg/day (calculated on the basis 
of combined content y- and 8-T3 present in 3 and 6 mg TRF fi-om refined edible 
grade RBO), caused a dose-dependent decline in plasma and lipoprotein lipids 
including apoB as well as enzymatic activity and protein mass of HMG-CoA 
reductase, in hyperlipidemic rats after 7 days of treatment. Thus, efficacy of 
hypohpidemic action of TRF or purified TRF is directly related to the total content 
of y- and 6-tocotrienol present in TRF or purified TRF isolated fi-om crude RBO of 
different cultivars of rice or from refined edible grade RBO. Consistent with 
earher results, administration of 3 and 6 mg equivalent doses of purified TRF/kg/ 
day from two cultivars of rice to hyperlipidemic rats for 7 days significantiy 
reduced the formation of TBARS and conjugated dienes in a dose-dependent 
manner. 
Drugs targeted to inhibit HMG-CoA reductase activity are extensively used 
to control hyperlipidemia including familial hypercholesterolemia (FH). Therefore, 
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based on hypolipidemic property of TRF a long-term therapy of a FH patient with 
severe skin xanthomas was undertaken. TRf treatment at a dose of 8 mg/kg/day 
caused a significant reduction in triglycerides, total cholesterol, LDL-C and apoB 
levels. There was a substantial increase in the levels of HDL-C (155%) and 
apoA-1 (166%). A highly significant increase in HDL subfi-action, HDL2-C 
(620%) was seen after 100 weeks of TRF treatment. TRF also caused a substantial 
improvement in the ratios of LDL-C/HDL-C, apoB/apoA-1 and HDL-C/total 
cholesterol, indicating the normalization of lipid parameters. Consistent with the 
reduction in triglycerides, total cholesterol and LDL-C concentrations and an 
increase in antiatherogenic HDL level, after TRF treatment, the rapid growth of 
skin xanthomas was arrested. In addition, a significant regression of xanthomas on 
buttocks extending to thighs, elbows and knee was observed after 20 weeks of 
TRF treatment. 
Similar to hypolipidemic impact of TRF isolated from RBO, in 
nonnolipidemic rats, intake of RBO by normolipidemic humans for 4 weeks was 
associated with a significant decline in plasma total cholesterol and LDL-C levels, 
with a significant increase in HDL-C level. Intake of RBO was also associated 
with a significant improvement in already normal ratios of LDL-C/HDL-C and 
HDL-C/TC, indicating a strong antiatherogenic property of RBO, rich in 
tocotrienols. 
Our combined results demonstrate a strong hypolipidemic and antioxidant 
action of TRF and purified TRF isolated from refined edible grade RBO or crude 
RBO, when administered to normolipidemic and hyperlipidemic rats. Similar to 
hypolipidemic effects of TRF in the rats, total cholesterol, LDL-C and apoB, 
which are positively associated with coronary heart disease, were significantly 
reduced in FH patient treated with TRF. Levels of plasma HDL-C and apoA-1, 
which are considered as anti-atherogenic, were significantly increased. In addition. 
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which are positively associated with coronary heart disease, were significantly 
reduced in FH patient treated with TRF. Levels of plasma HDL-C and apoA-1, 
which are considered as anti-atherogenic, were significantly increased. In addition, 
HDLj-C, which is considered as strong predictor of the presence and extent of 
CAD was significantly increased. 
Based on TRF-mediated dual therapeutic benefits, refined edible grade 
RBO, which has a fatty acid and glyceride composition similar to peanut oil, can 
be used as a major source of edible oil on daily basis. Daily use of RBO by normal 
population will prevent the occurrence of hyperlipidemia and cardiovascular 
diseases. Furthermore, daily consumption of RBO as cooking oil by subjects 
suffering fi'om lipid abnormalities will be useftil in the treatment of hyperlipidemia 
and CHD. In addition, variety of other traditional edible oils such as mustard oil, 
peanut oil, soybean oil, com oil, safflower oil, sunflower oil, etc., which lack in 
tocotrienols, can be supplemented with an optimal dose of 8 mg TRF/kg/day for 
maximal therapeutic benefits. Use of TRF-supplemented vegetable oil on daily 
basis will provide all the health benefits without compromising ones oil of choice. 
Furthermore, use of RBO, TRF or TRF-supplemented other edible oils will be an 
excellent source of vitamin E with substantial antioxidant activity. 
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